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Summary 
 
Osteoporosis, characterized by bone loss and increased fracture risk, is usually treated with 
exercises and medication. However, exact interactions of different treatments are not fully 
known yet. This study investigated the interaction of mechanical load on the 6
th
 caudal 
vertebra (CV) and bisphosphonate (BIS) or PTH treatment in ovariectomized (OVX) mice. In 
vivo micro-CT measurements of the 6
th
 CV were performed before OVX and during 
treatment. From the CT images static and dynamic bone parameters were evaluated. An OVX 
induced bone loss was observed. Loading improved all static parameters in OVX animals, 
except for trabecular number. BIS treatment had comparable effects as loading for most 
parameters. However, trabecular number increased. Adding loading to BIS treatment 
improved static parameters even more. PTH treatment caused similar or better results as 
combined BIS treatment and loading. When loading was combined with PTH treatment the 
improvement of the static parameters exceeded all other groups. For the dynamic parameters 
it can be said, that loading increased formation parameters and decreased resorption 
parameters. PTH increased formation parameters the most, while BIS related to similar 
formation parameters as vehicle. BIS treatment revealed its anticatabolic action in the 
resorption parameters. Bone resorption rate was reduced, as well as mineral resorption rate. 
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Zusammenfassung 
 
Die Behandlung von Osteoporose, welche durch Knochenmasseverlust und ein erhöhtes 
Frakturrisiko charakterisiert ist, erfolgt meist medikamentös und mit Sport. Das genaue 
Zusammenspiel verschiedener Behandlungsmethoden ist jedoch noch ungenügend erforscht. 
Diese Studie untersuchte die Interaktion von mechanischer Belastung (LOAD) des 6. 
Schwanzwirbels (SW) und der Behandlung mit Bisphosphonaten (BIS) oder PTH in 
ovariektomierten (OVX) Mäusen. Vor der OVX OP, sowie jeweils während der Behandlung 
wurden micro-CT-Aufnahmen des 6. SW angefertigt. Mit Hilfe dieser Aufnahmen wurden 
statische und dynamische Knochenparameter berechnet. OVX verursachte einen 
Knochenmasseverlust. Durch LOAD wurden alle statischen Paramter, ausser trabecular 
number verbessert. Ähnliche Effekte wurden nach der Behandlung mit BIS festgestellt, 
allerdings nahm hier die Anzahl der Trabekel zu. BIS Behandlung zusammen mit LOAD 
führte zu noch besseren statischen Parametern. Die Ergebnisse nach PTH Behandlung waren 
ähnlich oder besser als bei BIS und LOAD zusammen. Die grösste Verbesserung der 
Parameter wurde bei der Kombination von PTH und LOAD gesehen. Bei den dynamischen 
Parametern stiegen durch LOAD die Aufbauparameter und sanken die Resorptionsparameter. 
Unter PTH Behandlung stiegen die Aufbauparameter am stärksten an. Die antikatabolische 
Wirkungsweise von BIS wird bei den Resorptionsparametern deutlich, welche reduziert 
werden. 
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1 Introduction 
 
 
1.1 Motivation 
Osteoporosis is a major health problem, worldwide. It occurs mainly in the developed 
countries, and affects about 75 million people in Europe, USA and Japan. The World Health 
Organization (WHO) called it an “epidemic of the 21st century”[1]. As mainly elderly people, 
who represent a rapidly growing subpopulation, are suffering from this disease, the number of 
osteoporosis patients will increase dramatically in the future. Cooper et al. estimated, that in 
Europe the population of people aged 65 years or older will increase from 68 million in the 
year 1990 to over 133 million in 2050. An even greater increase in the elderly population is 
expected for Asia. Here the number will rise from 145 million in 1990 to 894 million in 2050 
[2]. The number of osteoporosis patients is expected to increase to a similar extend. 
The causes for osteoporosis can be manifold, but the consequences are always similar: Bone 
architecture is slowly deteriorated and bone mass is lost, resulting in an increased risk for 
fractures. In the past, according to WHO a bone was considered to be osteoporotic when the 
bone mineral density (BMD) was 2.5 standard deviations or more below the young adult 
mean [3]. Consequently, due to reduced BMD, bone rigidity is impaired and fractures may 
occur. However, as bone mineral density not always correlates with mechanical stability the 
definition of osteoporosis changed to be a combination of bone loss and increased fracture 
risk [4]. Patients with fractures have to be hospitalized and sometimes need intensive care 
afterwards. The life time risk to experience a hip fracture is one in six in white women. In 
comparison, the life time risk for breast cancer is one in nine [5]. Women after menopause are 
the largest patient group affected by osteoporosis, because decreasing estrogen levels can 
cause rapid bone loss. In women older than 45 years, osteoporosis is the reason for spending 
more days in hospital than many other diseases such as diabetes, myocardial infarction or 
breast cancer [6]. In Switzerland in the year 2000 62,535 people had to be hospitalized for 
fractures. Among these fractures 51% in women and 24% in men were caused by osteoporosis 
[7]. In Europe there were about four million new fractures in the year 2000, which is one 
fracture every eight seconds. About 3.79 million of them were considered to be caused by 
osteoporosis. Costs for all osteoporotic fractures in Europe were €36 billion in the year 2000 
and are expected to rise up to €76 billion in the year 2050 due to the increasing elderly 
population [8, 9]. Mortality rates are up to 20-24% in the first year after experiencing a hip 
fracture and are still elevated for at least 5 years. Additionally, among survivors about 40 % 
are not able to walk independently and 60 % still require assistance one year after the fracture 
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occurred [10-12]. Hence osteoporosis has a tremendous impact not only on national health 
care systems, but also on the personal wellbeing of the patients. Therefore, the demand to 
fully understand the mechanisms leading to bone loss and to find effective treatment options 
is high. 
However, as bone physiology is a complex and precisely regulated process, there are still a lot 
of questions that need to be answered. Different cell types are orchestrated by many endocrine 
and paracrine signals to maintain bone mass. The most important cells are osteoclasts, 
responsible for bone resorption, and osteoblasts, responsible for bone formation. Only if bone 
resorption and bone formation are in balance, a stable bone mass can be maintained. During 
childhood bone mass is increasing and reaches the peak bone mass at time of adolescence. 
Starting at the age of about 25 to 30 years, bone mass is decreasing again. This bone loss 
continues also in healthy persons for the rest of the life time [13, 14]. 
A common measure to try to prevent the onset of osteoporosis is to induce a high peak bone 
mass and maintain this by the application of food with high calcium and vitamin D content. 
Furthermore, bone mass can be improved by physical activity. This is important not only 
during childhood and adolescence, but also during the adult life. It has been shown that 
physical activity can reduce the risk of osteoporosis and fractures. Therapeutic exercise can 
increase or maintain bone mineral density in postmenopausal women and improve strength 
and function, even in elderly patients who already experienced hip replacement after a hip 
fracture [15-20]. Once osteoporosis is diagnosed, several pharmacological treatments are 
available. There are two different strategies how such medication acts on bone: Anabolic 
drugs target osteoblasts and increase bone formation, while antiresorptive drugs act on 
osteoclasts and impede bone resorption. So far the European Medicines Agency EMEA 
approved only one anabolic drug for osteoporosis treatment in Europe: Teriparatide, an 
analogue of the parathyroid hormone (PTH). It increases both bone formation and - with a 
certain delay - bone resorption. However, after about two years, bone remodeling parameters 
go back to baseline levels [21]. Moreover, in a rat study an incidence of osteosarcoma 
development occurred after treating the animals with high dose PTH for two years [22]. Due 
to these facts, teriparatide is approved for a treatment period of two years only in humans. 
However, within these two years a tremendous increase in bone mineral density, bone mass, 
bone strength, bone formation and bone micro architectural parameters can be observed in 
both human and animal studies [23-31]. For the second strategy, antiresorptive treatment, 
several medications are on the market. Bisphosphonates are the most commonly used drugs 
but there are also hormone replacement therapy, selective estrogen receptor modulators, 
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calcitonin and denosumab, an antibody that interrupts pro-resorptive signaling, available. 
Bisphosphonates have a high affinity to bone mineral and accumulate in osteoclasts. 
Therefore, they have a very long half-life. The biggest concern about bisphosphonates, 
besides having side effects like nausea, headache or bone pain, is that they are suspected to 
cause atypical femoral fractures and osteonecrosis of the jaw [32, 33]. Nevertheless, 
bisphosphonates show good results in improving deteriorated bone architecture and strength 
[34-40].  
It has been shown that with the appropriate treatment the risk of vertebral fracture can be 
reduced by 30-65 % [41]. However, patient adherence (the number of days a medication is 
taken) and patient compliance (the number of doses taken divided by the number of doses 
prescribed), are often poor. This can be due to side effects, simply forgetting to take the 
medication or unpleasant way of administration, as PTH, for example, has to be administered 
daily with a subcutaneous injection. A drug with good compliance is Zolendronate, a newly 
developed bisphosphonate that has to be administered just once a year via infusion [39]. 
Therefore, there is a great demand to further improve the available drugs. However, neither 
the pathways inducing osteoporosis nor the mechanisms of the drugs and their interaction 
with mechanical loading are fully understood yet. Hence, research has to focus on 
investigating these mechanisms closer in order to provide better medication. 
 
1.2 Aim 
The aim of this thesis was to investigate the effect of combined pharmacological treatment 
and mechanical loading on bone remodeling in ovariectomized mice. 
Ovariectomized mice are a common model for postmenopausal osteoporosis. First it was 
studied if the ovariectomized mice are susceptible to loading. The second aim was to study 
the effect of different pharmacological treatments in combination with mechanical loading. 
Both pharmacological strategies were investigated. The influence of an anabolic drug, namely 
PTH and an anticatabolic treatment, namely bisphosphonates, both in combination with 
loading was examined. To illustrate the effects at different time points of bone loss, all 
experiments were performed at an early and a late time point after ovariectomy. During all 
experiments the changes in static and dynamic bone parameters were monitored with in vivo 
micro-CT. With a method recently developed at our institute [42] not only bone 
microstructure, also bone formation and resorption can be monitored over time at a three 
dimensional level with in vivo micro-CT . This is a great advantage compared to conventional 
methods as histology and histomorphometry. With histology and histomorphometry data can 
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only be acquired from cross sectional studies, because the bones have to be processed and 
cannot be observed in living animals. Furthermore, only single slices can be evaluated at a 
two dimensional level. Now, with in vivo micro- CT it is possible to perform longitudinal 
studies and monitor the effect of treatment over a longer period of time. Moreover, the entire 
bone can be evaluated at a three dimensional level. Finally all experiments were summarized 
in a physiome map. With this summary the outcomes of the different experiments can be 
compared directly. A physiome map provides a powerful evaluation tool but could also be the 
basis to add data of future experiments. Furthermore, it can serve as input for computer 
simulations to be able to predict changes in bone morphology and bone morphometry due to 
diseases and due to different types of treatments. 
 
1.3 Experimental setup 
In all studies C57Bl/6J mice were ovariectomized (OVX) or sham operated (SHM) at the age 
of 15 weeks. In an earlier study at our institute, we investigated the time course of bone loss 
in OVX mice [43]. During this experiment ovariectomized mice were scanned biweekly for 
twelve weeks. It was shown that between two and eight weeks after ovariectomy a phase of 
rapid bone loss occurred, which was followed by a phase of slow bone loss where a plateau is 
reached. Between ten and twelve weeks after ovariectomy bone mass is kept stable at a very 
low level [43]. Based on these results, our experiments were performed in two series which 
differ in the starting point for the treatment. In the early loading series, treatment was started 
during the rapid bone loss period, five weeks after surgery. In the other experimental series, 
the late loading experimental series, treatment and loading started eleven weeks after 
ovariectomy. Three studies were performed in each experimental series. One study 
investigated the effect of loading on ovariectomized compared to sham operated mice to test 
whether OVX mice are mechanosensitive at all. In a second study, PTH or vehicle were 
injected and both were combined with loading. The last study investigated the effect of the 
combination of bisphosphonate or vehicle treatment and loading. All treatments were applied 
over four weeks. The pharmacological treatment was performed only in OVX mice, because 
treatment of mice with normal bone mass was not in the scope of our project. In all studies 
non-loaded mice were used as controls. At the beginning of each study ten mice were 
assigned to each group.  
The effect of pharmacological treatment in combination with loading was monitored with in 
vivo micro-CT in all studies. During the course of each study in vivo micro-CT scans were 
performed four times in total. The first scan was done before ovariectomy, the second at the 
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start of the loading and treatment period and the last two with a time lag of two weeks in the 
middle and at the end of the loading and treatment period. 
Due to in vivo micro-CT measurements all studies could be performed in a longitudinal 
fashion. With longitudinal studies the number of animals can be reduced. Furthermore the fact 
that all animals show inter-individually different reactions to the different treatment types can 
be overcome. 
 
 
2 Literature review 
 
 
2.1 Bone  
The human skeleton consists of about 200 bones of different shapes, length and function. 
However, the principle composition of a bone is always the same. It consists of a compact 
outer shell, called cortical bone, which contributes about 80% of the whole skeletal mass. 
Inside the bones there is a three dimensional network of trabeculae and in-between there is the 
bone marrow. With this construction bone is resistant and strong but still light weighted. The 
material which bone is made of consists of about 80 % dry matter, splitting up into 30% 
organic material, such as collagen and 70% inorganic material, mainly hydroxyapatite. With 
just 20% water content, bone has extremely little water compared to other organs. The 
functions of bone are manifold. Most obviously bones are responsible to give stability and 
shape to the entire body. As bones are very solid, they protect vital sensitive organs, such as 
the brain, heart and lungs. Furthermore, production of new blood cells is located in the bones. 
In new born humans hematopoiesis is almost exclusively located in the red bone marrow, 
which is present in all bones at that time point. As humans get older, the red bone marrow 
turns into yellow bone marrow in many bones and hematopoiesis is only located in some 
bones (e.g. pelvis), where red bone marrow is still remaining. Another very important 
function of bone is to keep the mineral metabolism of calcium and phosphate in homeostasis 
and to regulate blood pH by secreting buffer substances. It also serves as a reservoir for other 
minerals, such as magnesium and sodium. Furthermore some toxic substances can be cleared 
from the blood by binding in the bone matrix. 
 
2.1.1 Bone cells and their function 
Bone is a complex structure that has to be organized properly. In order to preserve healthy 
bone, different cells work together. The most important cells are osteoclasts, responsible for 
bone resorption, osteoblasts, responsible for bone formation and osteocytes, which are 
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embedded in the bone matrix and serve as mechanosensors. During bone remodeling, these 
cells are organized in the so called bone multicellular unit (BMU). In BMUs osteoclasts form 
a resorption cavity by resorbing bone. This cavity is filled later by osteoblasts with newly 
formed bone.  
As just mentioned, osteoclasts are the bone resorbing cells. They derive from hematopoietic 
stem cells and form large multinucleated cells. To resorb bone, they lower the pH by secreting 
hydrogen ions after attaching to the bone surface. This dissolves the mineral salts within the 
bone. Furthermore secreted proteolytic enzymes dissolve the organic matrix. With these 
processes osteoclasts form the resorption cavity. Osteoclasts are activated by PTH and 
inactivated by calcitonin.  
Osteoblasts are the bone forming cells. To form the bone matrix they secret type I collagen 
and the non-collagenous protein osteocalcin. Osteoblasts derive from multipotential 
mesenchymal stem cells in the bone marrow. These cells can differentiate into different cell 
lines, like adipocytes, chondrocytes or osteoblasts. To differentiate into an osteoblast, the 
expression of the transcription factors Runx2 and osterix are important, whereas the 
expression of other transcription factors favors the differentiation into adipocytes or 
chondrocytes. Osteoblasts refill the resorption cavity. When the cavity is refilled with new 
bone matrix, osteoblasts die from apoptosis, get embedded into the matrix and turn into 
osteocytes, or become lining cells and stay at the bone surface. 
Osteocytes develop from osteoblasts. They represent mature bone cells and are embedded in 
the mineralized bone matrix. Osteocytes account for the largest number of cells in the bone. 
They have long slender processes, which are connected with each other via small canaliculi. 
As they form a communication network with the help of these slender processes, osteocytes 
are also referred to as the “brain” of the bone [44]. Osteocytes can sense mechanical forces 
and their viability depends upon physiological levels of mechanical stimulation. If these levels 
drop, the cells go into apoptosis, which seems to be the trigger to recruit new osteoblasts and 
to generate a new bone multicellular unit (BMU) [45]. 
A fourth common bone cell type are bone lining cells. They evolve from osteoblasts and 
cover all inactive bone surfaces. These cells can re-differentiate into osteoblasts [46].  
To orchestrate all bone cells, a number of local, systemic and central factors are necessary. 
Local factors are for example prostaglandins and nitric oxide which are produced by 
osteocytes. Others are several growth factors such as transforming growth factor beta (TGF-
β), which are released from the dissolved bone matrix and exert their effects on osteoblast 
precursors by enhancing their differentiation or activation [47]. Systemic factors are sex 
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steroids, parathyroid hormone (PTH), calcitonin, vitamin D3 or cytokines. They derive 
directly from endocrine glands and immune cells and have different direct and indirect actions 
on bone cells [48]. At the central level, leptin, a hormone produced by fat cells, has been 
shown to have inhibitory effects on bone formation via binding to hypothalamic receptors. 
The antiosteogenic function is mediated by the sympathetic nervous system which favors 
bone resorption by increasing the expression of the ligand of transmembrane receptor 
activator of NF-κB (RANKL) in osteoblast progenitor cells [49].  
Osteoclast differentiation is initiated and supported by several factors: Osteoblasts produce 
macrophage colony stimulating factor (M-CSF) and RANKL, a ligand to the transmembrane 
receptor activator of NF-κB (RANK). RANK is expressed in osteoclast precursors which then 
differentiate as soon as RANKL is present. The expression of RANK in osteoclasts and 
RANKL in osteoblasts is stimulated by M-CSF. Binding of RANKL to RANK is not only 
important for the differentiation of osteoclast precursors, but also for their fusion to 
multinucleated cells and the activity and survival of osteoclasts [47]. Osteoblasts also produce 
osteoprotegerin (OPG) which is a decoy receptor for RANKL and inhibits osteoclast 
differentiation. Thus, the RANKL/OPG ratio is important for osteoclast differentiation and 
regulates the activity of RANK in osteoclast precursors [50]. 
The number of osteoblasts is dependent on the lineage specification process. When 
differentiation of osteoblast precursors proceeds, replication gets less, the cells mature and 
acquire differentiated characteristics. Replication, differentiation, and survival of osteoblast 
progenitors is influenced by several autocrine and paracrine factors such as Wnt proteins, 
bone morphogenic protein, several growth factors (TGF-β, IGF-1, FGF-2) and interleukins. 
Many of these growth factors are produced by osteoblasts and deposited in the bone matrix to 
be released during osteoclastic bone resorption [51]. Osteocytes also produce many factors 
regulating bone remodeling. These factors are for example, nitrogen oxide and prostaglandins, 
but also sclerostin, the product of the SOST gene. Sclerostin prevents binding of Wnt to its 
receptor and therefore has a restraining effect on osteoblast differentiation [52]. 
 
2.1.2 Bone remodeling 
Bone is remodeled during the entire life time. The remodeling serves different purposes, for 
example optimizing bone microarchitecture or release of calcium. Harold M. Frost defines 
remodeling as “processes which turn over lamellar bone; it does not cause large changes in its 
quantity, geometry or size and it continues throughout life.” In contrast, to modeling, which 
he defines as “bone resorptive and formative processes which are associated primarily with 
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growth (…) Modeling serves primarily to alter the amount of bone present, and to determine 
its geometry and size.”[53]. Remodeling provides skeletal integrity and maintains the bones 
mechanical properties by replacing old bone with new resistant bone. During walking and 
load bearing, bone is exposed to loading throughout the whole life. Due to this loading small 
micro cracks can occur. A single micro crack does not affect the bone stability at all, but if 
damage accumulates, the strength of the bone becomes impaired and fractures may occur. 
Micro cracks are detected by osteocytes, which then trigger the remodeling. 
Bone remodeling occurs in so-called basic multicellular units (BMU), where the osteoclast 
mediated bone resorption and the subsequent osteoblast mediated bone formation are coupled. 
BMUs have different morphological shapes in cortical and trabecular bone. In the cortex a 
cylindrical canal is formed, which is about 200 µm long in humans. At the tip osteoclasts 
form the “cutting cone” digging a tunnel by resorbing bone. They are followed by osteoblasts 
forming the “closing cone” and refilling the defect with new bone [54, 55]. In the trabecular 
bone, osteoclasts act first as well. However, they dig a trench rather than a tunnel. Therefore, 
a trabecular BMU can be morphologically regarded as half a cortical BMU [56]. 
The bone remodeling cycle consists of 5 steps: 1) initiation, 2) bone resorption, 3) reversal 4) 
bone formation, 5) mineralization. Bone remodeling is initiated by osteocytes and their 
secretion of signaling molecules. Lining cells are retracted and osteoclasts start resorbing 
bone. After some time, the reversal phase starts where pre-osteoblasts differentiate into 
osteoblasts. These cells assemble at the bottom of the resorption cavity and start formation of 
new bone by secretion of organic matrix (osteoid). While bone formation progresses some 
osteoblasts are entombed within the matrix and form osteocytes. However, most osteoblasts 
die by apoptosis. The whole process terminates when the cavity is refilled and the remaining 
osteoblasts turn into flat lining cells [51]. The secreted osteoid is later mineralized and 
represents the newly formed bone [57]. In humans, the resorption phase of the remodeling 
cycle stops after one or two months and is followed by an approximate 3 month period of 
bone formation [58]. The average bone formation rate per bone surface is 0.038 µm
2
/µm/d 
compared to 0.15 µm
2
/µm/d in mice. These different bone formation rates can be explained 
with the different osteoblast life spans, which is 10-12 days in mice but about 150 days in 
humans [51].  
In healthy bones, resorption and formation are balanced with equal amounts of resorbed and 
newly formed bone. However, during the course of aging, remodeling tends to become 
unbalanced. In women at the age of 40 years and in men at the age of 50 years each BMU is 
slightly smaller than the cavity where it sits, leading to 10-30% negative imbalance at the 
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endosteal surface, covering the trabecular bone and the inner surface of the cortical bone and 
a zero or slightly positive imbalance at the periosteal surface, covering the outer surface of the 
cortical bone [59]. However, the number of BMUs is increasing in age. During aging, these 
processes lead to cortical thinning, increased cortical porosity, decreased trabecular thickness 
and decreased trabecular connectivity density [60]. 
 
2.1.3 Impairment of bone remodeling 
Impairments of bone remodeling can occur at many different levels. Bone formation and 
resorption is unbalanced, when the activity or number of osteoblasts or osteoclasts is 
changing. The two processes can also be uncoupled, leading to excessive bone formation or 
resorption. While an imbalance can occur at any time in the remodeling cycle, whether during 
resorption or during formation, uncoupling happens only during the reversal phase, when 
bone resorption changes into bone formation. When formation and resorption are coupled and 
balanced, the activation frequency (the number of newly formed BMU within a certain bone 
volume and specified time) can still be changed. An increasing activation frequency results 
initially in net bone resorption until formation is up-regulated and a steady state is reached 
with overall increased bone turnover [53]. All mechanisms in bone remodeling are linked 
together tightly. Therefore, diseases arising from impairments in remodeling will always 
present in a heterogeneous fashion, combining different aspects of impaired bone remodeling. 
Osteopetroses (Marble bone disease) are a group of inherited diseases that are characterized 
by increased bone density. Their prevalence is between 1 in 250 000 birth for autosomal 
recessive forms and 1 in 20 000 births for the autosomal dominant form. Osteopetroses are 
classified according to their malignancy, age of occurrence or partially on the responsible 
mutation. Only the main forms are presented here. 
Infantile malignant osteopetrosis is the most severe form of the disease. It is transmitted 
autosomal recessive and caused in most cases by loss of function mutations of the proton 
pump (vATPase) or the chloride channel (ClC7) involved in the acid secretion of the 
osteoclast. The impairment of bone resorption results in missing marrow cavities (“bone in 
bone appearance”), compression of cranial nerves due to closure of their canals in the skull 
base and extramedullary blood formation. Without treatment, patients die within their first 
years because of pancytopenia and immunosuppression. The only known cure is bone marrow 
transplantation.  
The autosomal dominant form of osteopetrosis is also called Albers-Schönberg-disease. This 
disease is often not diagnosed before adulthood. Typical clinical findings are abnormal 
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fractures and “sandwich vertebrae" on x-rays. The disease can be caused by mutations of the 
ClC-7, however the function of the channel is not completely lost, which allows a reduced 
osteoclast function and bone resorption. Therefore bone accumulates during growth, but 
remains stable afterwards [61].  
Osteopetrosis with renal tubular acidosis is an autosomal recessively transmitted mutation of 
the gene encoding carbonic anhydrase II. This enzyme synthetizes the protons secreted by 
osteoclasts via the proton pump. As protons also result from other processes in the cell, acid 
secretion is not completely disabled. Therefore this disease is also called intermediate 
osteopetrosis. However as carbonic anhydrase II is also highly expressed in renal intercalated 
cells and cerebral neurons, defects of the enzyme result in renal tubular acidosis and cerebral 
calcification causing mental retardation. 
Sclerostosis and Van Buchem disease (hyperostosis corticalis generalisata) are autosomal 
recessive inherited diseases that are characterized by an overproduction of bone mass, but 
normal bone resorption. Typical clinical findings in sclerostosis are generalized skeletal 
overgrowth, mainly apparent in the skull and the mandibles, and a large stature. The thickened 
sclerotic skull results in narrowed foramina of the cranial nerves. This leads to hearing loss, 
neurological pain and atrophy of the optical nerve. It is a rare disease found in the Afrikaner 
population in South Africa. The clinical findings of Van Buchem disease are similar, however 
milder than in sclerostosis. A skeletal overgrowth with enlarged jaw, skull and long bones can 
be found as well. The increased thickness of the skull results in hearing problems, 
neurological pain and rarely blindness. This disease is very rare as well and was found in a 
Dutch population. While for sclerostosis a mutation in the SOST gene was found resulting in 
complete absence of its gene product sclerostin, the cause for Van Buchem disease a deletion 
downstream of the SOST gene. This deletion only decreases the gene expression. Therefore 
clinical findings in Van Buchem disease are milder than in sclerostosis [62, 63]. 
Osteogenesis imperfecta (brittle bone disease, OI) is a genetic disorder affecting bone 
formation. It is caused by a variety of mutations of genes encoding collagen I. Depending on 
the mutated gene, the structure of the collagen molecule can be more or less disturbed. 
Therefore, eight different types of the disease are distinguished; however, the symptoms can 
vary widely between patients. Type I (osteogenesis imperfecta tarda) is the most common 
form of OI. Patients produce collagen with normal structure, but in insufficient quantities. 
Fractures occur typically in childhood, after puberty the bones become more stable. Scoliosis 
due to vertebral fractures is common, but no other deformations occur. Hearing loss is 
possible. Type II is the most severe form and leads to death in the perinatal period caused by 
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numerous fractures, especially multiple rib fractures, and underdeveloped lungs leading to 
respiratory failure. The most severe non-lethal form is type III. Typical clinical findings are 
short stature, blue sclera, limb and spine deformities, loose joints and respiratory problems. In 
OI type III the amount of formed collagen is enough, however the structure is damaged. Type 
IV is characterized by mild to moderate bone deformities, a shorter stature than average and 
not properly formed collagen. By studying histological sections of type IV patients, 
investigators noticed that some patients had a distinct pattern of the histological appearance of 
the bone, either "mesh-like" or "fish-scale-like". Furthermore these patients had other features 
in their medical history in common. Therefore type V and VI were introduced. The 
underlying cause for both types has not been identified yet; however it is not a collagen 
mutation. Type V is characterized by moderate to severe bone fragility. Typically after 
surgical interventions these patients develop a hyperplastic callus. Furthermore, the 
interosseus membrane between ulna and radius becomes calcified leading to a restricted 
forearm rotation. The histological appearance of bones is "mesh-like". In type VI a higher 
amount of osteoid was found in histology and the bones present with a “fish scale 
appearance”. Types VII and VIII are recessive forms of OI. Both of them are caused by 
defects of genes affecting collagen formation. Typical clinical findings for type VII involve 
short stature, short humerus and femur and coxa vera. Type VIII presents with severe growth 
deficiency and is lethal at an early stage in life. Most of the treatment of OI aims on 
controlling symptoms and maximizing independent mobility. Therefore, rehabilitation and 
also insertion of intramedullary rods, to straighten femora and tibia are most common. 
Pharmacological treatment, such as bisphosphonates, growth hormones or PTH has been 
applied with varying success. However none of them can cure osteogenesis imperfecta [64, 
65].  
Paget’s disease is a slowly progressing chronic disease, mostly affecting older people. The 
causing agent is not known; viral infections like measles, canine distemper respiratory 
syncytial virus or slow virus disease are discussed [66]. Genetic predisposition might also be 
involved. The disease presents with locally increased bone turnover and affects different 
skeletal areas to different degrees in an asymmetric fashion. The remodeling is accelerated 
regionally with increased activation of new BMUs and increased bone resorption and 
formation. The mineralization of the osteoid is normal but faster than in normal bones. As 
recently remodeled bone is replaced quite soon the mean tissue age is decreasing [67]. The 
symptoms are often quite mild and patients do not notice that they have Paget's disease, 
however severe bone pain can be associated with this disease as well. 
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An increased remodeling rate can be found as well in primary hyperparathyroidism. In this 
disease the secretion of PTH is up-regulated, independent of blood calcium levels. PTH acts 
as a bone remodeling enhancer and activates new remodeling sites, leading to decreased 
BMD. It also inhibits the activity of osteoblasts and therefore slightly decreases the mineral 
apposition rate [67, 68].  
Osteomalacia or rickets in children is often caused by lack of sunlight resulting in reduced 
activation of vitamin D. Sometimes also insufficient intake of calcium and vitamin D itself 
can cause this disease. The mineralization rate is reduced and the mineralization lag time 
prolonged. Large volumes of unmineralized bone matrix can be found and the osteoid seams 
seem to be resistant to osteoclastic resorption. This increased osteoid volume is due to 
increased forming surface areas, increasing mineral apposition rate and prolonged 
mineralization lag times [67].  
One of the most famous impairments in bone remodeling is osteoporosis. This term includes a 
number of remodeling disturbances which all result in a decrease in bone mass and an 
increase in fracture risk. Osteoporosis will be described in detail in the following paragraphs. 
 
2.2 Osteoporosis as a health problem 
The term Osteoporosis consists of the two Greek words “osteon”, which means “bone” and 
“poros”, which means “pore”. This disease is characterized by low bone mass and an 
impairment of the microarchitecture of the bone, leading to bone instability and high fracture 
susceptibility. The World Health Organization (WHO) defines bones as osteoporotic when the 
bone mineral density (BMD) is 2.5 standard deviations or more below the young adult mean 
[69]. However, a more recent definition includes the increased susceptibility to fractures 
because not only bone mass is found to influence bone strength. Many patients who 
experienced a fracture have to stay in hospital for a longer time or depend on nursery day care 
afterwards. This creates an enormous amount of costs every year for the health care systems. 
In the year 2000 costs for all osteoporotic fractures in Europe were about €36 billion. Due to 
the increasing elderly population these costs are expected to more than double to €76 billion 
by the year 2050 [8]. It is estimated that about 75 million people are affected by osteoporosis 
in Europe, USA and Japan [1]. In terms of days spent in hospital, osteoporosis accounts for 
more days than many other common diseases, such as diabetes, myocardial infarction or 
breast cancer in women older than 45 years. Having such a high impact on the society, a lot of 
research has been done in the past years to improve the understanding of the disease 
mechanisms and provide better treatment of osteoporotic patients. 
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Osteoporosis is often recognized as a disease typically affecting older women. It is often 
called “silent epidemic” because it develops over the years without the patients noticing it. 
Bone loss is gradual and painless and usually a low impact fracture is the first noticed 
symptom. The life time risk to have an osteoporotic fracture is almost 40% for a white women 
aged 50 years or older and just 13% for white man over 50 years of age [70]. Nevertheless, 
the fracture related mortality rate in men is higher than in women [2, 71]. While in men most 
of the osteoporotic cases are due to other diseases and medication, such as malabsorption of 
calcium and vitamin D or glucocorticoid intake, in women the main reason developing 
osteoporosis is the postmenopausal lack of estrogen [72].  
To improve the treatment and identify osteoporotic patients already at an early stage, attention 
is increasingly focusing on evaluation of fracture risks [73-77]. Bone mineral density (BMD) 
and its decrease during aging is influenced by several factors. Riggs et al. could show that it 
depends for example on the skeletal site and on gender [78]. This study showed that the 
decrease in BMD of the proximal femur in men is just two third of that of women, whereas 
the decrease in BMD at the lumbar spine is one quarter of that of women. Another factor 
influencing BMD is the weight at the age of menopause but also weight loss, which seems to 
be even more important than baseline weight [79]. Patients with a higher baseline weight 
showed a reduced bone loss. The highest bone loss was found in women with 60 kg or less. 
This study also suggests that a sedentary life style leads to a higher bone loss while no 
significant decrease in BMD was found in active women. The baseline BMD at the age of 
menopause also seems to be important as women with a high baseline BMD showed a higher 
bone loss than those with low baseline BMD. However, osteoporosis is a multifactorial 
disease. Assessing just bone mineral density would neglect other important risk factors. 
Interestingly enough, many fractures occur in patients without densitometrical osteoporosis 
[80].  
In big meta-analysis studies, fracture risks, which are independent of BMD were evaluated. 
These risks are for example parental history of fractures, with higher risks in patients having 
maternal than paternal fracture history. Also, if the patients themselves had experienced 
previous fractures, regardless if osteoporotic or not, fracture risk increased. Furthermore, 
alcohol intake and smoking increase fracture risk. The consumption of more than 2 units of 
alcohol per day was found to have already a significant effect [81-85]. 
Because so many factors with different degrees of impact contribute to the risk of fractures a 
tool called FRAX™ has been developed by the WHO to evaluate the risk of patients 
considering all risk factors [74]. This tool includes computer simulations that are based on the 
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analysis of cohort models from Europe, North America, Asia and Australia. It does not only 
take BMD at the femur into consideration but also clinical risk factors like gender, smoking, 
body weight, history of previous fractures and intake of medication. 
 
2.2.1 Types of Osteoporosis and their pathogenesis 
In 1947 Albright described two types of osteoporosis: postmenopausal osteoporosis, occurring 
right after menopause and senile osteoporosis affecting people later in life [86]. Because 
researchers did not find a bimodal distribution, this concept was not widely accepted. In the 
beginning of 1980s Riggs and Melton confirmed Albrights findings and renamed 
postmenopausal osteoporosis into Type I osteoporosis and senile osteoporosis into Type II 
osteoporosis [87]. Both, Type I and Type II osteoporosis belong to the primary osteoporoses 
where also the idiopathic osteoporosis, which affects mainly young people, can be added. The 
manifestation of primary osteoporosis is strongly influenced by the environment and lifestyle 
rather than determined polygenetically. The other big group of osteoporoses are the secondary 
osteoporoses. This kind of disease attributes to a secondary cause, such as malnutrition, 
anorexia, gastro intestinal disorders causing malabsorption, hypogonadism, 
hyperparathyroidism, thyrotoxicosis, immobilization, alcohol abuse, anticonvulsant drugs, 
corticosteroid therapy or radiation therapy. To distinguish between secondary and primary 
osteoporosis can be important for the choice of treatment. In secondary osteoporosis one 
should try to adjust the causes that lead to osteoporosis, whereas in primary osteoporosis the 
only chance is to treat the bone loss itself. 
This chapter will first focus on the primary osteoporosis and give some insight into the 
pathogenesis of the different types. Later a short overview over some secondary causes for 
osteoporosis will be given. 
 
Postmenopausal (Type I) osteoporosis 
Menopause is a process with complex endocrine changes. It lasts for many years and finally 
leads to the end of menses. Pathognomonic for the reduction in ovarian function is the 
decrease in 17β-estradiol concentration, which is the major hormone during the women’s 
productive life [88].  
Due to the sex steroid deficiency, the bone remodeling is unbalanced and stimulated. The 
accelerated bone remodeling consequently leads to bone loss, as resorption is much faster 
than bone formation. This hormone dependent increase in progressive bone resorption is 
mainly present in the first 5-10 years after menopause and represents the main pathogenic 
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factor in postmenopausal osteoporosis, although age related bone loss and suboptimal skeletal 
development must not be neglected as contributing factors [89]. It is generally known that 
estrogens have their main effect on the reproductive organs of a woman and therefore many 
estrogen receptors are present in these organs. Nevertheless, estrogen receptors can also be 
found in bone marrow stromal cells, osteoblasts, osteoclasts and osteoclast progenitors albeit 
to a much lesser degree [90]. Estrogens have a protectoral effect by balancing bone resorption 
and formation. They act multi-effective on osteoclasts. Osteoclast formation is decreased, 
while their apoptosis is increased and the capacity of mature osteoclasts to resorb bone is 
reduced. Furthermore, estrogens show an antiapoptotic effect on osteoblasts [91, 92]. Bone 
resorption is also hindered by an estrogen related decrease in osteoclastogenesis which is 
currently regarded as the main mechanism of estrogen action [93]. The blockade of 
osteoclasts is achieved with several pathways and the stimulation of bone resorption after 
estrogen deficiency is mainly due to a cytokine driven increase in osteoclast formation. 
Proliferation and differentiation of osteoclasts is dependent upon an equilibrium of cytokines, 
which can act autocrine and paracrine, such as RANK ligand (RANKL) and macrophage 
colony-stimulating factor (M-CSF). These factors are produced by bone marrow stromal cells, 
osteoblasts and activated T-cells [94]. RANKL not only binds to RANK, which is expressed 
on the surface of osteoclasts and their precursors, but also to osteoprotegerin (OPG). This is a 
soluble decoy receptor produced by many hematopoietic cells. When osteoblastic cells where 
treated with 17β-estradiol, mRNA and protein levels of OPG increased dose dependently. 
Thus OPG is an important antiosteoclastogenic cytokine, because it binds RANKL and 
therefore hinders it’s binding to RANK [94-96]. Several other cytokines are responsible for 
the up regulation of osteoclast formation. They are present in different conditions, such as 
inflammation, hyperparathyroidism or estrogen deficiency. One of these factors is tumor 
necrosis factor alpha (TNF-α), which enhances the stromal cell production of RANKL and M-
CSF and augments the responsiveness of osteoclast precursors to RANKL. Moreover, it 
stimulates osteoclast activity and inhibits osteoblastogenesis [97, 98]. In a study performed on 
transgenic mice insensitive to TNF-α, ovariectomy failed to induce bone loss, as it also did in 
TNF-α knockout mice and mice lacking a TNF-α receptor. In normal animals, not the 
production of TNF- α but the number of TNF producing T-cells is up-regulated after 
ovariectomy, by promoting T-cell activation which results in increased T-cell proliferation 
and life span [99, 100]. The gene expression of TNF-α and M-CSF is inhibited by sufficient 
levels of estrogen [101, 102]. 
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Another cytokine augmenting the effects of RANKL and M-CSF is interleukin 1 (IL-1). It is 
enhanced by TNF-α and also acts as a downstream effector of TNF-α as there is an IL-1 
dependent and independent pathway for the osteoclastogenic effect of TNF-α [103]. It 
promotes RANKL expression and stimulates osteoclast life span and activity. By converging 
their pathways, TNF-α and IL-1 combine their effects and thus produce a potent signal for 
osteoclastogenesis and inhibition of osteoblast function. They also have potent antiapoptotic 
effects on osteoclasts and prolong their life span [95]. A study with ovariectomized rats 
showed that the levels of TNF-α and IL-1 increased after ovariectomy, while bone mineral 
density was decreasing. Blocking IL-1 and TNF-α led to inhibition of osteoclastogenesis, 
reduced osteoclast activity and stimulated bone formation [104]. Not only IL-1, but also IL-6 
levels rise after menopause. Osteoclastogenesis is increased by high IL-6 levels, while the 
production of IL-6 is suppressed by estrogens. In IL-6 knockout mice bone loss after 
ovariectomy was prevented by averting the increase in osteoclast numbers [93]. Interleukin 7 
(IL-7) is another cytokine and potent inducer of bone destruction. After ovariectomy it has 
been shown that IL-7 levels are significantly up regulated. When IL-7 was neutralized in vivo, 
ovariectomy induced bone loss was prevented and bone formation seemed to be stimulated 
[105].  
In general, it can be said that the protective action of sex steroids is dependent on the ratio of 
RANKL to cytokine induced osteoclastogenesis and levels of OPG. With the loss of sex 
steroids, there is a lack of the apoptotic effect on osteoclasts and a dramatic increase of 
apoptosis in osteoblasts and osteocytes. Therefore, the activity of osteoclasts compared to the 
activity of osteoblasts is much higher than in normal subjects. [90]. 
As a result of the deeper cavities digged by osteoclasts, bone trabeculae become thinner and 
are resorbed eventually thus leading to reduced bone strength and a higher fracture risk [106]. 
For example in rats the compressive strength of a vertebral body and the bending strength of 
the femur  have been found to be decreased after ovariectomy [107]. However, the literature 
about mineral content in osteoporotic bones is somewhat inconsistent. Some studies revealed 
no changes or slight decrease after loss of sex steroids, whereas others could show an increase 
of mineral content and an altered type of collagen and even a lack of collagen [108-110]. A 
study performed on ovariectomized rats revealed an increased stiffness, yield strength, yield 
strain, ultimate stress and an increased cross-sectional area at the tibia compared to normal 
rats. At the tissue level, the mineral content was elevated in contrast to the overall bone 
mineral density, which was reduced [106]. Another study observed a reduction of the mineral 
to matrix ratio in the center of bone trabeculae [111]. These studies taken together provide 
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strong evidence for changes at the tissue level during the development of osteoporosis. These 
changes also affect mechanical strength of osteoporotic bone. Precise mechanisms for the 
increase in tissue level properties, such as bone strength and stiffness and mineral content are 
still not completely clear. However, a computer simulation revealed that, if tissue stiffness is 
increasing, the bone structures changes to bones with lower bone mass and increased 
anisotropy, as it is typical for osteoporotic bones [112]. An alternative theory is that, as some 
trabeculae disappear during development of osteoporosis, the remaining trabeculae undergo a 
compensatory shift in mineral content to counteract the loss of structural strength [106]. 
However, this compensatory shift can only protect from osteoporotic fractures until a certain 
amount of bone loss. Afterwards, it is not sufficient anymore and osteoporotic fractures occur. 
 
Senile (Type II) osteoporosis 
Riggs et al. discovered that the BMD of healthy subjects at the age of 90 is about 50% less in 
the femur and about 40% less in the spine compared to 20 year old subjects. The authors 
showed that this decrease is linear in both sexes, but the rate of decrease was about two third 
lower in man than in women [78]. At the age of 75, the regression for the proximal femoral 
BMD had decreased to more than two standard deviations below that of a normal young adult. 
Senile osteoporosis usually occurs in people older than 75 years. It may affect half of the 
aging women and one fourth of aging men, giving a female to male ratio of 2:1 [78, 87]. 
Patients experience hip fractures as well as spine, pelvis or humerus fractures. In most of the 
elderly subjects, decreased calcium absorption was found, leading to decreased plasma 
calcium levels. The data about levels of vitamin D3 is somewhat inconsistent. Some studies 
found a decrease in vitamin D3 levels [113, 114], others found no change in vitamin D3 levels 
with age [115, 116]. Nevertheless, calcium absorption was only increased in women not 
having experienced vertebral fractures before. This leads to the hypothesis that the circulating 
vitamin D3 does not bind properly to the intestinal receptor in women having senile 
osteoporosis. Thus it hinders the active, vitamin D dependent transport of calcium, which 
results in calcium malabsorption [117-119]. A major difference to postmenopausal 
osteoporosis is the increased serum level of PTH [87]. This could possibly be due to the 
malabsorption of calcium leading to hypocalcaemia which induces a secondary 
hyperparathyroidism with increased PTH levels and increased bone turnover. 
At the micro architectural level of bone, there are three generally accepted processes leading 
to bone loss in senile osteoporosis. This bone loss appears in all compartments of the bone. 
The most important process is the bone loss in the trabecular region. The second one is the 
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continued net bone resorption at the endocortical surface and the third process is occurring in 
the cortex by a decrease of cortical bone [120]. As a result of the endosteal resorption the 
cortex becomes porous at the interface to the cancellous bone. When the endosteal resorption 
continues, the remaining structures are more the shape of trabeculae. Consequently these 
structures are accounted for cancellous bone [121-123]. 
It has been shown that the rate of bone loss varies at different skeletal sites throughout life. 
Trabecular bone loss, for example already starts at young adulthood in men and women, while 
cortical bone loss begins perimenopausal in women and after the age of 75 years in men 
[124]. Rates of trabecular bone loss were found to be similar at peripheral sites (distal radius 
and distal tibia) in postmenopausal women compared to premenopausal women. Nevertheless, 
in women in the lumbar spine the rate was 60% higher than at the peripheral sites. Similar 
findings could be seen in men where the rates of trabecular bone loss at peripheral sites were 
similar to those in younger men. However, in the lumbar spine a twofold greater rate was 
found in older men. In the cortical area another scenario appeared in both sexes. In 
premenopausal women no significant bone loss was found, in young men just a very low, but 
significant bone loss. This bone loss accelerated substantially in subjects over 50 years, it 
even increased 2-4 fold in men after the age of 50. This shows that there is a constant loss of 
bone throughout adult life, which is accelerated in elderly people in the cortical area leading 
to a deteriorated micro architectural structure of the bones. 
While trabecular bone volume is decreasing, bone marrow adipose tissue is increasing and 
can fill up to 90% of the bone marrow cavity [125]. As both, osteoblasts and adipocytes 
derive from mesenchymal stem cells and can differentiate into each other, it has been 
postulated that pluripotent mesenchymal stem cells, located in bone marrow stroma are 
redirected from the osteogenic program to the adipogenic program, thus leading to reduced 
numbers of osteoblasts in elderly people [126]. 
Not only the loss in bone mass, but also the micro architectural changes in the trabecular 
region need to be taken into consideration. Their importance for the development of 
osteoporosis and subsequent fractures was first highlighted by Parfitt [127]. He investigated 
the structural changes with age and showed that the decrease in trabecular plate density rather 
than plate thickness had the main contribution to the decrease in bone volume. This leads to 
the conclusion that with age the mainly continuous trabecular network, which is typical for 
young people, is transformed into a mainly discontinuous network being typical for the 
elderly. While studies for trabecular separation (Tb. Sp) all come to the same conclusion 
[128-130], findings for trabecular thickness (Tb. Th) are more controversial. One study did 
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not see any significant decrease [131] while others could show a significant decrease either in 
all trabeculae [132] or in the horizontal trabeculae only [128, 129]. In a study using micro-
computed tomography Tb. Sp and Tb. Th were studied globally and locally at a three 
dimensional level [133]. Here an increase in Tb. Sp was found. In Tb. Th no age-related 
changes were seen at a global level but at the local level, where the thickness was investigated 
separately for plates and rods. In the lumbar spine of elderly subjects, Tb. Th was increased at 
both levels. As Stauber et al. also saw a decreasing number of rods, they hypothesized that 
with age the trabeculae first become thinner and eventually vanish. In the lumbar spine, 
trabeculae are rod like already in very young people. As during aging rods become thinner 
and very thin rods eventually vanish, the trabecular bone structure is transformed to longer 
and on average thicker rods. In the femoral head trabeculae are plate like the entire life. 
Changes during aging occur as thinning and perforation of the plates, leading to new plates. 
As at the same time interconnecting trabeculae are lost, connectivity density can either 
increase or decrease. Therefore, Stauber et al. stated that the femoral head is not a good 
skeletal site to study age related changes. 
According to the quantum concept [59] there is a balance between the amount of bone 
resorbed from the surface by osteoclasts and the refilling of the cavity by the osteoblasts. An 
imbalance in these two processes results in bone loss. Parfitt stated that rapid bone loss, which 
usually occurs after menopause, is due to deep osteoclastic penetration of the bone, whereas 
slow bone loss, which is typical for senile osteoporosis is due to a shallower deposition of 
bone by osteoblasts [127]. This decrease in osteoblast activity is due to a decreased number of 
osteoblasts, shorter lifespan and higher frequency of apoptosis [57]. Osteoblast number is not 
only reduced by increased adipogenesis, but also because of an increased apoptosis of 
osteoblast precursor cells, shown in SAMP6 mice, which age prematurely [134]. In another 
study performed with mice it was shown that osteoblastic cells from aged animals have a 
much greater potential to induce osteoclastogenesis than cells from younger animals. This is 
associated with a higher expression of RANKL and M-CSF, which both contribute to the 
recruitment and formation of osteoclasts [135]. This mechanism shifts the imbalance of 
osteoblasts and osteoclasts even more towards osteoclasts in elderly subjects. 
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Idiopathic osteoporosis 
Idiopathic diseases are diseases with unknown causes. They are diagnosed after excluding all 
other possible reasons. 
The idiopathic juvenile osteoporosis was first described in detail by Dent and Friedman in 
1965 [136]. As it is an extremely rare disease, not even 200 cases have been reported in 
literature [137]. It affects young children, with no gender predilection between 8 and 14 years 
and is in contrast to the other types of osteoporosis self limitating. Before its limitation it is an 
acute disease which runs for 2-4 years [138]. During this acute phase growth arrests and 
multiple fractures occur. Typical symptoms are a gradual onset of pain in the back, the hip, 
knee, feet, difficulties and slowness in walking and an abnormal gait [139]. Often the children 
have vertebral compression fractures and fractures of the long bones. Wedge shaped, 
biconcave vertebrae are found as well. In radiologic studies, new abnormal formed bone may 
be present in the metaphyseal areas, which appear as a radiolucent submetaphyseal band and 
represent the so called “neo osseous osteoporosis” which is typical for idiopathic juvenile 
osteoporosis [137]. The bone mineralization rate is below the normal [140] and bone turnover 
measured in terms of activation frequency and bone surface-based remodeling parameters is 
much lower in affected than in healthy children [141]. The pathogenesis of the disease is 
unknown. Because of its close relationship to puberty, the influence of hormonal factors has 
been taken into consideration, but no direct evidence has been found. To diagnose idiopathic 
juvenile osteoporosis any secondary causes for osteoporosis, such as treatment with steroids, 
have to be excluded.  
 
Secondary osteoporosis 
Secondary osteoporosis means by definition that the bone loss results from a specific, well-
defined primary clinical disorder or is a side effect of treatment. It is reversible, once the 
disease is treated or causative treatment is stopped. To treat secondary osteoporosis, the cause 
for bone loss has to be determined first. Differing numbers about the prevalence of secondary 
osteoporosis can be found in literature. It is estimated that in about 20 % of the 
postmenopausal osteoporosis cases another underlying secondary cause is the actual reason. 
In men, secondary osteoporosis is about 64 % of all cases [142, 143]. As there is a huge 
variety of underlying diseases, just a few will be explained in more detail in this paragraph. 
Diseases are for example endocrine disorders, such as Cushing syndrome, diabetes mellitus, 
hyperthyroidism, hyperparathyroidism or gastrointestinal diseases, gastrectomy, chronic 
active hepatitis, alcohol related liver diseases, malabsorption syndromes, pancreatic 
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insufficiency or any other diseases, for instance leukemia, multiple myeloma, amyloidosis, 
multiple sclerosis and rheumatoid arthritis. 
 
2.2.2 Pharmacological treatment 
The intention of every osteoporosis treatment is to reduce the fracture risk of a patient and 
increase the quality of life. Usually BMD is measured to monitor the success of treatment, but 
not all reduction in fracture risk can be explained by this parameter. Also bone quality is an 
important parameter, but as this is difficult to measure, BMD is still the standard measure in 
clinics [144]. 
Medical management strategies in osteoporosis treatment include change of life style, such as 
to quit smoking, moderate intake of alcohol, adequate protein, calcium and vitamin D intake 
and the avoidance of immobility [41]. However, these measures are only supportive to the 
pharmacological treatment. 
Pharmacological treatment of osteoporosis can follow two different strategies: Antiresorptive 
drugs aim at the maintenance of the existing bone by decreasing or stopping the net bone loss, 
while anabolic drugs increase bone mass. Most of the drugs available on the market are 
antiresorptive drugs, such as bisphosphonates, calcitonin, hormone replacement therapy and 
selective estrogen receptor modulators (SERM). These drugs reduce the activation frequency, 
which represents the number of remodeling events, in trabecular and cortical bone. If the 
surface based remodeling is reduced, the number of weak spots is reduced as well, which 
lowers the chances to create discontinuities in the trabecular network [47]. A new drug was 
approved by the FDA in the U.S. and also in the European Union in the year 2010. 
Denosumab is a RANKL antibody that blocks the binding of RANKL to its receptor RANK. 
This imitates OPG function and therefore suppresses bone resorption by inhibiting the 
development and activity of osteoclasts [145]. Anabolic drugs of which PTH is the best 
known example increase bone turnover and change the balance towards a net bone gain. As 
bone resorption and formation are coupled processes, it has always to be kept in mind that by 
modulating one of the processes, the other is also affected. This means that antiresorptive 
drugs not only impair osteoclast function but secondly also osteoblast function. Furthermore 
when administering anabolic drugs a subsequent increase in osteoclast activity can be seen 
[47]. Therefore, an ideal drug would stimulate osteoblasts and inhibit osteoclasts at the same 
time. Strontium ranelate is such a drug stimulating bone formation and inhibiting bone 
resorption, however its mechanism of action is not known so far. But in vitro studies revealed 
that it can activate calcium sensing receptors in osteoblasts because of its similarities to 
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calcium. Activation of these receptors has positive effects on pre-osteoblast replication and 
differentiation, collagen type I synthesis and bone matrix mineralization. Furthermore, OPG 
levels are increased and RANKL decreased, leading to inhibition of osteoclast differentiation 
and activity [146].  
 
Antiresorptives – Bisphosphonates 
The most common antiresorptive drugs are bisphosphonates. Bisphosphonates are compounds 
derived from pyrophosphates where the two phosphate groups are connected via a carbon 
group (P-C-P). They are resistant to enzymatic degradation. Therefore, they show a very long 
half-life in the body, which can be in bone even as long as the half-life of the tissue itself. 
Bisphosphonates have a high affinity to bone mineral and inhibit the crystallization of calcium 
carbonate and calcium phosphate. The inhibition of osteolysis is mediated by a reduced 
number of osteoclasts and bone forming units. Bisphosphonates accumulate in osteoclasts and 
show four mechanisms of action [147]: First they inhibit the recruitment of precursors, 
secondly the adhesion of osteoclasts to bone is impaired, then osteoclast activity is inhibited 
and finally osteoclast apoptosis is induced [147, 148]. Meanwhile two generations of 
bisphosphonates are available. The second generation, such as zolendronate and risendronate 
contains a nitrogen atom in its alkyl chain, which is not present in the first generation, 
represented by etidronate or clodronate. Bisphosphonates of the first generation are 
incorporated into non-hydrolysable cytotoxic ATP analogues in osteoclasts and cause 
apoptosis of these cells. Bisphosphonates containing a nitrogen atom are more potent than the 
first generation. They inhibit the mevalonat pathway, resulting in an impaired cell function 
and eventually apoptosis [149]. It has also been shown that bisphosphonates are able to 
stimulate osteoblasts to produce an osteoclast inhibitory factor [150]. Side effects after oral 
administration are nausea, diarrhea and it may even cause esophageal cancer. But also more 
severe effects, like osteonecrosis of the jaw or atypical subtrochanteric and diaphyseal 
femoral fractures are associated with bisphosphonate treatment [32, 33]. Sometimes 
hypocalcaemia can be seen due to complexation with calcium ions in the gut. 
It is known that bisphosphonates decrease bone remodeling. Therefore, some authors [151-
153] were arguing if this could also affect the adaptation to mechanical loading negatively. 
For example Feher et al. tested the effect of different bisphosphonates on the load induced 
bone formation in the rat ulna [154]. In vivo loading was performed every other day for one 
week after bisphosphonate injection. Calcein was injected on day one and the second time 9 
days after the last loading bout to label actively forming periosteal surfaces. Five days after 
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the last calcein injection animals were killed. In non-loaded animals, no significant 
differences were found in periosteal bone formation rates between bisphosphonate treated and 
control animals. However, loading in bisphosphonate treated animals increased bone 
formation compared to non-loaded bisphosphonate treated animals. Vehicle treated animals 
were loaded as well, however the effect of loading in bisphosphonate treated animals was 
significantly higher than in vehicle treated ones. This proves that mechanical loading still 
exerts stimulatory effects on bones, no matter which bisphosphonate was injected. As 
bisphosphonates decrease bone remodeling it is interesting to see whether the effects of early 
or late start of bisphosphonate treatment are the same. In one study, performed in 
ovariectomized rats, bisphosphonate was injected either right after ovariectomy or eight 
weeks after ovariectomy [37]. In the early treatment group no microstructural changes could 
be seen compared to sham operated animals. With late injection of bisphosphonates the 
microstructural parameters were still better than without any treatment, but not as good as 
with early onset of treatment. These findings support the thesis that with the reduction in bone 
remodeling adverse effects of estrogen deficiency can be inhibited best at an early time point 
after ovariectomy. Therefore bisphosphonates counteract directly the effects of loss of 
estrogen. These findings were endorsed by another study, where rats were injected with 
bisphosphonates two weeks after ovariectomy [155]. Already four weeks after the injection 
the microstructural parameters were back to baseline levels. After six weeks, an increase in 
bone parameters was found, values were similar to those of sham animals. This proportion 
was maintained until the end of the study after 12 weeks. Also the effects of different dosing 
were investigated in ovariectomized rats. In this study the authors could show a dose 
dependent improvement in bone micro architectural structure after injection of 
bisphosphonates. However, the bending modulus and cortical strength did also increase, but 
not dose dependently. Higher doses of bisphosphonates just increased the structural properties 
but not subsequently the tissue character [156]. 
 
Anabolics – Parathyroid hormone (PTH) 
The level of free calcium in the blood is strictly regulated. As soon as it drops, PTH is 
secreted from parathyroid cells. PTH increases plasma calcium levels, by increasing bone 
resorption, calcium reabsorption in the kidneys and intestinal Ca absorption via an increase in 
Vitamin D levels. In bones it induces osteolysis. Osteoclasts do not have PTH receptors. 
However, when PTH binds to osteoblasts, RANKL is built into the plasma membrane of 
osteoblasts, which can then interact with RANK, located on osteoclasts. RANKL activates 
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RANK and therefore activates osteoclastogenesis [157, 158]. To exert these effects, PTH 
secretion is controlled tightly and can be adjusted to the actual need during the entire day. The 
secretion is regulated via a Ca-sensing receptor on parathyroid cells. Long term high PTH 
levels lead to increased bone remodeling and resorption. However, when PTH is administered 
intermittently (e.g. once daily) in a high concentration, it was found to have an anabolic effect 
on bone. Most bone formation with PTH treatment is occurring at sites of previous resorption 
in pre-existing BMU and adjacent to these BMU. In humans, an increased bone formation is 
manifest already 28 days after the onset of therapy and the accretion of bone mass is most 
rapid during the first 6 to 12 months of PTH treatment. [51, 159] This anabolic effect is 
caused by an increase in the osteoblast number by activation of survival signals and delaying 
of osteoblast apoptosis as shown in mice. [51] Also quiescent lining cells are activated. 
Kousteni et al. showed that PTH overrides the mechanisms that limit osteoblast number. In 
replicating osteoblast progenitor cells it induces the exit from the cell cycle by reducing the 
number of cells in S-phase and increasing the number of cells in G0/G1 and G2+M phase. 
Thereby it sets stage for pro-differentiating and pro-survival effects [160]. An experiment 
performed in mice revealed an evident decline in osteoblast apoptosis after two days of daily 
PTH injections [161]. After four injections the prevalence of apoptotic osteoblast was reduced 
by 50%. However, a study performed in humans showed an increase of osteoblast apoptosis 
after 28 days of intermittent PTH injection, but also a positive correlation between osteoblast 
apoptosis and bone formation rate [28, 161]. Moreover, intermittent PTH shifts the 
differentiation from mesenchymal stem cells towards osteoblasts and away from adipocytes. 
A decrease in adipocytes in the bone marrow was found in monkeys treated with intermittent 
PTH [22]. PTH acts via two molecular pathways: Binding to a G-protein coupled receptor it 
subsequently mediates the activation of adenylate cyclase, increasing the levels of cAMP and 
activating the protein kinase A. The second path is the Gaq mediated activation of protein 
kinase C. Studies have shown, that the cAMP pathway is the important one to increase 
osteoblast number. An increase in cAMP also results in higher levels of IGF-1, which 
increases the differentiation and has positive effects on survival of osteoblasts. Also FGF-2 
levels are elevated. This elevated levels enhance proliferation and reduce apoptosis of 
osteoblast progenitor cells [51]. Intermittent PTH also increases Runx2 mRNA, activity and 
protein levels. In contrast, constant PTH levels cause a sustained decrease in Runx2 levels 
[51, 162-164]. Osteocytes as primary mechanosensory cells in bone are involved in the 
anabolic actions of intermittent PTH, as well. A reduction in sclerostin mRNA has been found 
after administration of PTH. This explains the synergistic effects of PTH and mechanical load 
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bearing, because with mechanical loading, sclerostin levels decrease as well [165, 166]. In 
osteoclasts, intermittent PTH transiently increases RANKL levels and thus increases 
resorption activity. This increased resorption counterbalances the increased release of 
osteogenic growth factors from the bone matrix. However, at an early time point after the 
onset of treatment, the number of osteoblasts is increasing, but neither number nor activity of 
osteoclasts is elevated. Only at a later time point increased resorption can be monitored. To 
maximize bone formation rate and minimize bone resorption rate it is suggested to administer 
PTH for short periods in a cyclic fashion [51, 167, 168]. 
Recently a study to gain better insights into the mode of action of PTH was published [169]. 
The authors continuously infused PTH or soluble RANKL into female mice for 5 days. As 
PTH increases RANKL levels, the authors wanted to investigate which effects are due to 
increased RANKL levels and which are caused by other mechanisms. The number of 
osteoclasts and osteoblasts were increased with both infusions. However, the osteoblasts to 
osteoclasts ratio and bone formation rate were increased a lot more after PTH infusion. PTH 
also maintained cancellous bone, which was lost with RANKL infusion. Furthermore, an 
increase in the number of blood vessels in the bone marrow was visible only with PTH 
infusion. Therefore, the authors state, that besides the activation of an osteoclast dependent 
pathway, other mechanisms contribute to the actions of PTH. This study investigated the 
anabolic effect of intermittent PTH in female mice. However other studies also focused on 
male animals. Male rats were administered to intermittent PTH injections five weeks after 
orchiectomy [23]. With these injections the orchiectomy induced bone loss could be reversed. 
Even more bone was gained as there was a 155 % recovery after 6 weeks of PTH injections. 
Several studies also investigate in the combinatorial effect of intermittent PTH injection and 
loading. Growing mice were subjected to loading or PTH treatment for 6 weeks [170]. After 
these 6 weeks an increase in BMD and BMC could be seen in all groups, however, this 
increase was more prominent with PTH treatment. Nevertheless, the strength increased to a 
similar extends in both groups. These findings emphasize the theory that PTH induces bone 
formation everywhere in the bone, while loading induces formation only at sites where there 
is a mechanobiological need. Therefore, to increase the bone strength by 20 % with loading 
just 4 % increase in BMC was needed, whereas with PTH injection BMC had to increase by 
11 % to improve bone strength by 20 %. In another study, mice were injected intermittently 
with PTH for 6 weeks [171]. During the last two weeks they were additionally subjected to 
loading 3 times a week. This study found a synergistic effect of loading and PTH injection in 
the trabecular and cortical bone.  
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2.3 Bone and biomechanics 
 
2.3.1 Bone mechanobiology  
At the end of the 19
th
 century Julius Wolff stated that healthy bone will always adapt to the 
loads applied to it. If loading increases, bone remodeling changes the inner architecture. 
Trabeculae will become thicker or the cortex will thicken as well. In contrast, if loading 
decreases, more bone will be resorbed and the bone will become weaker due to increased 
remodeling [172]. Almost 100 years later Frost proposed the mechanostat theory. He said that 
bone mass always “fits the typical mechanical usage of healthy skeletons in a special sense: 
the mass can be over-adequate but never inadequate.”[173]. This implies the need for a 
mechanism to control the process of gaining and loosing bone mass. Frost compared this to a 
thermostat, which can be turned ON and OFF, and called this control mechanism 
“mechanostat”. Weight bearing and mechanical loading deform the bone and cause 
compression and tension. In vivo experiments showed that bones react differently to different 
strains. Below 100-300 micro strain remodeling is enhanced. This leads to bone loss as it can 
be said that one BMU resorbs 20 parts of bone and replaces 19 parts. In contrast, high 
mechanical loading reduces the number of BMU and the ratio of resorbed to replaced bone is 
shifted towards the replaced bone. If strains are between 1500-3000 micro strains or even 
higher, modeling occurs, which leads to increased cortical bone deposition resulting in lower 
peak strains. Hence, the mechanostat can be turned ON and OFF. Between 300 and 1500 
micro strains there is the so called “lazy zone” where bone mass is maintained. Apart from 
modeling and remodeling, growth is the second biological mechanism that belongs to the 
mechanostat. Longitudinal growth can be enhanced by mechanical usage and is retarded by 
disuse, but not reversed. This mechanostat mechanism can be made over reactive or deaf by 
several diseases or agents, such as intake of glucocorticoids. The three main principles in 
mechanoregulation of bone are: transduction of the loading signal, sensing of the transduced 
signal and cell response to the loading impulse [174]. Mechanosensation is a multiscale 
process translating the mechanical signal from the organ level to smaller scales and creating a 
biological respond, starting at the biochemical level scaling up to the organ level. When the 
bone is loaded, stresses and strains are perceived at the tissue level causing pericellular 
mechanical changes which then present the mechanical stimuli to the cells [175]. But where 
are the elements in the bone sensing mechanical loading? In principle all eukaryotic cells are 
mechanosensitive, but osteocytes have been shown to be the main mechanosensory cells in 
bone [176]. Osteocytes sit in lacunae and have long slender processes that extend in small 
canals (canaliculi) within the matrix. They connect with each other, but also with lining cells 
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and osteoblasts via gap junctions, forming a complex three-dimensional network of 
communicating cells within the bone [177]. Osteocytes respond to the different strain fields 
occurring around the lacuna. In the front of the cutting cone, where low strains occur, they 
increase osteoclast activity, whereas around the closing cone, where strains are high, 
osteoblast activity is facilitated [178]. The exact pathways of how osteocytes sense 
mechanical loading are not fully understood, yet. However, the fluid flow in the canalicular 
system seems to be the main mechanism informing the cells about the level of loading [179]. 
Not only for mechanotransduction, but also to supply all osteocytes, especially the deeper 
located ones, with nutrients and to exchange waste, this fluid flow is very important [176, 
180, 181]. During loading fluid shifts occur, which create shear forces and streaming 
potentials. These shear forces are sensed by osteocytes that have filamentous attachments 
from the cell membrane to the walls of the canaliculi [182]. Strains needed to induce cell 
response in vitro are about 1 - 10 % strain, which is much higher than the maximum strains 
seen in vivo with just about 0.2 - 0.3 %. Therefore, bone seems to enhance the mechanical 
loading signal. The fluid flow transmits the mechanical information and transduces small 
strains into larger signals, which then can be easily detected by the osteocytes [179, 181]. The 
lacunae in which osteocytes reside could also be involved in amplifying the loading signal 
[175]. Bone formation is more enhanced by dynamic than by static load. Therefore strain rate, 
rather than amplitude, is important to induce bone formation. Nevertheless, both magnitude 
and frequency are important parameters for bone formation. Low magnitude, high frequency 
strains are quite common in nature and are capable of stimulating bone growth. Vibration, 
also a typical high frequency low magnitude type of loading, has been shown in several 
animal studies to have positive effects on both cortical and cancellous bone [183]. Recently, 
also human trials confirmed these findings [184, 185]. High rates of loading, for example in 
high impact physical activity, have a great osteogenic potential. But high magnitude low 
frequency strain rates are osteogenic as well, although they do not occur very often in 
physiological activity [186, 187]. Besides the mechanical effect, the electrokinetic effect 
which occurs due to streaming potentials, evoked by convective transport of ions, plays an 
important role in activating osteocytes [188]. The fluid flow activates integrins and opens ion 
channels. Integrins are transmembrane proteins that bind to the extracellular matrix (ECM). 
Their activation leads to changes in ECM protein formation and also to stimulation of growth 
factor signaling in bone stromal cells. After opening of stretch activated ion channels the 
calcium levels in the cells increase. Intracellular calcium levels are also increased by an IP3 
mediated calcium release from internal stores [189, 190]. Increasing levels of calcium, IP3 and 
2 Literature review 2.3 Bone and biomechanics 
 
~ 34 ~ 
cAMP lead to the production of signaling molecules, secretion of prostaglandins and nitric 
oxide (NO). NO production in osteocytes increases rapidly after applying mechanical stress. 
In animal studies, bone resorption caused by immobilization was inhibited by treatment with 
indomethacin, a non-steroidal anti-inflammatory drug [191, 192]. 
The effect of loading on bone seems to be a local phenomenon. As shown in several studies, 
loading of one bone does not affect any other bone in the body [193]. Furthermore, it has been 
shown that there seems to be a sex related difference in the response to mechanical load. In a 
study performed on rats, growing male rats gained 4 to 6 times more bone with loading than 
female rats. Also in mature rats the male ones showed a higher response to loading than 
females. However, in female rats a higher bone density was observed, which could explain the 
reduced response to mechanical loading. These differences in loading response have already 
been shown in tennis players, where the load induced bone gain was a lot bigger in male 
players than in female [194, 195]. 
 
2.3.2 Mechanical intervention in osteoporosis 
It is widely known and accepted that physical exercise is necessary to maintain bone mass and 
to achieve a high peak bone mass during growth. Athletes are known to have a higher BMD 
than people with a sedentary life style. Especially athletes engaged in high impact sports, for 
example jumping, showed a higher BMD than athletes not performing high impact sports 
[196]. However, not every exercise can be recommended in every part of the lifetime. In order 
to gain a peak BMD as high as possible, the International Osteoporosis Foundation (IOF) 
recommends children and adolescents to make a lifelong commitment for an active life and 
participate in weight bearing activities such as basketball, volleyball or gymnastics, which are 
more effective than weight supporting activities, such as swimming or cycling. Preferably, an 
activity that works all muscle groups should be selected. Furthermore, young people should 
avoid immobilization and eat a well-balanced diet, which is rich in calcium and proteins. 
Young adults and premenopausal women should do sports in order to maintain BMD and thus 
prevent osteoporosis. In postmenopausal women, maintenance of bone strength is important 
as well. Nevertheless, the main goal of physical therapy in these women is usually to increase 
muscle mass in order to reduce the risk for falls and to improve body balance and strength 
[197]. In patients already diagnosed with osteoporosis, the IOF recommends that the exercises 
should target posture, balance, gait, coordination and hip and trunk stabilization. It is 
important to note that dynamic abdominal exercises, such as sit ups or trunk flexions, must be 
avoided as they can cause vertebral crush fractures. Also exercises involving abrupt or 
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explosive loading or high impact loading should be avoided. Furthermore, normal daily 
activities like bending downwards to pick up objects can cause adverse effects like fractures. 
Therefore, proper instructions how to perform everyday tasks should be given.  
Under a mechanobiological point of view, these recommendations are quite reasonable. Bone 
adapts to the mechanical load applied to it during growth and adulthood. In the adult body 
repeated load bearing leads to energy accumulation and therefore occurrence of micro-
fractures. To remove this damage a well-balanced bone remodeling is important [44]. If bone 
remodeling is impaired this can lead to bone damage already at normal levels of loading. The 
bone can also be damaged if an overload occurs due to loading which exceeds the bone 
strength [198]. In elderly people often muscle atrophy, so called sarcopenia, can be seen. The 
reduced muscle strength disturbs the dynamic and static balance of the body thus leading to 
increased risk of falls [199]. To prevent the onset of osteoporosis, daily physical activity with 
exercises containing weight bearing and dynamic elements, such as walking, jumping, 
dancing, weight lifting, should be performed. But also exercises without mechanical loading 
to improve muscle strength, balance and general condition are recommended [44]. A study 
performed on postmenopausal women with established osteopenia showed that very intensive 
exercise with high mechanical loading could increase BMD at the lumbar vertebrae. No 
increase in pain was seen, which could have resulted from micro-fractures due to overloading 
of the bone. However, it must be said that the subjects tested in this study were quite active 
already before the start of the study [200]. Another study in elderly women with low bone 
mass investigated the effects of stretching, agility or resistance training on cortical bone 
density [201]. The authors saw a loss of cortical bone density in women, just doing stretching, 
whereas women performing agility training gained 0.5% in cortical bone density and women 
doing resistance training gained 1.4% in cortical bone density. Another study on 
postmenopausal women subjected one upper limb to exercise and used the contralateral side 
as control. The findings are somewhat contradictory to other studies. It was shown that high 
intensity, low repetition resistance exercise is effective in increasing BMD, whereas low 
intensity, high repetition endurance exercise does not show any effects [202]. Positive effects 
of high impact exercise have also been shown in several other studies performed in 
premenopausal women [203, 204]. However, other studies could show that dynamic strains 
rather than static strains are important for bone remodeling and modeling and that even at low 
magnitude, but high frequency an osteogenic potential can be observed. An animal 
experiment showed an increase in both bone quality and quantity. It was performed on sheep 
whose hind legs were stimulated for 20 minutes per day with extremely low level high 
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frequency strains [205]. A review paper about randomized trials of the effect of exercise on 
bone states that exercise in general reduces the rate of bone loss at the spine in 
postmenopausal women, and has positive effects on the bone mass of the lumbar spine in 
premenopausal women. However, at the femoral neck two of five studies did not find any 
positive effect of exercise on bone mass. In general, the magnitude of the effect of exercise on 
bone mass seems to be similar to that of calcium supplementation and just a little less than 
that of pharmacological intervention in osteoporosis [206]. However, patient compliance is a 
big issue. Especially when physical activity is recommended, it usually needs a lot more self-
motivation and effort to perform the kind of activity suggested by the doctor. For such 
patients whole body vibration could be an alternative as it increases muscle strength, BMD, 
body balance and position without having to put too much effort onto the exercise. It is also 
better accepted by older people [207]. In another study bone loss in tail suspended rats was 
inhibited by putting these rats 10 minutes per day on a vibration plate, whereas 10 minutes of 
normal load bearing had no effect [208]. When postmenopausal women were assigned to 1 
year treatment of low magnitude high frequency mechanical stimuli a weight dependent effect 
was observed.  Women weighing less than 65 kg lost 3.32 % BMD in the spine without 
treatment, while women allocated to the treatment gained 0.18 % BMD. This indicates that 
the treatment although not anabolic, could at least prevent bone loss. However, women 
weighing more than 65 kg did not lose any bone. Therefore, no effect of the vibrational 
treatment could be seen. Also in this study patient compliance was a big issue. The authors 
calculated that the ideal subject with 100 % compliance could have an increase of up to 7 % 
in the lumbar spine. It was also proposed in the paper that due to sarcopenia less muscle 
dynamics are experienced. Usually there are dynamics of about 20-50 Hz during long term 
activities such as quiet standing. A decrease in this dynamics contributes to bone loss. The 
authors stated that reintroducing low magnitude high frequency stimulation could re-establish 
a regulatory stimulus to the bone tissue and prevent bone loss [209]. 
Taking together all the findings of these studies it is hard to give suggestions for clinical 
application. There are also hot debates about what kind of exercise and which amount is the 
best in osteoporotic patients. Due to ethical reasons there are no randomized control trials in 
humans that use fracture incidence as an outcome. Usually just changes in BMD are 
investigated. But when looking at pharmaceutical treatment where just small increases in 
BMD already provide a high protectoral effect for fractures, one can question if the same 
holds true for the effects of mechanical loading. In conclusion, it can be said that osteoporotic 
patients should be encouraged to be as active as possible. Daily walking as well as daily 
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physical activity such as housework or gardening should be promoted. However, it should be 
emphasized that no excessive loading or weight bearing must be performed. Low magnitude 
vibration seems to provide a good alternative with hardly any side effects for people lacking 
motivation and could be well used together with pharmacological treatment [198]. 
 
2.4 Animal models in postmenopausal osteoporosis and mechanobiology  
Animal experiments are essential in many fields of research. They are required by law when 
new drugs for treatment and prevention of diseases are tested. But also in basic research they 
are a valuable tool to gain insight into signaling pathways and cellular, biochemical, 
molecular and biomechanical mechanisms. Such experiments often serve as models for 
human disorders. Of course, for many research questions, in vitro setups are available. 
However, such models are not complex enough to gain insight into whole regulation 
mechanisms. But also animal models have their limitations. These are due to the fact that 
animals are not humans and biological mechanisms in different species are similar but not the 
same. Therefore a careful choice of the model is essential. The animal model should replicate 
human conditions as close as possible. Of course, other considerations like ethical and 
legislative aspects, laboratory safety, handling of the animals, and the costs to maintain the 
animals and the necessary facility must not be neglected.  [210, 211].  
 
2.4.1 Animal models in postmenopausal osteoporosis 
In opposite to humans, most animal species do not experience menopause. Therefore, to study 
the changes during menopause in animals, this phase has to be induced artificially. For this, 
the big species differences in the ovulatory cycle must be taken in consideration. Women have 
a menstrual cycle which lasts about 28 days. In animals, cycles occur between 5 days in mice 
and up to 18 weeks in dogs. Also, not all species show all phases within each cycle. For 
example in cats the ovulation only occurs after mating, while in mice the ovulation always 
occurs, but the Corpus Luteum only develops after mating.. While women maintain their 
cycle all over the year, many animal species show reproductive activity only during special 
seasons. Another factor that has to be taken into consideration is the number of offspring a 
species produces per year. For example, rodents can have several litters with up to 16 puppies 
throughout the year. Therefore, they are able to mobilize higher amounts of calcium in a 
shorter period of time for lactation. But of course they also must have a good anabolic 
capacity to replace the lost bone quickly after the end of lactation. Hence animals with a 
smaller litter size are closer to the human conditions. Usually large animals have less 
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offspring than small rodents [212]. However, the body of animals with seasonal ovulatory 
arrest like sheep is adapted to phases with low estrogen levels but without bone loss.  
The cause for postmenopausal osteoporosis is the decrease of estrogen levels. The easiest 
method to stop the ovulatory cycle and stop estrogen production in animals is ovariectomy. 
But also chemical castration, the stop of the cycle by hormone application is possible. In 
opposite to ovariectomy this method is reversible.  
 
When new drugs for osteoporosis treatment or prevention are supposed to be tested, the Food 
and Drug Administration (FDA) requires tests on two animal species [213]. The first species 
is the rat, because it is well characterized and develops after ovariectomy similar bone loss as 
in humans. However, rodents do not show haversian remodeling as it is typical in humans. 
Furthermore, some people argue that rats do not show remodeling at all but only modeling, 
although it has been shown that rats demonstrate a gradual transition from modeling to 
remodeling over the course of aging [210]. Thus a second species, is required, that shows 
haversian remodeling [210, 214]. Usually non-human primates are used to fulfill this 
requirement. 
In the following section some animal models will be described briefly. 
The use of the selective estrogen receptor modulator Tamoxifen and the bone anabolic effect 
of treatment with intermittent PTH were first identified in rats [211]. As mentioned before, 
the rat is a well described animal model for postmenopausal osteoporosis with a very 
reproducible site specific development of cancellous osteopenia. The rat is widely available, 
inexpensive, grows rapidly and has a short lifetime. However, there are also some 
disadvantages: the cancellous bone represents a smaller fraction of the total bone mass than in 
humans, and the whole skeleton contributes a smaller fraction of the total body mass 
compared to humans [211]. Furthermore, some bones show lifelong longitudinal growth, as 
the epiphyses do not close in all bones. In male rats, the epiphyses of long bones can be open 
until the age of 30 months, whereas in female rats the proximal tibia stops longitudinal growth 
around the age of 15 months and in the lumbar vertebra around 21 months [210]. However, if 
a mature rat is castrated, the effects on bone are quite similar to the ones seen in women after 
menopause. Cancellous and endocortical bone loss is apparent, together with an increased rate 
of bone remodeling and an imbalance between bone formation and resorption [214]. A 
significant bone loss in the proximal tibial metaphysis was observed 14 days, in the femoral 
neck 30 days and in the lumbar vertebra 60 days after the castration [210]. However, in long 
bone epiphyses and caudal vertebrae no ovariectomy induced bone loss was observed. 
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Nevertheless, when biomechanical testing was performed on bones from ovariectomized rats, 
it was obvious that these bones do loose significantly in bone strength [214].  
Mice are even smaller than rats, so housing them is even cheaper. However, due to their small 
size, they have small bones with even smaller trabecular compartments. Therefore, mice are 
used less often in osteoporosis studies than rats. Nevertheless, due to the growing interest in 
genetically altered animals, mice are interesting and valuable animals in osteoporosis 
research. Well defined inbred strains and a large number of genetically modified mice are 
available. These inbred strains differ widely in bone parameters, such as BV/TV or trabecular 
number and therefore also show different reactions to loading or ovariectomy. In a study 
comparing the effect of ovariectomy in five different inbred strains it was shown, that all mice 
lost in vertebral trabecular BV/TV except for C3H/HeJ mice, which are known to have high 
basal values of trabecular BV/TV. However, in the proximal tibia the decline in trabecular 
BV/TV is even greater in C3H/HeJ than in C57BL/6J mice, which have a very low trabecular 
BV/TV baseline. The changes in cortical properties did not vary between mouse strains [215]. 
However there are important differences between mice and men: In mice, administration of 
estrogens induces endocortical bone formation, which eventually leads to osteosclerosis. This 
pathological effect cannot be observed in humans [216]. Data on administration of 
intermittent PTH suggests that mice seem to be resistant to the anabolic effects of PTH and 
that the anabolic effect that can be seen is more in the cortical than in the trabecular bone 
[211].  
In dogs the structure of mature bone is close to human bone. Dogs also show haversian and 
cancellous remodeling, albeit having 25% shorter remodeling cycles and a cancellous bone 
turnover rate which is about 2-3 times higher than that of humans. However, 36 weeks after 
ovariectomy Beagles did show no significant reduction in bone mineral content or mechanical 
strength in the lumbar vertebra [212]. However, one has to keep in mind that dogs show a 
completely different reproductive cycle than humans. Ovulation takes place once or twice per 
year. Every ovulation follows a luteal phase of 64 days, independent of the occurrence of 
pregnancy. This is followed by an acyclic phase of about 3 months, until the next ovulation is 
prepared. Dogs do not show bone loss during the long acyclic phase, therefore, ovariectomy 
during this phase might be without any effect. Moreover, as the body is adapted to long 
phases with a lack of estrogen also ovariectomy during the cyclic phase might not show any 
effect. 
Sheep are often used in orthopedic research for implant testing, due to the comfortable body 
size. Housing them is quite cheap and they can be trained to perform simple routine tasks, like 
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treadmill walking. There is some data suggesting bone loss after ovariectomy; however, other 
studies also found a rebound effect after a while. Ovariectomy in retired breeders could 
decrease BMD of the femur but not in the lumbar spine. Nevertheless, another study could 
show a progressive bone loss in the 5
th
 lumbar vertebra 24 months after ovariectomy [217, 
218]. However in another study osteoporosis could only be induced in sheep when 
ovariectomy was combined with a calcium and vitamin D deficient diet and steroid therapy 
[219].  
As none of the species mentioned above can mimic human conditions in the bone during and 
after menopause perfectly, mostly non-human primates are used if a large animal model is 
required. These animals show high bone turnover after ovariectomy as in humans. Jee et al. 
found two years after ovariectomy a spinal osteopenia was apparent with about 11-15% lower 
bone mass. Also other parameters such as increased serum and urine markers for bone 
turnover and histological evident increased bone formation rates are similar to the conditions 
found in humans [214]. 
 
2.4.2 Animal models for unloading and loading 
Healthy bone adapts to different loading conditions. Unloading reduces bone formation and 
increases bone resorption with subsequently decreasing bone volume. Animal models with 
unloading are used to mimic the processes that occur during disuse, immobilization and 
microgravity and the resulting disuse osteoporosis. The two most common models for 
immobilization are hind limb elevation and neurectomy. For hind limb elevation or tail 
suspension as it is also called, a special cage is needed to fix the tail to the top of the cage. 
That way that the forelimbs are still weight bearing and can serve as control, while the hind 
limbs remain unloaded. With this setup a cephalic fluid flow is provoked, which is similar as 
in bed rest or spaceflight. Unloading experiments up to 4 weeks did not show any signs of 
elevated stress levels in the animals [174, 220]. After two weeks, a bone mass deficit of 5-
20% was obvious, the cancellous bone volume was reduced by 50%, osteoblast surface was 
decreased and osteoclast surface increased. In young animals, after an unloading period of 
two weeks bone formation rate and cell number went back to normal values, but the deficit in 
bone mass was maintained. When the animals were reloaded bone formation rate went up 
again and a slow but steady gain in bone mass was observed. However, it is not clear if a 
complete restoration of the bone mass can be achieved [174, 221]. Due to the cephalic fluid 
flow it is not easy to distinguish whether the observed effects result from the unloading or 
changes in blood flow. However, this model does not require any surgery and the animals do 
2 Literature review 2.4 Animal models in postmenopausal osteoporosis 
and mechanobiology 
 
~ 41 ~ 
not seem to be stressed to a large extend. Moreover, the forelimbs can serve as a control and 
no additional control groups are required. Therefore this is an often used unloading model in 
mice and rats [174]. Nevertheless, this model is forbidden in Switzerland due to ethical 
reasons. 
Bone changes induced by neurectomy are similar to those seen in patients suffering from 
chronic spinal cord injury. To mimic such defects, about 1cm of the sciatic or femoral nerve 
or the plexus brachialis are dissected to induce a paralysis. Neurectomy reduces bone 
formation and cancellous bone volume. Bone resorption and blood flow within the bone are 
increased [222, 223]. 
The other methods used to immobilize animals are limb tapping or casting, tenotomy and 
spaceflight. In the first one, either a rear limb is tied against the abdomen, or a cast is put 
around the limb to prevent it from touching the ground. In both procedures the contra-lateral 
limb can serve as a control. However, the risk of overloading in this limb is high. Further, the 
animals seem to be stressed as weight gain in growing animals was reduced compared to 
controls [174]. This weight loss was shown in ovariectomized rats were the right hind limb 
was immobilized by attaching it to the abdomen and subsequently the left hind limb was 
loaded. After 60 days of unloading, cancellous bone mass and bone formation rate were 
decreased significantly compared to normal ovariectomized rats. However, in the left hind 
limb, which was loaded, bone loss was prevented and bone resorption rate decreased 
compared to castrated control rats [224]. Tenotomy is used to mimic the changes after tendon 
injury. However, the surgery performed to do the tenotomy can already have negative effects 
on the bone and sometimes a regrowth of the tendons is possible. Spaceflight is hardly ever 
used as it is very expensive and complicated to perform these experiments. However, it is an 
ideal model to study the effects of microgravity [174]. 
In skeletal loading, two main types of models are used: bending and compression models. 
Four point bending is used most often as it represents normal bone loading patterns best. In 
compression models, usually axial compression is applied upon the ulna, tibia or caudal 
vertebrae of turkeys and rodents. Strain gauges can be attached to the cortical surface to 
sufficiently measure the strain. The advantage of applying strain gauges is that the loading is 
well defined and can be adjusted. Therefore reproducibility is very high. Also multiple 
loading bouts over a long period of time can be performed [174]. Among the first axial 
compression loading models was the compression of the ulna of roosters. Two incisions were 
made in the proximal and distal epiphysis of the ulna and the cut ends were covered with 
cups, which were held by stainless steel pins. These pins penetrated the skin dorsally and 
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ventrally. Once per day they were connected to the loading device and a compressive force 
with a frequency of 0.5 Hz was applied onto the ulna. When applying 36 or more cycles per 
day, intracortical resorption was inhibited and periosteal and endosteal new bone was formed 
[225]. In a similar approach using turkeys, strain gauges were attached to the ulna. At strains 
of 0.001 bone was maintained. If the strains were lower, bone loss with increased remodeling, 
endosteal resorption and intracortical porosity was observed. Applied strains higher than 
0.001 proved to be osteogenic with periosteal and endosteal bone formation but only little 
changes in intracortical remodeling [226]. Axial loading of the ulna is also performed in 
rodents. A study validating this model in the mouse showed that with loads up to 2000 µε 
lamellar periosteal bone formation is present, but no endosteal bone formation. However, if 
strains exceed 3000 µε, lamellar endosteal bone formation is apparent and at the periosteal 
site lamellar and woven bone formation occurs. To axially load a mouse ulna, the flexed 
carpus and elbow are placed into felt padded cups that are positioned on top of each other. 
The upper cup holds the carpus and is attached to an actuator. The lower cup holds the elbow 
and is placed on a dynamic load cell. Due to the anatomical shape of the ulna, the axial 
compression produces a medial to lateral bending, inducing strains that are similar to the ones 
during normal locomotion [227]. More recent studies investigating the combined effect of 
loading and pharmacological treatment have been performed. In a mouse tibia loading model 
the effects of the bisphosphonate zolendronate and loading have been investigated. To load 
the tibia, the knee and ankle were bended. The moving pad was put on the knee and the fixed 
pad on the ankle. Then an axial compression with loading of 18 N and a frequency of 2 Hz 
was applied for one minute on the tibia. Due to the anatomical curvature of the bone, this 
loading results in compressive and bending strains. When loading was applied without the 
bisphosphonate, cortical thickness and bone area increased. The combination of zolendronate 
and loading also had positive effects. However, at the most loaded site of the tibia, were the 
highest strains were present, the effect was significantly decreased compared to the sum of the 
effects. This lead to the hypothesis, that the combination of zolendronate and loading is not 
beneficial at very high levels of strain [228]. Another study investigated the combined effect 
of loading and intermittent PTH application. Mice were treated with PTH or vehicle for 6 
weeks. In the last two weeks of treatment, the right ulna and tibia were additionally subjected 
to loading. In the tibia the loads were sufficient to stimulate an osteogenic effect in the vehicle 
treated animals, resulting in increased trabecular number, thickness, and increased cortical 
and trabecular bone volume. However, at the ulna the applied load itself was not sufficient to 
induce any osteogenic effect. In combination with intermittent PTH these loads could induce 
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osteogenic effects in the cortical regions [171]. This combined effect was also studied in rat 
caudal vertebrae. K-wires were inserted into the 7
th
 and 9
th
 caudal vertebra and a uniaxial load 
of 50 N or 100 N was applied. Loading or intermittent injection of PTH resulted in increased 
bone formation rate and mineral apposition rate. However, bone formation rate declined to the 
level of control animals after four weeks of both treatments. With the combination of loading 
and PTH treatment the increase in bone formation rate was sustained. In the first week the 
increase resulted mainly in increasing mineral apposition rate, and in the 2
nd
 and 4
th
 week in 
increasing labeled bone surface [165]. To study the effects of bending, four point bending was 
performed on tibiae of rats. The right foot was secured and the lower right leg positioned 
between four loading pads. The two upper pads were positioned at the lateral side and the 
lower pads at the medial side of the leg. As the distance between the upper pads was shorter 
than between the lower pads, loading generated tension on the medial and compression on the 
lateral surface. The results showed an increased formation surface at the medial periosteum of 
the tibia and fibula and an increased mineral apposition rate compared to the non-loaded limb 
[229]. In another study a loading-strain-dependency was demonstrated. Bone formation was 
increased and the newly formed bone appeared normal at low strains. However, if the strains 
exceed far beyond physiological loading levels, mainly woven bone is found [230]. When 
applying load to mice, the mouse strain needs to be taken into consideration when the results 
are interpreted. For example C57BL/6J mice have a lower BMD and therefore react a lot 
better to loading than C3H/HeJ mice which show much higher BMD [231]. Similar effects 
were found in another study where C57BL/6J and C3H/HeJ mice were submitted to four point 
bending tests. In the non-loaded limbs the total area and the marrow area of the tibial 
diaphysis were significantly bigger in C57BL/6J mice than in C3H/HeJ mice. After loading, 
the periosteal and endocortical formation surface were bigger in the mice having a low bone 
mineral density. Woven bone was found in both strains as a result to loading. New bone of 
mice with low bone mineral density contained 98% of woven bone, while that of C3H/HeJ 
mice consisted of 90% woven bone [231]. 
A third type of loading is vibration. In one study ovariectomized rats were put in a box on top 
of a vibration motor 30 minutes per day for 90 days. Vibration at 45 Hz increased periosteal 
bone formation and inhibited endocortical resorption and the decline in maximum bending 
stress. In contrast, rats that just underwent ovariectomy without any vibration showed a 
smaller increase in periosteal bone formation, but endocortical resorption and the decline in 
maximum bending stress was not inhibited [183]. 
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Treadmill running induces loading as well. Ovariectomized and sham operated rats were 
subjected to slow running or fast running at the treadmill. In the sham group the exercise did 
not affect any of the mechanical or histomorphometric parameters. However, when comparing 
ovariectomized exercising to non-exercising rats trabecular bone loss was reduced 
significantly. Ovariectomy induced an increased bone formation rate and mineral apposition 
rate. This rate was decreased at the periosteum in rats exercising on the treadmill, but 
increased at the endosteum [232]. 
 
2.4.3 Quantitative assessment of bone remodeling 
Bone remodeling happens at the microscopic level. Therefore, for a long time histology was 
the only method to measure parameters of bone remodeling. Until today it is a widely used 
method and “gold standard” for evaluation of several parameters. With the help of 
histomorphometry trabecular architectural parameters such as trabecular thickness, trabecular 
number or trabecular bone pattern factor [233] can be determined. Staining with histological 
or immunochemistry methods helps detecting different cell types, newly formed osteoid and 
different stages of cell activity. In addition to these static parameters, dynamic parameters can 
be evaluated as well in histomorphometry. This was done already as early as 1969 by Frost 
[53]. For this, the patient or experimental animal is treated with a fluorescent dye that is 
accumulated in bone during mineralization. A second dose of fluorescent label, like 
tetracyclin, calcein or alizarin is applied several days to weeks after the first dose. This results 
in two labels in the bone. The distance between these labels represents mineral apposition rate 
[234]. Further labeled surface is measured to estimate mineralizing surface. From this 
parameters bone formation rate can be calculated. Bone resorption cannot be measured so 
clearly, because there is no way to assess bone surface before resorption started. However, 
osteoclast number, assessed by TRAP-staining and eroded surface can be used to estimate 
bone resorption activity. Histology has the big disadvantage of the need of bone being 
extracted from the body. In patients or large animals this means that a biopsy has to be taken, 
an invasive and painful process. In small animals like rodents, the animal has to be sacrificed. 
This prevents the longitudinal monitoring of bone remodeling. 
In clinical routine, bone mineral density (BMD) is used to estimate fracture risk of a patient. 
Repeated measurements of bone mass in the same location can be used to assess overall bone 
loss or bone gain, which represents net remodeling rates. However, half of the women 
presenting with fractures still have a high BMD. Furthermore, BMD does not reflect bone 
quality, such as trabecular bone architecture, cortical bone thickness or geometry, osteon and 
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osteocyte density and damage accumulation [235]. Moreover, it is impossible to measure 
bone formation or resorption.  
To measure bone mass, typically radiological methods are applied, most commonly dual-
energy X-ray absorptiometry (DEXA). With DEXA mineral content in a defined area is 
measured. This results in areal bone mineral density, also called bone mineral content (BMC). 
As a two dimensional method, DEXA is dependent on bone geometry and works reliably only 
in patients with normal anatomy. 
A method to assess BMD in three dimension is quantitative computed tomography (QCT). 
However, with this method the patient is exposed to a high radiation dose. Peripheral QCT 
(pQCT) measurements are used to assess bone mineral density in the extremities, typically at 
the distal radius or tibia. Both CT-based methods give reliable values for BMD, cortical 
thickness and can distinguish between cortical and trabecular bone, but their resolution is too 
low, to assess more parameters like trabecular thickness or number.  
Imaging techniques providing a spatial resolution of 100 µm or less represent the 
microscopical level of imaging. Here, mainly the architecture of trabecular structures, like 
trabecular thickness, trabecular separation and structure model index can be assessed using 
micro computed tomography (micro-CT) or magnet resonance imaging (MRI), for example 
[236]. Both, CT and MRI are non-destructive. A high resolution method for the three-
dimensional assessment of bone parameters is micro-CT. However, it is restricted to small 
sample size (a few centimeters in diameter and length) and uses a high radiation dose. 
Therefore for a long time it was applied to specimen only, which made it a method for 
endpoint analysis. With the development of in vivo micro-CT a few years ago, longitudinal 
measurements of bone parameters can be conducted at least in small laboratory animals. In 
vivo micro-CT measures the same parameters as known from specimen scanners such as Full 
BV/TV, Trab BV/TV, Tb. Th, Tb. N, cort % BV [237]. Nowadays, resolution of in vivo 
micro-CT scanners goes up to around 10 µm. This resolution is sufficient to evaluate 
trabecular structures in mice, which have a trabecular thickness of about 30 to 50 µm [237]. In 
one study, for example, the effect of mechanical loading on bone micro-architecture was 
monitored weekly with in vivo micro-CT over a time course of four weeks [238]. As already 
mentioned, until recently histomorphometry was the only method to determine bone 
remodeling parameters and is still the gold standard. However, in 2011 Schulte et al. 
published a method to calculate bone formation rate, mineral apposition rate, mineralizing 
surface and even bone resorption rate, mineral resorption rate and eroded surface out of 
sequential micro-CT images taken from the same animal. The authors found good correlation 
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of the parameters with dynamic histomorphometric evaluation and applied the method to an in 
vivo loading model of mice [239]. Unfortunately, high resolution in vivo micro-CT imaging is 
limited to small animals like mice and rats. To achieve high resolution, the scanning time is 
long. Therefore, only small volumes can be scanned, also to avoid exposure to very high 
amounts of radiation. Therefore micro-CT imaging is not yet applicable to clinical purposes 
[211].  
Another interesting imaging method to evaluate bone parameters is magnetic resonance 
imaging (MRI), as it does not use any ionizing radiation. Trabecular structures are visible as a 
negative contrast, because bone itself does not contain many hydrogen molecules, but the 
surrounding marrow does. Due to the high signal-to-noise-ratio and high number of trabeculae 
and surrounding fat marrow, resulting in a high contrast, most of the in vivo studies have been 
performed at sites of the peripheral skeleton [236, 240]. Possible resolution ranges up to the 
diameter of a single trabecula. However, imaging time takes much longer than with CT, and 
trabecular thickness can be easily overestimated [235]. In one study, ultra short echo time 
MRI was used to detect changes in phosphorous and water content in bones of ovariectomized 
rats. The authors showed a decrease in phosphorous content which indicates a decreased 
mineralization and a higher water content in the ovariectomized compared to sham operated 
rats. These changes were reversed with the administration of the bisphosphonate alendronate. 
After injecting alendronate, phosphorous content increased dose dependently and water 
content decreased. However, these measurements were just performed in vitro [241]. 
 
2.4.4 Ethical aspects of animal models 
As seen in the previous paragraphs animal models are widely used. Not only in the field of 
imaging and bone biomechanics, also in many other fields of basic research as well as applied 
research animal models are very valuable. Scientists from all fields depend on animals models 
to answer their questions. However, performing experiments with living animals always raises 
ethical concerns. It is well known that animals do feel pain and anxiety. Many people argue 
that animals cannot decide whether they want to participate in animal experiments or not, 
which raises the question of the free will of animal and also the dignity of animals. Ethical 
questions cannot be answered entirely and it is hard to give a “right” or “wrong” decision for 
each single situation. Each researcher should scrutinize their own attitude towards animal 
experiments and the associated ethical concerns.  
This paragraph will only focus on one concept, the three R concept, which is a guideline 
towards good animal experiments. 
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The three R concept was first introduced by Russel and Burch in 1959 in their book “The 
Principles of Humane Experimental Technique” [242]. The three Rs stand for Replacement, 
Reduction and Refinement and have become a widely used principle in research using animal 
experiments. National and international legislations and guidelines follow this concept and 
therefore aim to assure a good quality of animal welfare. In the Swiss Animal Welfare Act, 
several articles can be applied directly onto the three R concept [243]. Article 17 states that 
animal experiments that can induce pain, distress, damage or fear must be limited to the 
indispensable degree. This is followed up in article 19, saying that animal experiments are 
unacceptable if the information gained from this experiment stands in no relation to the pain, 
distress or fear induced by the experiment. Finally in article 20 it is stated that animal 
experiments are only to be allowed if it can be proven that the same information cannot be 
achieved with appropriate alternative methods. 
The first R “replacement” was defined by Russel and Burch as “any scientific method 
employing non sentient material which (…) may replace methods which use conscious living 
vertebrates.” [242]. They also distinguished between absolute replacement, where no sentient 
vertebrates are needed at all, and relative replacement, meaning to perform non-recovery 
experiments on intact but deeply anaesthetized living beings and the painless killing of 
animals to get cells and tissues. Furthermore, replacement can be divided into direct 
replacement, where the experiments provide the same information, and indirect replacement, 
where the gained information is different, but can be used for a similar purpose as that for 
which the animal experiment would have been used for [244]. Such alternative experiments 
are often welcome, as they can save money and time. However, of course not all animal 
experiments can be replaced by just one alternative experiment; sometimes several 
experiments have to be combined to get the information. Typical alternative experiments are 
the use of cell and tissue cultures or computational models. Probably the best known 
replacement model is the use of blood cells instead of rabbits for testing on pyrogenes in 
medicinal products. It is expected to save 200 000 rabbits per year with these new methods in 
the EU [245]. A new form of replacement is the use of in silico models. For example a lot of 
effort is put into the computational modeling of bone modeling and remodeling and its 
response to mechanical load. This model will be expanded to predict the outcome of 
pharmacological treatment and loading in human osteoporotic bone. This could in future 
substitute animal experiments for drug testing or understanding basic principles in bone 
remodeling at least to some extend [246-248]. Though, due to the very complex nature of 
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living beings, not all animal experiments can be replaced, as sometimes the interaction of a lot 
of different body functions is needed. 
The second R represents “Reduction”, which means to keep the number of used animals as 
low as possible. For this, sound experimental planning and the use of statistical tools to 
estimate the necessary sample number (e.g. power analysis) are essential. First of all 
researches should check if the same or similar experiments already have been performed in 
another lab. This can be done for example with databases as provided by the German Federal 
Ministry of Education and Research [249]. Second, when planning group sizes it needs to be 
taken into account that inter-individual variability between humans or animals of one species 
sometimes results in quite different reactions to treatments and high variances within 
experimental groups. Therefore, a certain group size is needed to obtain statistically evaluable 
results [250]. With a good standardization of the experimental procedure, the housing 
conditions of the animals and the animals themselves, using inbred strains, these inter-
individual variations can be reduced, but not overcome. A longitudinal study design can 
reduce the group size a lot compared to cross sectional studies, because in longitudinal studies 
each animal can serve as its own control. In a study performed previously in our lab, the bone 
response to mechanical loading in mice was monitored over 4 weeks with in vivo micro-CT 
measurements. Lambers et al. could see a significant increase in trabecular BV/TV in the 
mice of the 8N loading group compared to the 0N group. This increase was not only seen in 
the averaged group values but also in single mice [238]. Therefore, much less animals are 
needed per study.  
The last R stands for “Refinement”. This means that the amount of stress or pain the animal is 
exposed to should be kept as low as possible. This implicates the use of a proper pain 
treatment, which is also required by the law in Switzerland. Furthermore, the handling of the 
animals should not cause any or as less stress as possible. Therefore, well trained personnel 
and continuous education of the staff is necessary. Also by offering adequate housing 
conditions, animal experiments can be refined. Hence, one has to know the natural habits of 
laboratory animals, for example that rodents are social animals and must not be kept single, or 
that a cage without any enrichment can provoke stereotype habits, which are a way to 
compensate stress [245]. 
In conclusion, it can be said, that the first aim should always be to replace animal experiments 
with other methods. If this is not possible as few as possible animals should be used and the 
conditions for the animals in the experiments concerning housing, handling and pain 
treatment should be as good as possible. When following these rules, scientists are aware that 
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animals have their own needs, that cannot be neglected and furthermore researchers know 
about the importance to find alternatives to animal experiments. 
 
 
3 Materials and Methods 
 
 
3.1 Experimental setup 
To study the effects of mechanical loading and pharmacological treatment on the 6
th
 caudal 
vertebra of ovariectomized (OVX) C57BL/6 mice, two experimental series were performed 
with a total of 240 animals. 
In one of the experimental series, the early loading series, there was a time-lag of 5 weeks 
between the castration and the start of loading and treatment. The other experimental series 
was the late loading series, where the time-lag between ovariectomy and start of loading and 
treatment was 11 weeks. Each of the series includes three different studies. 
In the ovariectomy study the effect of mechanical loading on the 6
th
 caudal vertebra in 
ovariectomized mice was investigated to see if they react to mechanical loading the same way 
as sham operated mice do. Sham (SHM) operated mice served as a control group. All the 
mice, ovariectomized or sham operated were assigned into groups subjected to 0N or 8N 
loading.  
Then the effects of two pharmacological treatments in addition to loading were investigated. 
The PTH study looked at the combinatorial effect of mechanical loading plus treatment with 
PTH on ovariectomized animals. In this study vehicle (VEH) treated, ovariectomized animals 
served as a control group and similarly to other studies all animals were assigned into 0N or 
8N loading groups. Finally, in bisphosphonate study the combinatorial effects of mechanical 
loading and treatment with the bisphosphonate (BIS) zolendronate on ovariectomized mice 
were investigated. Similarly to the previous study, vehicle treated, ovariectomized animals 
served as a control group, and a load of either 0N or 8N was applied to all the animals. 
A detailed overview over the experimental time schedule and different groups can be found in 
Figure 1 and Tables 1-3. 
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Figure 1: Experimental time schedule 
 
OVARIECTOMY OVX OVX SHM SHM 
TREATMENT NO NO NO NO 
LOADING 0N 8N 0N 8N 
NR OF 
ANIMALS 
10 10 10 10 
Table 1: Ovariectomy study, only loading was administered to mice 
 
OVARIECTOMY OVX OVX OVX OVX 
TREATMENT PTH PTH VEH VEH 
LOADING 0N 8N 0N 8N 
NR OF 
ANIMALS 
10 10 10 10 
Table 2: PTH study, both PTH treatment and loading were administered to mice 
 
OVARIECTOMY OVX OVX OVX OVX 
TREATMENT BIS BIS VEH VEH 
LOADING 0N 8N 0N 8N 
NR OF 
ANIMALS 
10 10 10 10 
Table 3: Bisphosphonate study, both BIS treatment and loading were administered to mice 
Tables 1-3: All studies were performed in both experimental series, Early and Late Loading. Control groups are marked in 
grey. 
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3.2 Animals 
The animals were purchased in groups of 20 from Harlan (Füllinsdorf, Switzerland). Due to 
the closure of the breeding facility in Füllinsdorf in June 2010, the mouse strain 
C5BL/6JRccHsd was transferred to Horst, The Netherlands. Consequently the last 40 mice 
which were ordered in August for the PTH study of the early loading experimental series had 
to be obtained from Harlan (Horst, The Netherlands). 
The mice were allowed to settle at least one week before experiments started. Animals were 
housed in groups of 5 in cages of type II-long in Scantainers (Scantainer 
Classic 
, SCANBUR, 
SA) with filter tops. Room temperature in the Scantainer was 22°C, humidity 50% and the 
airflow at the scantainer was 25-40 x/h. The day-/night-cycle was 12 hours darkness, followed 
by 12 hours of light.  
All mice were provided sterilized standard mouse chow ad libitum and had free access to tap 
water. Cages were changed once a week by a professional animal caretaker. Additionally, the 
weight of all animals was checked once a week and routine animal controls were performed 
regularly. 
All experiments were approved by the local animal care and use committee (Kantonales 
Veterinäramt Zürich, license number 171/2008). 
 
3.3 Ovariectomy  
Ovariectomy was performed at the age of 15 weeks. The mice were shaved dorsally and 
laterally for about 2 cm starting at the last two ribs going caudal. Weighing of the mice was 
done before the surgery and on the 3 days following the surgery together with the 
administration of the pain medication. 
Isoflurane (Attane TM Isoflurane ad us.vet, MINRAID INC. Orchard Park, New York) was 
used for inhalation anesthesia. For induction of anesthesia mice were placed into a transparent 
induction chamber, which was filled with an oxygen-isoflurane mixture. The oxygen flow 
was set to 400 ml/min and the isoflurane concentration was at 4 - 5 %. During the induction 
phase the animals were monitored constantly. After approximately 1-2 minutes, surgical 
tolerance stadium was reached. The mice were placed onto the operation table with the head 
in a facemask. Anesthesia was maintained with 2 % isoflurane. To prevent eyes from 
desiccation, an eye cream (Vitamin A Augensalbe, Bausch & Lomb Swiss AG, Zug, 
Switzerland) was applied. For pain relief 2 mg/kg Meloxicam (Metacam 5mg/ml ad us vet, 
Böhringer Ingelheim, Deutschland) were administered subcutaneously in the neck before the 
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start of the surgery. Skin disinfection was performed with an alcoholic skin disinfectant 
(Kodan Tinktur forte, Schülke & Mayr GmbH, Norderstedt, Germany). 
A small skin incision was made at the flank. The skin was loosened by blunt preparation and 
redundant subcutaneous fat was removed. Internal organs seen through the thin abdominal 
muscles were used for orientation. An incision into the muscle layer at the area of the fat pad 
of the ovaries was performed with the scissors. The ipsilateral ovary was grabbed and 
externalized with an anatomical forceps. After blunt preparation of the Ligamentum latum 
uteri, preserving the Arteria and Vena uterina, a hemostat was placed to clamp the vessels and 
the uterus about 0.5 cm caudal of the tip of the uterine horn. The tip of the uterine horn with 
the attached ovary was then torn off and the hemostat remained for some time to prevent any 
bleeding from the big vessels. After the hemostat was removed the remaining part of the 
uterus horn was repositioned into the abdomen and the muscle layer was closed with an 
interrupted suture. Braided vicryl thread in a needle thread combination (Ethicon 6-0 13 mm, 
3/8c Polyglactin, violet braided , Johnson & Johnson Intl, Brussels, Belgium) with an 
atraumatic needle was used for suturing. The skin was closed with staples (Precise 3M Health 
Care, Neuss, Germany) and a spray dressing (OPSITE permeable spray dressing, Smith & 
Nephew Medical Limited, Hull, England) was applied. The removal of the contra-lateral 
ovary was performed in the same way. 1 ml of warm saline (0.9 % Natriumchloridlösung, B. 
Braun Medical AG, Switzerland) was deposited into the abdomen before closing the muscle 
layer. 
The operation procedure for mice that underwent sham surgery was the same. However, in 
sham operated mice the ovaries and uterus horn were not removed, but exposed and visually 
examined before being repositioned into the abdomen. 
After surgery the mice were transferred into a pre-warmed cage. During the waking up phase 
the animals were monitored constantly. Once awake and walking around the mice were 
placed back into their home cage. 
A health check was done in the evening on the day of the surgery and then daily for the 
following three days. If necessary, lost staples were replaced. Meloxicam was injected every 
24 hours for 2 days at a dose of 2 mg/kg and on the third day 1.5 mg/kg. If necessary, the 
mice were checked more frequently. A health monitoring sheet was filled out on the day of 
surgery, and for the following three days. Weight, social behavior, body position and motion, 
habitus and wound condition were noted. The staples were removed 10 days after the surgery. 
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3.4 Pinning procedure 
Pinning of the 5
th
 and 7
th
 caudal vertebra was performed such that there were at least 3 weeks 
for the mice to recover until the loading started. To prepare the operation, stainless steel pins 
(Austerlitz insect Pins®, stainless steel, Fine Science Tools) were cut to the appropriate length 
of about 2.5 cm and autoclaved. The operation itself was performed under inhalation 
anesthesia with isoflurane. For the pinning operation the same anesthetic protocol as for 
ovariectomy was used. After 1- 2 minutes in the induction chamber, surgical tolerance 
stadium was reached. Each mouse was then positioned on the operation table such that the 
head was inside the facemask and anesthesia was maintained with 2 % isoflurane. An eye 
cream (Vitamin A Augensalbe, Bausch & Lomb Swiss AG, Zug, Switzerland) was applied. 
The tail was thoroughly disinfected with alcoholic skin disinfectant (Kodan Tinktur forte, 
Schülke & Mayr GmbH, Norderstedt, Germany). The pins were put into the pinning device.  
 
Figure 2: Pinning device with inserted Pins 
As seen in Figure 2, the pinning device consists of two parts. The pins are inserted into the 
bronze part of the device. Their position is marked in the acrylic glass part with radio opaque 
markers, which are integrated at the exact same position as the holes for the pins in the bronze 
part. The tail is placed in between these two parts, which are then connected by two location 
pins to enable to press the parts together and prevent the tail from moving. To ensure that the 
tail is straight and not flexed, a horizontal indentation has been made on the acrylic part (see 
Figure 3 and 4). A more detailed description of the pinning device can be found elsewhere 
[251] 
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Figure 3: Mouse tail fixed in pinning device  Figure 4: black arrows show indentation  
With a digital mobile C-arm (OEC MiniView 6800, GE Medical Systems) the position of the 
pins compared to the tail vertebrae was verified and if necessary the position of the pinning 
device was adjusted until the markers pointed to the middle of the 5
th
 and 7
th
 caudal vertebra.  
 
Figure 5: fluoroscopic image to determine correct position of pins 
To determine the correct position of the pins the vertebrae were counted starting with the first 
caudal vertebra at the pelvis and going in the distal direction, as shown in Figure 5. When the 
pinning device was localized at the desired position, the pins were inserted into the tail by 
pushing them with the plug and stabilizing the transparent part of the pinning device with the 
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fingers. The device was then removed and a control image was taken with the C-arm to verify 
that the pins were inserted into the vertebra and not into the intervertebral disk. 
 
Figure 6: Bending device  
The pins were then bent with the bending device, shown in Figure 6. The device itself consists 
of two parts, both manufactured out of metal. The lower part serves as a tail holder, while the 
upper part is used to bend the pins. The tail is placed into the space in the middle of the lower 
part. The pins are then fixed with two u-shaped metal blocks with the ends pointing into the 
left and right cavities of the lower part. By inserting the upper part into the cavities and 
hammering it, the tips of the pins are bent downwards. After bending, the pins were shortened 
and twisted 90°having the ends of the distal pin facing caudal and the ends of the proximal 
pin facing cranial as shown in Figure 7. This prevents the pins from falling out, reduces 
injuries of the mice and at the same time the pins are already in a correct position to put them 
into the loading device. The procedure of bending and cutting the pins is illustrated in Figure 
7 and Figure 8. 
 
Figure 7: tail with pins in bending device Figure 8: bended and rotated pins, black lines mark position 
for cutting  
Finally the tail was sprayed again with Kodan and the mice were transferred to a pre-warmed 
cage to recover. Once fully awake the animals were placed back into their home cage. Both 
the pinning device and the bending device were developed at our institute [251]. 
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The mice were checked on a daily basis for the following three days for general appearance 
and possible swelling around the pins. The animals were excluded from the study if severe 
swelling and redness around the pins was noticed. Thereafter the skin around the pins was 
checked for swelling and redness weekly, along with weighing of the animals. If a severe 
swelling occurred, such that the end of the pins were not visible anymore the animals were 
excluded from the study. 
The animals were allowed to move freely with the pins during the whole experiment and 
loading was performed as it is described in section 3.5. 
 
3.5 Loading and pharmacological treatment 
After the ovariectomy a time lag of 5 or 11 weeks respectively allowed the mice to develop 
ovariectomy-induced osteopenia. After this time the mice were exposed to mechanical 
loading of the 6
th
 caudal vertebra and pharmacological treatment.  
 
Loading 
Mechanical loading was applied three times per week for 4 weeks using the Caudal Vertebrae 
Axial Compression Device (CVAD), developed by Webster [251]. This device was used to 
perform axial cyclic compression of the 6
th
 caudal vertebra. A detailed description can be 
found elsewhere [251]. In short, the device consists of a linear actuator (LA25-42-000A, Bei-
Kimco Magnetics, Vista, USA) which is coupled to a 10N load cell (13/2443 – 16 
TRANSMETRA haltec GmbH, Neuhausen, Switzerland). An applicator, into which the distal 
pin is inserted, connects directly to the load cell. The distal part of the tail is threaded through 
a screw cap and a hole into the applicator. A horizontal slot, which was cut into the front face 
of the applicator, secures the correct positioning of the distal pin with its ends facing in the 
caudal direction. By clamping the proximal pin onto a steel base plate, the load applied to the 
distal pin is directly transferred to the 6
th
 caudal vertebra. The loading protocol was 
programmed using LabView 7.0 (National Instruments). This program sends signals to the 
actuator. The inner core of the actuator is connected to the load cell and the applicator with 
the pins inserted. By the signals of the program the loading device can move forwards and 
backwards. To avoid damages of the tail vertebra due to sudden impulses, the force applied to 
the target vertebra was ramped up to 1Ns
-1
, before a cyclic load of 8N was applied. The force 
is controlled with a proportional-integral-derivative controller in a closed loop feedback. 
During the loading 3,000 cycles are performed with a frequency of 10 Hz, resulting in a 
loading duration of 5 minutes. During this time the mice were anesthetized using Isoflurane. 
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The mice assigned to the 0N loading group, were treated identically to the other group, 
namely the tail was placed into the loading device without applying loading. Anesthesia was 
performed for the equivalent time. After loading mice were transferred into a pre-warmed 
cage for waking up. Once fully awake they were placed back into their home cage. 
 
 
Figure 9: mouse in loading device, picture taken from [251] 
 
Pharmacological treatment 
In two studies of each experimental series pharmacological treatment was administered in 
combination with the mechanical loading on the 6
th
 caudal vertebra. In one study PTH (hPTH 
1-34, Bachem AG, Switzerland) or the corresponding vehicle was injected. In the other the 
bisphosphonate zolendronate (Zometa 4mg/5ml; Novartis Pharma Schweiz AG, Bern) was 
administered. 
In the PTH study a dose of 80 µg/kg of PTH or vehicle was injected daily for 4 weeks, 
starting 5 or 11 weeks after the ovariectomy. The PTH was dissolved in 0.9 % NaCl (0.9% 
Natriumchloridlösung, B. Braun Medical AG, Switzerland) and 2 % heat inactivated mouse 
serum (Immundiagnostik AG, Bensheim, Germany). The pH was adjusted to 7.4 with 0.01N 
hydrochloric acid (HCl). To inactivate the mouse serum it was heated for 30 minutes in a 
56°C water bath. The vehicle consisted of 0.9% NaCl, heat inactivated mouse serum and HCl 
to adjust the pH.  
In the bisphosphonate study a zolendronate dose of 100 µg/kg or vehicle, which consisted of 
0.9 % NaCl, was injected subcutaneously once 5 or 11 weeks after the ovariectomy. To be 
able to inject 0.01 ml/g mouse the Zolendronate was diluted with 0.9 % NaCl. 
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3.6 CT-measurements 
During the study the loaded 6
th
 caudal vertebra of each mouse was scanned 4 times with an in 
vivo micro-CT scanner (vivaCT 40, Scanco Medical, Brüttisellen, Switzerland). The first CT-
scan was performed at the time of the castration to provide baseline values. When the loading 
and treatment period started (that is after 5 or 11 weeks, respectively), the mice were scanned 
for the second time, followed by the last two scans at a two week interval. 
During CT-measurements, the animals underwent isoflurane anesthesia, which was 
maintained at a concentration of 2 %. The mice were placed in an in house designed mouse 
holder. To prevent the animals from cooling down to a critical temperature the mouse holder 
was heated to 35°C. As seen in Figure 10 a carbon tube is connected to the mouse holder. The 
tail was threaded through a small opening into this tube and clamped tightly in order to fix the 
tail in a straight position and to prevent it from moving and subsequently eliminate the 
possibility of motion artifacts appearing during the scans. An eye cream was applied before 
the scans started. 
 
 
Figure 10: mouse holder 
The x-ray tube was operated at 55 kVp, 145 µA, with an integration time of 200 ms. No frame 
averaging was applied. Scans were performed with an isotropic voxel resolution of 10.5 µm. 
The total scanning time for two stacks (2 x 211 slices) was 22 minutes. In a few occasions the 
6
th
 caudal vertebra was too long for two stacks, especially in the ovariectomized mice. Here 3 
stacks had to be scanned, prolonging the scanning time by 10 minutes. Before the scan was 
started a scout view was taken to define the region of interest. In animals that have not had the 
pins inserted yet the 6
th
 caudal vertebra was identified by counting the tail vertebrae starting at 
the pelvis. Otherwise, the vertebra in between the two pinned ones was the desired vertebra 
for scanning. 
After the scans mice were allowed to recover in a pre-warmed cage. When they were fully 
awake, they were transferred back into their home cage. 
To assure consistent image quality the calibration of the scanner for mineral equivalent value 
was checked weekly following a standard protocol with a hydroxyapatite phantom provided 
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by the manufacturer. Additionally, a monthly check was performed with a thin wire included 
in the same phantom to check the in plane spatial resolution. 
 
3.7 Image processing and evaluation 
After scanning images were processed in order to allow evaluation of the data. In the 
processing step first they were reconstructed with a rotation angle such that the median line 
was aligned to 0° in the dorso-ventral direction in all vertebrae. Thereafter, a three 
dimensional file with a size of 300 x 300 x 422 voxels was produced by cutting out the region 
of interest. To avoid stack artifacts, a stack correction was performed, where the 1
st
 slice of 
the 2
nd
 stack was registered on the last slice of the first stack and then translation was applied 
to complete the second stack. The images were Gaussian-filtered (sigma 1.2, support 1) and a 
global threshold of 220, representing 22 % of the maximum grey level-value, was applied. 
After the processing automatic masks were created on these binary images. The masks were 
programmed in-house and based on a method described elsewhere [252]. They were used to 
select full, trabecular and cortical regions in the bone and to calculate structural parameters of 
all regions. To obtain the trabecular mask, a distance transformation was applied to the outer 
mask leading to an inner mask. Afterwards the top and bottom 10% of the mask were 
removed, to exclude the growth plate from trabecular evaluation. Furthermore, the central 
26% of the metaphysis were excluded in the trabecular region, which is void of trabecular 
bone. 
 
Figure 11: overview of all masks: a) outer mask includes all bone, b) inner mask after distance transformation from 
outer mask, c) trabecular mask with growth plates and center 26% excluded, d) cortical mask with trabecular 
structures removed  adopted from [252] 
 
For each scan morphometric (static) and dynamic parameters were evaluated.  
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The following morphometric parameters were calculated [253, 254]: For the full bone 
compartment, that is the bone consisting of trabecular bone, cortical bone and the growth 
plate, the bone volume (Full BV, [mm
3
]) and total volume of interest (Full TV, [mm
3
] were 
calculated and their ratio, the bone volume fraction (Full BV/TV, [%]) was derived. In the 
trabecular compartment trabecular bone volume density (Trab BV/TV, [%]) was calculated 
the same way as Full BV/TV. With the spheric fitting method [255] trabecular thickness 
(Tb.Th, [µm]) was estimated. Spheres with the largest possible diameter still completely 
within the trabeculae (Tb.Th), were fitted into the structures. These diameters were averaged 
and used to calculate the average thickness. To calculate the trabecular number (Tb.N, 
[1/mm]) the distance-transformation method [256] was used, where the mean distance 
between the mid axes of the trabeculae was measured. Tb.N is given as the inverse of this 
value. The cortical mask was calculated by taking the middle 75% of the inner mask and 
removing the trabecular structure. The cortical bone volume (Cort BV [mm
3
]) and total 
volume of interest (Cort TV, [mm
3
]) were calculated. The ratio of these two parameters is 
given as percent cortical bone volume (cort % BV). Using the distance-transformation method 
the cortical thickness (Ct.Th, [µm]) was calculated. All these parameters represent static 
parameters. 
To calculate the dynamic parameters, two binary images from the single measurements of 
each mouse were added onto each other resulting in a three colored image. Voxels that were 
present in both images are visualized in grey, voxels that were found in only the first image, 
in blue, and voxels that were seen only in the last image were shown in yellow as can be seen 
in Figure 12.  
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Figure 12 scans from first and last measurement from a PTH treated loaded mouse registered onto each other, blue 
areas represent resorbed bone, yellow areas formed bone and grey areas bone that was present in both images 
 
With the help of these three colored volumes the direct three dimensional extraction of 
dynamic bone formation and bone resorption parameters was performed. A detailed 
description of the registration and calculation of the dynamic parameters can be found 
elsewhere [42]. Mineral apposition rate (MAR, [µm/d]) was calculated by applying a distance 
transformation algorithm to the isolated volumes of formed bone of the three colored images. 
It is defined as the mean thickness of formed bone divided by the days in between the 
measurements. Mineral resorption rate (MRR, [µm/d]) was calculated in the same fashion as 
MAR, using the volume of resorbed bone instead of formed bone. Mineralizing surface (MS, 
[%]) was calculated from the three colored image by separating the contact areas between 
formed and constant bone voxels. Eroded surface (ES, [%]) was calculated similarly using the 
area of eroded bone instead of formed bone. Bone formation rate per bone volume per day 
(BFR, [%/d]) was described as the amount of formed bone volume per original bone volume 
per day. It is determined by dividing the volume of formed bone by the initial bone volume. 
Using the volumes of the resorbed areas the bone resorption rate per bone volume per day 
(BRR, [%/d]) was calculated. With using the volumes and not surfaces to calculate bone 
formation and bone resorption it is possible to evaluate these parameters in a three 
dimensional way. This is an advantage compared to histology. In histology it is only possible 
to evaluate surfaces but not volumes. 
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3.8 Physiome map 
In order to gain a better overview over the combined effects of different pharmacological 
treatment and loading in ovariectomized mice a physiome map was created for each static 
parameter. 
The data of all 214 mice at the age of 15 weeks, just before ovariectomy was pooled and set to 
100 % to see the effect of ovariectomy. However, to get an overview over the distribution of 
the original data, standard deviation of the original data was plotted at this point as well. In 
addition, the data of the second measurement was normalized to the first time point and the 
mice were pooled for ovariectomy and sham operation. Therefore, at 20 and 26 weeks of age 
two data points were plotted, representing the normalized pooled data with the corresponding 
standard deviation of all 91 ovariectomized and 16 sham operated animals respectively. After 
this point, lines are split up according to the different loading and treatment groups (SHM 8N 
and 0N, BIS 8N and 0N, PTH 8N and 0N). The ovariectomized and vehicle treated groups 
should show the same development during the studies, because they all represent 
ovariectomized mice that are not treated with pharmacologically active substances. Therefore 
OVX 8N mice were pooled together with the VEH 8N mice from the PTH and 
bisphosphonate study in the OVX/VEH 8N group, and OVX 0N mice were pooled together 
with the VEH 0N mice from these studies in the OVX/VEH 0N groups. This results in 8 
different groups each for start of loading and treatment period at the age of 20 and 26 weeks 
respectively.  
Because the mice had different bone mass at the age of 15 weeks and hence bone loss after 
ovariectomy was not identical, the data of each mouse of the measurements performed during 
the treatment and loading period was normalized to its second measurement. This second 
measurement was always executed at the beginning of the treatment and loading period at 
weeks 20 and 26, respectively. With this second normalization the scope of evaluation can be 
placed on the effects of treatment and loading without any bias due to individually different 
baseline values. To be able to fit this normalized values into the complete graph, the percent 
changes during the treatment and loading period were recalculated to represent a percent 
change of the value of the second measurement, which was normalized to the first 
measurement. To do so, the percent difference of the third and fourth measurement, in 
comparison to the second measurement, was calculated. Then this percent change was 
calculated for the value of the normalized second measurement and plotted at the third and 
fourth time points. Again standard deviations, referring to the normalized values were plotted.
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Figure 13 is an example for such a physiome map for Trab BV/TV. 
 
Figure 13: physiome map of Trab BV/TV 
 
 
3.9 Statistical analysis 
Descriptive statistics with mean and standard deviation was performed for each time point for 
each group of both experimental series. To compare the effects of the different loading and 
treatment regimens the data of the static parameters of each mouse was normalized to its 
second measurement, which was taken at the beginning of the loading and treatment period. 
Then for each study in each experimental series a univariate ANOVA with a LSD post hoc 
test was performed. Effects were considered significant if p-values were below 0.05. For 
dynamic parameters, univariate ANOVA was performed for each study with the original data. 
Again a LSD post hoc test was performed and p-values below 0.05 were considered to be 
significant. To be able to compare the course of the different groups of the static parameters 
during 4 weeks of loading and treatment the graphs were plotted using values normalized to 
the second measurement. With this normalization the different absolute values at the 
beginning of the loading and treatment period were all set to 100 %. For dynamic parameters 
the absolute values of the first two weeks and the last two weeks were compared between the 
groups. Therefore, the graphs for dynamic parameters were plotted using original values. 
To test the combined pharmacological treatment and mechanical loading effects on the static 
parameters for synergistic or additive effects a one-way ANOVA was performed for each 
study. Therefore, the different loading and treatment combinations were assigned to groups, 
namely: vehicle 0N representing group 1, vehicle 8N representing group 2, pharmacological 
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treatment 0N representing group 3 and pharmacological treatment 8N representing group 4. 
Then a contrast test with the contrast vector (1, -1, -1, 1) was performed. When p-values were 
below 0.05 and indicating significance no additive effect was observed for this parameter. If 
the evaluated contrast value was negative the effect on this parameter was less than additive. 
If this value was positive the effect was considered to be synergistic. All p-values above 0.05 
indicated an additive effect. 
To analyze static parameters in the physiome map the data of the third and fourth 
measurement of each mouse was normalized to the second measurement. Then the values of 
ovariectomized loaded and vehicle treated loaded mice were pooled for each experimental 
series as well as the values for ovariectomized none loaded and vehicle treated non-loaded 
mice. For the normalized data a univariate ANOVA with LSD post hoc test was performed 
for each experimental series and p-values below 0.05 were considered to be significant. 
All statistical analysis was performed using SPSS Statistics 17.0 (SPSS Inc, Chicago IL, 
USA). 
 
 
4 Results 
 
 
4.1 Outcome of ovariectomy and pinning operation 
At the age of 15 weeks all mice underwent ovariectomy or sham operation. During the lag 
period of 5 or 11 weeks, pins were inserted into the 5
th
 and 7
th
 caudal vertebra. 
The ovariectomy and sham operations could be performed without any complications. Five 
mice out of 240 that underwent surgery died during the procedure or immediately afterwards. 
Animals were monitored daily for 3 days after surgery, together with the administration of 
pain killers. According to the score sheet, monitoring included weighing, evaluation of 
habitus, body posture, wound and social behavior. Animals showed typically a moderate 
weight loss of 1-2 g after OVX. After one week, the original body weight was regained. A 
few mice showed a delayed cleaning of the wound, however until the second day all wounds 
were clean from the applied wound spray. Slight inflammations could be seen in some mice in 
the first three days, but the inflammation did not progress and healed within a few days. 
Staples lost within the first 4 days were replaced. Otherwise no signs of impaired wound 
healing or other adverse effects could be seen. During the lag period, until the treatment and 
loading started, mice were weighed weekly. A clear difference in weight gain between 
castrated and sham operated mice was visible. The mean weight in mice that underwent 
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ovariectomy in the early loading group was 21.3 g before the operation at the age of 15 weeks 
and 24.5 g 5 weeks after the castration at the age of 20 weeks. Corresponding values for sham 
operated mice are 20.1 g at the age of 15 weeks and 22.3 g at the age of 20 weeks. In the late 
loading groups mean weight in mice that underwent ovariectomy was 22.1 g at the age of 15 
weeks, before the operation and in mice that underwent sham operation 21.8 g. After the lag 
period of 11 weeks the mean weight in ovariectomized mice was 26.6 g and in sham operated 
mice 25.1 g. The weight development early and late loading series can be seen in Table 4. 
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WEIGHT [gram] 
Group / age 15 weeks 20 weeks 22 weeks 24 weeks 
OVX 8N 19.6 ± 1.2 23.9 ± 2.5 23.7 ± 2.1 23.9 ±2.4 
OVX 0N 20.1 ± 1.3 24.9 ± 1.3 24.8 ± 1.4 24.7 ± 1.7 
SHM 8N 20.4 ± 1.0 22.4 ± 0.7 22.3 ± 1.0 22.5 ± 0.7 
SHM 0N 19.7 ± 0.8 19.7 ± 1.3 22.0 ± 1.4 21.9 ± 1.3 
PTH 8N 21.3 ± 1.4 24.6 ± 1.5 25.0 ± 1.4 24.8 ± 1.1 
PTH 0N 21.6 ± 0.9 25.2 ± 1.3 25.5 ± 1.2 25.7 ± 1.2 
VEH (PTH) 8N 21.3 ± 0.9 23.9 ± 1.1 23.6 ± 1.1 23.6 ± 1.1 
VEH (PTH) 0N 21.5 ± 0.8 24.7 ± 1.3 24.8 ± 1.3 24.4 ± 0.9 
BIS 8N 21.0 ± 0.8 24.4 ± 1.7 24.4 ± 1.6 24.8 ± 1.7 
BIS 0N 20.3 ± 1.0 23.7 ± 1.4 23.5 ± 1.1 24.0 ± 1.2 
VEH (BIS) 8N 20.9 ± 1.5 24.4 ± 2.3 24.5 ± 1.9 24.7 ± 2.0 
VEH (BIS) 0N 20.5 ± 1.2 23.5 ± 1.2 23.6 ± 1.0 23.9 ± 1.0 
a) early loading series 
 
WEIGHT [gram] 
Group / age 15 weeks 26 weeks 28 weeks 30 weeks 
OVX 8N 22.2 ± 1.7 27.0 ± 3.7 25.9 ± 3.3 25.2 ± 3.3 
OVX 0N 21.3 ± 1.0 26.6 ± 2.3 25.7 ± 2.0 25.0 ± 1.9 
SHM 8N 21.8 ± 1.5 25.1 ± 2.3 25.2 ± 2.2 24.7 ± 2.0 
SHM 0N 21.6 ± 0.8 25.1 ± 3.1 24.3 ± 2.3 24.4 ± 2.7 
PTH 8N 22.4 ± 1.3 26.2 ± 1.9 26.1 ± 1.5 26.0 ± 1.4 
PTH 0N 21.7 ± 1.2 27.0 ± 3.1 26.0 ± 2.0 25.6 ± 1.9 
VEH (PTH) 8N 21.6 ± 1.6 25.5 ± 3.2 24.0 ± 2.2 24.2 ± 2.0 
VEH (PTH) 0N 21.9 ± 2.0 26.2 ± 2.7 24.9 ± 2.0 24.7 ± 1.9 
BIS 8N 20.9 ± 0.8 25.4 ± 1.8 24.7 ± 1.8 25.1 ± 1.6 
BIS 0N 20.4 ± 2.4 25.0 ± 3.8 24.5 ± 3.9 24.8 ± 3.95 
VEH (BIS) 8N 21.2 ± 1.2 25.6 ± 2.3 24.6 ± 2.4 25.2 ± 2.6 
VEH (BIS) 0N 20.9 ± 0.8 26.1 ± 1.6 25.4 ± 1.7 25.5 ± 1.7 
b) late loading series 
Table 4: weight during experimental series; a) early loading series, b) late loading series; values are presented as mean ± 
standard deviation 
 
 
The pinning procedure could be performed without any major difficulties. With the help of 
the fluoroscope the pins were positioned correctly. Just one mouse had to be sacrificed as one 
pin was inserted between the vertebrae by mistake. After pinning the mice were checked 
regularly. No inflammation or swelling was visible immediately after the pinning. However, 
after several weeks some mice developed a small swelling. If possible these mice were 
subjected to the 0N group. In total 15 out of 240 mice had to be sacrificed before the end of 
the experiment as the tissue around the pins was too swollen to fit them in the loading device 
or the pins got loose and were eventually lost completely which made it impossible to put 
them into the loading device. 
 
4.2 Effect of ovariectomy 
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Full bone 
At the age of 15 weeks mice are still growing. Therefore we saw in sham mice an increase in 
full bone total volume by 5.2 % five weeks and by 5.7 % 11 weeks after the surgery. Not only 
the total volume, but also the bone volume increased during this time. Hence full bone volume 
density was increased by 5.8 % in the early loading experimental series and by 7.2 % in the 
late loading experimental series.  
Sex hormones block growth hormone production. Therefore animals castrated before growth 
stops, often show an additional growth spurt. Indeed, in our mice we observed an increased 
growth in vertebral length, which was visible already during the measurements. The axial 
field of view had to be increased in some mice. In the OVX mice, the total volume of the 
vertebrae increased 9.6 % in the early treatment groups and by 12.1 % in the late treatment 
groups. However, as expected, bone volume fraction decreased by about 5 % in both 
experimental series, resulting in a loss of full bone volume density of 13.2 % at five weeks 
and 15.6 % at eleven weeks after ovariectomy. 
 
Trabecular compartment 
Also in the trabecular compartment an increase in total volume and bone volume was 
observed in the sham operated mice. This resulted in an increase of trabecular bone volume 
density by 13.4 % five weeks and 11.8 % eleven weeks after surgery. However, this increase 
in Trab BV/TV was not due to an increased number of trabeculae. After the lag period Tb.N 
was decreased by around 4 %. Therefore only the thickening of trabeculae by 14.4 % in the 
early loading experimental series and by 11.7 % in the late loading experimental series 
contributed to the increased Trab BV/TV. 
In OVX mice, as expected, trabecular bone volume decreased in both experimental studies 
resulting in a decrease of trabecular bone volume density by 24.1 % in the early experimental 
series and by 29.7 % in the late experimental series. This lower Trab BV/TV results out of 
loss of trabeculae and thinning of existing trabeculae. Interestingly, in the early experimental 
series the loss of 3.7 % of Tb.N is similar to that seen in sham operated mice, whereas in the 
late loading experimental series the decrease by 8.9 % is clearly higher in OVX than in SHM 
mice by 4 %. 
 
 
 
Cortical compartment 
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The cortical compartment increased as well in sham operated mice. After the lag period the 
cortex was thickened by 4.7 % and 4.2 % respectively.  
The increase of Trab BV/TV in OVX mice was also on the expense of cortical thickness. Five 
weeks after ovariectomy cort % BV was decreased by 3.8 % and eleven weeks after surgery 
by 9.6 %. 
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Parameter 
Group 
Full TV [mm³] Full BV [mm³] Full BV/TV [%] Ct.Th [µm] cort % BV [%] Tb.N [1/mm] Tb.Th [µm] Trab BV/TV [%] 
early loading         
SHM  
15 weeks 
20 weeks 
7.7 ± 0.5 
8.1 ± 0.5 
3.9 ± 0.3 
4.3 ± 0.3 
50.7 ± 3.2 
53.7 ± 2.6 
141.4 ± 9.1 
148.2 ± 8.3 
37.4 ± 2.8 
39.1 ± 2.3 
3.2 ± 0.3 
3.0 ± 0.3 
67.8 ± 4.6 
77.7 ± 5.3 
17.8 ± 2.1 
20.1 ± 2.2 
OVX           
15 weeks 
20 weeks 
7.6 ± 0.5 
8.4 ± 0.5 
4.0 ± 0.3 
3.8 ± 0.3 
52.2 ± 2.7 
45.3 ± 2.7 
143.8 ± 7.7 
138.2 ± 7.3 
38.4 ± 2.4 
33.8 ± 2.4 
3.0 ± 0.3 
2.9 ± 0.2 
73.2 ± 5.6 
64.8 ± 3.9 
18.2 ± 2.5 
13.7 ± 1.8 
late loading 
        SHM 
15 weeks 
26 weeks 
7.7 ± 0.4 
8.2 ± 0.4 
3.9 ± 0.3 
4.5 ± 0.4 
51.1 ± 2.6 
54.7 ± 2.5 
144.6 ± 7.1  
150.8 ± 9.1 
38.2 ± 1.9 
39.9 ± 2.1 
3.0 ± 0.2 
2.9 ± 0.2 
72.1 ± 5.1 
80.5 ± 6.8 
17.2 ± 2.4 
19.2 ± 2.6 
OVX          
15 weeks 
26 weeks 
7.7 ± 0.5 
8.7 ± 0.5 
4.2 ± 0.4 
4.0 ± 0.3 
54.2 ± 3.0 
45.7 ± 2.8 
151.2 ± 8.6 
136.4 ± 8.3 
40.4 ± 2.6 
33.6 ± 2.5 
3.0 ± 0.2 
2.7 ± 0.2 
75.7 ± 4.7 
66.3 ± 4.7 
18.6 ± 2.7 
12.9 ± 1.7 
 Table 5: static values of ovariectomized and sham operated groups before and after ovariectomy / sham operation. Values presented as means ± standard deviation 
 
Parameter 
Group 
Full TV [%] Full BV [%] Full BV/TV [%] Ct.Th [%] cort % BV [%] Tb.N [%] Tb.Th [%] Trab BV/TV [%] 
early loading         
SHM  
15 weeks 
20 weeks 
100.0 
105.2 ± 2.0 
100.0 
111.3 ± 4.7 
100.0  
105.8 ± 2.8 
100.0 
104.7 ± 2.6 
100.0  
104.4 ± 3.4 
100.0  
95.8 ± 3.9 
100.0 
114.4 ± 5.3 
100.00 
113.4 ± 7.3 
OVX           
15 weeks 
20 weeks 
100.0 
109.6 ± 2.5 
100.0 
95.1 ± 5.1 
100.0 
86.8 ± 4.6 
100.0 
96.2 ± 4.1 
100.0 
88.2 ± 5.5 
100.0 
96.4 ± 5.2 
100.0 
88.8 ± 6.1 
100.00 
75.9 ± 9.8 
late loading 
        SHM 
15 weeks 
26 weeks 
100.0 
105.7 ± 1.7 
100.0 
113.3 ± 4.0 
100.0 
107.2 ± 2.7 
100.0 
104.2 ± 3.0 
100.0 
104.6 ± 3.5 
100.0 
95.9 ± 5.8 
100.0 
111.7 ± 6.7 
100.00 
111.8 ± 5.7 
OVX          
15 weeks 
26 weeks 
100.0 
112.1 ± 2.4 
100.0 
94.5 ± 7.0 
100.0 
84.4 ± 6.4 
100.0 
90.4 ± 5.3 
100.0 
83.3 ± 6.8 
100.0 
91.1 ± 6.7 
100.0 
87.9 ± 7.7 
100.00 
70.3 ± 12.4 
 Table 6: static values of ovariectomized and sham operated groups before and after ovariectomy / sham operation. Values presented as means ± standard deviation 
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4.3 Loading in ovariectomized mice 
In the following experiments, we tested whether bones of OVX mice are mechanosensitive 
and can adapt to increased mechanical load. Mechanical loading started 5 or 11 weeks after 
surgery. Age matched sham operated animals served as controls.  
Early loading – static parameters 
Figure 14 shows overlaid CT images representing the loading period for each group. It can be 
seen, that with loading bone formation is higher than without. Furthermore in the OVX 0N 
group a lot of bone resorption can be observed which represents the on-going bone loss after 
ovariectomy. 
 
Figure 14: Visualization of bone development during 4 weeks of loading period. CT images of week 20 and 24 are 
overlaid and registered. Blue represents resorbed bone, yellow newly formed bone and grey constant bone. 
 
Sham 0N (n=7) 
At the age of 15 weeks mice are not fully grown yet. Therefore intact non-loaded mice 
represent normal growing mice. Hence, an increase in Full TV of 1.8 % from 8.1 ± 0.6 mm³ 
to 8.3 ± 0.7 mm³ was observed in the investigated bone (Figure 15a). Full bone volume 
increased even more by 6.8 % from 4.7 mm³ to 4.9 mm³ which resulted in an increase in full 
bone volume fraction by 4.9 % (Figure 15c). This increase was caused by thickening of the 
cortical and trabecular bone. Cortical thickening was 2.7 % from 144.7 ± 6.2 µm to 
148.6 ± 7.1 µm (Figure 15d), resulting in an increase in cortical %BV by of 3.6 % (Figure 15 
e). Trabecular number remained stable over the time (Fig15f). Due to trabecular thickening of 
7.2 %, trabecular bone volume fraction increased by 10.9 % from 20.1 ± 3.1 % to 22.3 ± 3.1 
% (Figure 15h). 
Sham 8N (n=9) 
Mechanical loading of 8N increased bone growth only slightly. Intact loaded mice showed an 
increase in Full TV of 2.4 % during the 4 weeks loading period (Figure 15a). The increase in 
full bone volume by 9.9 % from 4.4± 0.2 mm³ to 4.7 ± 0.2 mm³ was higher than in SHM 0N 
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animals, although not significantly (Figure 15b). Also the cortical compartment was not 
affected significantly by mechanical loading. In the trabecular compartment, 8N loading 
thickened trabeculae by 14.4 %, which is significantly more than in the control group ( 
g). However, trabecular number was not changed during the loading period. Loading induced 
an increase in trabecular bone volume fraction by 17.3 % (Figure 15h), which is a visible 
trend compared to the increase in non-loaded mice.  
Ovariectomized 0N (n=10) 
Due to estrogen depletion in ovariectomized animals growth hormones are not blocked 
anymore. Therefore OVX 0N mice showed a higher total volume than sham operated mice 
already at the age of 20 weeks. With a 2.7 % increase from 8.5 ± 0.4 mm³ to 8.7 ± 0.4 mm³ in 
Full TV the development over time was similar to sham operated mice, although a trend was 
visible towards a larger rise (Figure 15a). Full bone volume and hence Full BV/TV were 
increased only slightly, by 5.1 % and 2.3%, respectively (Figure 15b, c). Cortical thickness 
and cortical %BV remained stable and so did trabecular BV/TV. However, trabecular number 
was reduced by 9.1 % (Figure 15f), which is compensated by trabecular thickening of 5.0% 
(Figure 15g).  
Ovariectomized 8N (n=10) 
Loading increased all parameters significantly more compared to non-loaded ovariectomized 
animals, except for trabecular number.  
With an increase in TV by 3.9 % from 8.3± 0.7 mm³ to 8.6 ± 0.7 mm³ bone growth was even 
significantly higher than in intact mice (Figure 15a). Also bone volume was increasing 
significantly more than in sham operated mice as Full BV was increasing by 1.4 % from 
3.8± 0.4 mm³ to 4.5 ± 0.4 mm³ (Figure 15b). Hence full bone volume density was 
significantly increased in ovariectomized loaded mice as well. The cortex was thickened by 
5.0 % and cort % BV increased by 8.6 % (Figure 15d). However, the strongest impact of 
loading was seen in the trabecular compartment, where bone volume fraction was increased 
by 28.1 % from 13.8 ± 1.7 % to 17.6 ± 2.1 % (Figure 15h). This was caused by a thickening 
of the trabeculae by 27.3 % (Figure 15g). That is an increase from 63.3 ± 4.5 µm to 
80.4 ± 5.0 µm. The loss of trabecular number could not be prevented by loading. It was with 
10.5 % not significantly different from the 0N group (Figure 15f).  
 
The absolute values of all static parameters of the early loading study are shown in Table 7. 
Normalized values can be seen in Table 8. 
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Figure 15: static parameters of 
ovariectomy study from early 
loading experimental series. 
Measurements normalized to first 
measurement at beginning of 
loading period. a), b) parameters 
from full bone; c)-g) parameters 
from trabecular compartment; h), 
I) cortical parameters 
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Early loading – dynamic parameters 
Bone formation parameters 
Intact non-loaded mice showed a BFR of 1.1 ± 0.3 %/d during the first two weeks of the 
observations. Loading did not increase this rate (1.2 ± 0.2 %/d) significantly. During the last 
two weeks of the loading period, a drop in BFR was observed in both groups. As expected, 
ovariectomy increased BFR significantly to 1.5 ± 0.4 %/d in OVX 0N. The highest BFR was 
observed in the loaded OVX group with 2.1 ± 0.5 %/d, which is significantly higher than in 
any other group of this study. In the second half of the observation period, BFR also dropped 
in the OVX groups. (Figure 16a) 
Mineral apposition rate was at 1.3 µm/d in both sham operated groups during the first two 
weeks of the study. Due to a drop in the non-loaded group during the last two weeks, SHM 
0N animals showed the significantly lowest rate at this time. Ovariectomy increased MAR 
during the first two weeks to 1.4 ± 0.2 µm/d in non-loaded and to 1.5 ± 0.1 µm/d in loaded 
animals. During the last two weeks a drop in both groups was observed. (Figure 16b) 
Mineralizing surface in intact non-loaded animals was at 47.7 ± 8.4 % during the first two 
weeks. This was increased significantly in loaded animals (54.0 ± 5.9 %). A drop in both 
groups was observed during the last two weeks of the observation period. Ovariectomy 
decreased MS significantly. With 38.0 ± 4.5 % during the first two weeks, OVX 0N showed 
the lowest MS of all groups in this study. Loading in ovariectomized mice increased 
mineralizing surface significantly to similar values as in sham operated loaded mice 
(52.5 ± 4.1 %). In contrast to the two intact groups, MS increased during the last two weeks in 
the ovariectomized animals resulting in almost similar values for sham operated and 
ovariectomized non-loaded animals and significantly higher values for ovariectomized loaded 
animals. (Figure 16c) 
Bone resorption parameters 
The bone resorption rate in intact non-loaded mice was 1.0 ± 0.7 %/d during the first two 
weeks of the experiment. In loaded animals a clear trend towards a decreased BRR was 
observed (0.7 ± 0.1 %/d in SHM 8N). During the last two weeks a drop could be noticed for 
non-loaded animals. However, in SHM 8N mice BRR remained stable during the entire 
experiment. As ovariectomy induces a high turnover osteoporosis, not only bone formation 
but also bone resorption was increased in ovariectomized animals. With a rate of 
2.1 ± 0.4 %/d during the first two weeks, OVX 0N animals showed the highest BRR of the 
entire study. Loading reduced bone resorption significantly in ovariectomized animals. The 
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OVX 8N group had a BRR of 1.1 ± 0.2 %/d during the first two weeks. In both OVX groups a 
drop could be observed during the last two weeks of the study. (Figure 16d) 
A similar pattern was observed for mineral resorption rate. During the first two weeks SHM 
0N mice showed a MRR of 1.8 ± 0.5 µm/d. This was reduced to 1.7 ± 0.2 µm/d in the loaded 
group. During the last two weeks a drop was observed in both groups. With 1.3 ± 0.3 µm/d 
SHM 0N mice had the lowest MRR of all groups in this study. Ovariectomy increased MRR 
significantly (2.1 ± 0.2 µm/d). Loading reduced MRR in ovariectomized animals as well. 
During the last two weeks a drop in both groups was observed and no differences between 
loaded and non-loaded ovariectomized animals was detected anymore. (Figure 16e) 
Intact non- loaded animals showed an eroded surface of 32.1 ± 6.7 % during the first two 
weeks of the observation. Loading reduced the amount of surface significantly to 
27.2 ± 5.3 %. While ES dropped in SHM 0N it increased in SHM 8N animals during the last 
two weeks, resulting in an eroded surface of about 29 % in both groups. Interestingly, 
ovariectomy did not change the percentage of eroded surface. OVX 0N animals show similar 
values as SHM 0N (30.2 ± 3.8 % and 28.4 ± 2.5 %, respectively). The effect of loading was 
intensified in ovariectomized animals, compared to intact mice. With an eroded surface of 
about 22 % at both time points OVX 8N mice had the smallest ES of all groups at any time 
point in this study. (Figure 16f) 
 
The absolute values for the dynamic parameters can be seen in Table 12.
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Figure 16: dynamic parameters of ovariectomy study in early loading experimental series. Upper row shows bone formation parameters, lower row shows bone resorption parameters 
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Late loading – static parameters 
Figure 17 shows overlaid CT images representing the loading period for each group. The 
advanced bone loss can be observed in the OVX 0N group, as hardly any trabecular structure 
is remaining. However loading improves trabecular structure in both, sham operated and 
OVX groups. 
 
Figure 17: Visualization of bone development during 4 weeks of loading period. CT images of week 26 and 30 are 
overlaid and registered. Blue represents resorbed bone, yellow newly formed bone and grey constant bone. 
 
 
Sham 0N (n=8) 
At the age of 26 weeks, mice are fully mature and hence grow only very slowly. Therefore 
Full TV was stable during the 4 weeks observation period and ranged from 8.3 ± 0.2 mm³ at 
the age of 26 weeks to 8.4 ± 0.2 mm³ at the age of 30 weeks (Figure 18a). Bone volume did 
not change as well and so did full bone volume fraction. Cortical thickness and %BV were not 
changed during the course of the experiment. Also in the trabecular compartment no changes 
were observed. (Figure 18b-h)  
Sham 8N (n=8) 
Loading did not have an effect on the size of the bone. Full TV remained stable at similar 
values as in the SHM 0N group (Figure 18a). However, bone volume was increased by 4.9 % 
from 4.3 ± 0.4 mm³ to 4.6 ± 0.5 mm³ (Figure 18b). Hence also full bone volume density was 
increased by loading by 3.7 % (Figure 18c). The effect on the cortex was very small as well. 
The cortex was thickened by 2.2 % from 146.2 ± 7.6 µm to 149.3 ± 8.8 µm (Fig 3d). This 
resulted in an increase of %BV by 2.2 % (Figure 18e). Trabecular number was not changed in 
loaded mice throughout the experiment. Nevertheless, loading induced a thickening by 4.6 % 
from 78.25 ± 7.0 µm to 81.9 ± 8.0 µm (Figure 18g). This resulted in a 6.5 % increase in Trab 
BV/TV (Figure 18h). It has to be admitted, that although trends in loaded animals towards 
increased values are visible they are only small and none of them is significant.  
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Ovariectomized 0N (n=10) 
Eleven weeks after ovariectomy bone loss had reached a plateau. Also intense bone growth, 
due to the lack of estrogens, which used to block growth hormones, was not visible any more. 
Therefore, Full TV was stable at 8.6 ± 0.4 mm³ to 8.7 ± 0.4 mm³ (Figure 18a). No changes 
were observed as well for bone volume and bone volume density. However, in the cortical 
compartment some effect of ovariectomy could still be assessed. The cortex thinned by 1.8 % 
from 133.2 ± 4.7 µm to 130.9 ± 7.6 µm (Figure 18d). This did not influence %BV as it 
remained stable during the experiment. Loss of trabecular number proceeded as well as this 
value was diminished by 2.1 % (Figure 18f). However, trabecular thickness was not affected 
and eventually Trab BV/TV increased by 9.0 % during the course of the observation period 
(Figure 18h). 
 
Ovariectomized 8N (n=6) 
Loading in ovariectomized animals did not influence the total volume of the vertebra. 
However, bone volume fraction was increased by 7.8 % from 4.1 ± 0.4 mm³ to 4.4 ± 0.4 mm³ 
(Figure 18b). This resulted in an increase of full bone volume density of 6.3 % (Figure 18c). 
In the cortical part loading counteracted on the effects of estrogen depletion and thickened the 
cortex by 1.6 % (Figure 18d) and increased %BV by 2.5 % (Figure 18e). The loss of 
trabeculae could not be stopped by loading as Tb.N was decreased by 2.6 %. Although 
trabeculae got less, the remaining trabeculae were thickened due to loading by 11.1 % from 
65.2 ± 5.0 µm to 72.3 ± 3.0 µm (Figure 18g). This resulted in an increase of Trab BV/TV by 
16.2 % (Figure 18h).  
 
The original values of all static parameters of the late loading experimental series can be seen 
in Table 7. The values of the data normalized to the second measurement at week 26 can be 
seen in Table 8.
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Figure 18: static parameters of 
ovariectomy study from late loading 
experimental series. Measurements 
normalized to first measurement at 
beginning of loading period. a), b) 
parameters from full bone; c)-g) 
parameters from trabecular compartment; 
h), I) cortical parameters 
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Late loading – dynamic parameters 
 
Bone formation parameters 
In the first two weeks of the late loading study SHM 0N animals had a BFR of 
0.54 ± 0.12 %/d. Interestingly loading did not increase BFR. During the first two weeks SHM 
8N mice had a BFR of 0.49 ± 0.17 %/d. In the last two weeks a drop in BFR was seen in both 
groups. Ovariectomy increased bone formation to 0.84 ± 0.15 %/d. In ovariectomized animals 
loading induced a clear trend to increase BFR, as it is 1.01 ± 0.33 %/d in OVX 8N animals 
during the first two weeks of loading. A drop during the last two weeks of the observation 
period was observed in these groups as well. However, both ovariectomized groups showed a 
significant higher BFR than sham operated groups. (Figure 19a) 
Mineral apposition rate was similar in both intact groups at both time points. Ovariectomy 
increased MAR, however not significantly. With loading a small trend was observed towards 
an increased MAR at both time points. (Figure 19b) 
Mineralizing surface covered 45.51 ± 3.52 % in intact non-loaded mice. A similar value was 
observed in the loaded group with 42.10 ± 5.76 %. Ovariectomy did not influence the 
percentage of mineralizing surface. With 42.95 ± 3.19 % OVX 0N mice showed similar 
values as sham operated animals. However, in ovariectomized animals loading increased MS 
surface significantly to 48.74 ± 4.53 % during the first two weeks of loading. While MS 
surface was decreased in the non-loaded mice during the last two weeks of the experiment it 
was increased in OVX 8N animals to 51.18 ± 5.16 %. (Figure 19c) 
 
Bone resorption parameters 
Bone resorption rate in SHM 0N animals was at 0.41 ± 0.16 %/d during the first two weeks of 
the study. In the loaded group a trend towards a decreased BRR could be observed 
(0.32 ± 0.08 %/d). During the last two weeks of the experiment BRR dropped in both groups. 
As ovariectomy induces a high bone turnover osteoporosis it increased BRR significantly to 
0.64 ± 0.23 %/d during the first two weeks of the study. Again a trend was observed in the 
loaded group towards a decreased BRR (0.53 ± 0.23 %/d). During the last two weeks of the 
study a drop of BRR was observed in both ovariectomized groups as well. (Figure 19d) 
Mineral resorption rate in intact non-loaded mice was 1.33 ± 0.30 µm/d at the beginning of 
the study. Loading reduced this rate significantly to 1.04 ± 0.20 µm/d. During the last two 
weeks a drop of MRR was observed in both groups. Ovariectomy did not influence mineral 
resorption rate. With a rate of 1.29 ± 0.20 µm/d during the first two weeks OVX 0N mice had 
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a similar value as SHM 0N mice. At this time point no difference could be observed between 
loaded and non-loaded ovariectomized animals. However, during the last two weeks, loading 
increased MRR in these animals, while in non-loaded mice even a drop in mineral resorption 
rate could be observed. (Figure 19e) 
Eroded surface was similar in both sham operated groups during the first two weeks of the 
study. However during the last two weeks a trend for a decrease of the eroded surface due to 
loading was observed. At this time point SHM 0N mice had an ES of 28.67 ± 2.37 %, while it 
covered 25.27 ± 2.97 % in the loaded group. In the ovariectomized group a trend towards a 
reduced ES was observed. Loading lessened the amount to 22.54 ± 3.32 %. (Figure 19f) 
 
The values for all dynamic parameters of the early and the late loading experimental series 
can be seen in Table 9. 
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Figure 19: dynamic parameters of ovariectomy study in early loading experimental series. Upper row shows bone formation parameters, lower row shows bone resorption parameters 
 ~ 84 ~ 
Parameter 
group 
Full TV [mm³] Full BV [mm³] Full BV/TV [%] Ct.Th [µm] cort % BV [%] Tb.N [1/mm] Tb.Th [µm] Trab BV/TV [%] 
early loading         
SHM 0N 
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.7 ± 0.6 
8.1 ± 0.6 
8.2 ± 0.7 
8.3 ± 0.7 
3.8 ± 0.3 
4.3 ± 0.3 
4.4 ± 0.3 
4.6 ± 0.3 
49.1 ± 3.5 
52.7 ± 2.9 
54.4 ± 3.1 
55.3 ± 3.1 
137.2 ± 7.3 
144.7 ± 6.2 
147.2 ± 7.3 
148.6 ± 7.1 
36.2 ± 2.8 
38.3 ± 2.2 
39.3 ± 2.3 
39.6 ± 2.3 
3.2 ± 0.3 
3.0 ± 0.3 
3.0 ± 0.3 
3.0 ± 0.3 
66.0 ± 4.7 
77.0 ± 3.7 
80.0 ± 4.5 
82.5 ± 5.3 
17.3 ± 2.9 
20.1 ± 3.1 
21.5 ± 3.5 
22.3 ± 3.7 
SHM 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.7 ± 0.4 
8.1 ± 0.3 
8.2 ± 0.3 
8.2 ± 0.3 
4.0 ± 0.3 
4.4 ± 0.2 
4.6 ± 0.3 
4.7 ± 0.2 
52.0 ± 2.4 
54.4 ± 2.2 
56.9 ± 2.4 
57.6 ± 2.1 
144.7 ± 9.5 
150.9 ± 9.1 
154.7 ± 10.5 
155.7 ± 7.6 
38.5 ± 2.6 
39.8 ± 2.3 
41 ± 2.6 
41.0 ± 1.8 
3.1 ± 0.2 
3.0 ± 0.3 
3.0 ± 0.3 
3.0 ± 0.2 
69.2 ± 4.2 
78.2 ± 6.4 
84.0 ± 6.4 
88.7 ± 6.4 
18.2 ± 1.3 
20.2 ± 1.5 
22.0 ± 1.4 
23.2 ± 1.3 
OVX 0N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.6 ± 0.4 
8.5 ± 0.4 
8.6 ± 0.5 
8.7 ± 0.4 
4.0 ± 0.4 
3.7 ± 0.3 
3.8 ± 0.3 
3.9 ± 0.2 
52.4 ± 2.7 
44.1 ± 3.1 
44.4 ± 2.8 
45.1 ± 2.4 
144.8 ± 5.7 
136.3 ± 6.4 
134.9 ± 5.9 
135.6 ± 4.7 
38.9 ± 1.5 
33.2 ± 2.3 
33.2 ± 2.1 
33.6 ± 1.8 
3.1 ± 0.3 
2.9 ± 0.3 
2.7 ± 0.2 
2.6 ± 0.2 
69.3 ± 6.1 
62.2 ± 4.5 
63.0 ± 3.8 
65.2 ± 4.2 
18.1 ± 4.1 
12.4 ± 2.3 
11.8 ± 1.8 
12.2 ± 1.8 
OVX 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.4 ± 0.6 
8.3 ± 0.7 
8.5 ± 0.7 
8.6 ± 0.7 
4.0 ± 0.4 
3.8 ± 0.4 
4.2 ± 0.4 
4.5 ± 0.4 
53.2 ± 1.9 
45.7 ± 2.3 
49.2 ± 2.0 
51.6 ± 2.0 
146.4 ± 6.0 
139.0 ± 7.4 
141.5 ± 6.4 
145.8 ± 7.1 
39.8 ± 1.5 
34.1 ± 1.9 
35.6 ± 1.5 
37.0 ± 1.4 
3.2 ± 0.2 
3.0 ± 0.3 
2.8 ± 0.3 
2.7 ± 0.3 
70.1 ± 5.0 
63.3 ± 4.5 
71.1 ± 4.1 
80.4 ± 5.0 
18.8 ± 1.9 
13.8 ± 1.7 
15.6 ± 1.5 
17.6 ± 2.1 
late loading 
        SHM 0N 
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.9 ± 0.3 
8.3 ± 0.2 
8.4 ± 0.2 
8.4 ± 0.2 
4.1 ± 0.4 
4.6 ± 0.4 
4.7 ± 0.4 
4.7 ± 0.4 
51.5 ± 3.2 
55.1 ± 3.1 
55.6 ± 3.0 
56.0 ± 3.2 
148.0 ± 7.2 
155.4 ± 8.6 
156.2 ± 8.9 
156.7 ± 9.3 
38.8 ± 2.1 
40.6 ± 2.4 
40.9 ± 2.5 
41.0 ± 2.6 
3.0 ± 0.3 
2.7 ± 0.2 
2.7 ± 0.2 
2.7 ± 0.2 
72.9 ± 5.4 
82.7 ± 6.2 
83.7 ± 5.8 
84.7 ± 5.8 
17.3 ± 3.0 
19.0 ± 3.1 
19.6 ± 2.8 
19.9 ± 2.9 
SHM 8N         
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.5 ± 0.4 
8.0 ± 0.5 
8.0 ± 0.5 
8.1 ± 0.5 
3.8 ± 0.2 
4.3 ± 0.4 
4.4 ± 0.4 
4.5 ± 0.5 
50.6 ± 1.8 
54.3 ± 2.0 
55.3 ± 2.2 
56.3 ± 2.3 
141.2 ± 5.3 
146.2 ± 7.6 
147.5 ± 8.3 
149.3 ± 8.8 
37.5 ± 1.5 
39.1 ± 1.5 
39.5 ± 1.6 
40.0 ± 1.8 
3.0 ± 0.2 
3.0 ± 0.2 
3.0 ± 0.2 
3.0 ± 0.2 
71.3 ± 5.0 
78.3 ± 7.0 
79.8 ± 7.4 
81.9 ± 8.0 
17.2 ± 1.9 
19.5 ± 2.1 
20.0 ± 2.4 
20.7 ± 2.6 
OVX 0N         
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.8 ± 0.4 
8.6 ± 0.4 
8.7 ± 0.4 
8.7 ± 0.4 
4.0 ± 0.3 
3.9 ± 0.3 
3.9 ± 0.3 
4.0 ± 0.3 
52.0 ± 2.7 
44.9 ± 2.0 
45.3 ± 2.1 
45.5 ± 2.6 
148.5 ± 7.5 
133.2 ± 4.7 
132.1 ±4.8 
130.9 ± 7.6 
39.1 ± 2.3 
33.2 ± 1.5 
33.2 ± 1.6 
33.0 ± 2.2 
2.9 ± 0.2 
2.5 ± 0.3 
2.5 ± 0.3 
2.5 ± 0.3 
74.5 ± 5.9 
64.4 ± 4.0 
65.5 ± 3.9 
66.1 ± 4.7 
17.3 ± 2.4 
11.8 ± 1.7 
12.5 ± 1.9 
12.9 ± 2.3 
OVX 8N         
15 weeks 
26 weeks 
28 weeks 
30 weeks 
8.1 ± 0.8 
8.9 ± 0.8 
8.9 ± 0.8 
9.0 ± 0.8 
4.3 ± 0.7 
4.1 ± 0.4 
4.3 ± 0.4 
4.4 ± 0.4 
52.6 ± 4.0 
46.2 ± 2.2 
47.8 ± 1.8 
49.0 ± 2.2 
150.7 ± 12.8 
137.5 ± 7.9 
138.4 ± 7.1 
139.6 ± 5.4 
39.2 ± 3.5 
33.8 ± 1.6 
34.3 ± 1.3 
34.7 ± 1.5 
3.0 ± 0.1 
2.7 ± 0.1 
2.7 ± 0.2 
2.7 ± 0.2 
74.7 ± 6.3 
65.2 ± 5.0 
67.7 ± 4.1 
72.3 ± 3.0 
18.2 ± 2.7 
13.4 ± 2.2 
14.5 ± 2.1 
15.5 ± 1.9 
 Table 7: absolute values of static parameters of ovariectomy studies in early and late loading experimental series. Expressed as mean ± standard deviation 
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Parameter 
Group 
Full TV [%] Full BV [%] Full BV/TV [%] Ct.Th [%] cort % BV [%] Tb.N [%] Tb.Th [%] Trab BV/TV [%] 
early loading         
SHM 0N 
20 weeks 
22 weeks 
24 weeks 
100.0 
100.5 ± 1.8 
101.8 ± 2.8 
a)
 
100.0 
103.7 ± 1.8 
106.8 ± 2.8 
a)
 
100.00  
103.1 ± 1.1 
105.0 ± 1.7 
a)
 
100.00 
101.7 ± 1.2 
102.7 ± 1.7
 b)
 
100.00  
102.7 ± 1.3 
103.6 ± 1.9
 a)
 
100.00  
98.5 ± 2.1 
98.7 ± 2.0
 a)b)
 
100.00 
104.0 ± 1.7 
107.2 ± 3.6
 a)c)
 
100.00 
106.9 ± 2.9 
110.9 ± 4.2
 a)b)
 
SHM 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
101.0 ± 1.4 
102.4 ± 3.1 
a)
 
100.0 
105.5 ± 1.4 
109.9 ± 3.1
 a)b)
 
100.00  
104.4 ± 1.9 
107.4 ± 2.6 
a)b)
 
100.00 
102.1 ± 1.0 
104.7 ± 2.4
 b)
 
100.00 
102.6 ± 1.9 
104.6 ± 2.5
 a)
 
100.00 
99.7 ± 2.2 
98.1 ± 3.8
 a)b)
 
100.00 
107.5 ± 3.5 
114.4 ± 5.9
 a)b)d)
 
)
100.00 
109.3 ± 3.9 
117.3 ± 5.7
 a)b)
 
 OVX 0N         
20 weeks 
22 weeks 
24 weeks 
100.0 
101.3 ± 2.6 
102.7 ± 4.5 
a)
 
100.0 
102.0 ± 2.6 
105.1 ± 4.5
 a)c)
 
100.00 
100.6 ± 2.3 
102.3 ± 3.1 
a)
 
100.00 
99.0 ± 1.3 
99.6 ± 2.6
 a)c)d)
 
100.00 
100.0 ± 2.0 
101.4 ± 3.2
 a)
 
100.00 
94.0 ± 2.6 
90.9 ± 3.4
 c)d)
 
100.00 
101.4 ± 3.1 
105.0 ± 5.7
 a)c)
 
100.00 
95.8 ± 6.6 
99.4 ± 9.2
 a)c)d
 
OVX 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
102.0 ± 3.5 
103.9 ± 6.0 
b)c)d)
 
100.0 
109.9 ± 3.5 
117.4 ± 6.0 
b)c)d)
 
100.00 
107.8 ± 2.6 
113.1 ± 5.0 
b)c)d)
 
100.00 
101.9 ± 1.9 
105.0 ± 3.8
 b)
 
100.00 
104.6 ± 2.8 
108.6 ± 45.0
 b)c)d)
 
100.00 
93.5 ± 2.5 
89.5 ± 2.4
 c)d)
 
100.00 
112.6 ± 3.8 
127.3 ± 7.2
 b)c)d)
 
100.00 
113.8 ± 7.9 
128.1 ±14.2 
b)c)d)
 
late loading 
        SHM 0N 
26 weeks 
28 weeks 
30 weeks 
100.0 
100.6 ± 0.7 
101.1 ± 1.1 
100.0 
101.6 ± 0.7 
102.6 ± 1.1
 a)
 
100.00 
101.0 ± 0.4 
101.5 ± 1.0
 a)
 
100.00 
100.5 ± 0.6 
100.8 ± 1.1
 b)
 
100.00 
100.7 ± 0.8 
100.6 ± 1.2 
100.00 
100.4 ± 1.7 
100.4 ± 2.0
 a)b)
 
100.00 
101.2 ± 1.3 
102.2 ± 1.7
 a)
 
100.00 
103.3 ± 3.1 
104.9 ± 4.6
 a)
 
SHM 8N         
26 weeks 
28 weeks 
30 weeks 
100.0 
100.5 ± 0.9 
101.1 ± 1.3 
100.0 
102.3 ± 0.9 
104.9 ± 1.3
 a)b)
 
100.00 
101.8 ± 0.5 
103.7 ± 0.9
 a)b)
 
100.00 
100.9 ± 0.8 
102.2 ± 1.3
 b)
 
100.00 
100.9 ± 0.6 
102.2 ± 1.1
 b)
 
100.00 
100.1 ± 0.5 
100.1 ± 0.9
 a)b)
 
100.00 
101.9 ± 0.9 
104.6 ± 1.8
 a)
 
100.00 
103.0 ± 2.3 
106.5 ± 3.7
 a)
 
OVX 0N         
26 weeks 
28 weeks 
30 weeks 
100.0 
100.5 ± 1.1 
101.0 ± 3.2 
100.0 
101.3 ± 1.1 
102.3 ± 3.2
 a)c)
 
100.00 
100.8 ± 1.0 
101.3 ± 2.7
 a)c)
 
100.00 
99.2 ± 0.8 
98.2 ± 3.2
 a)c)d)
 
100.00 
99.9 ± 0.9 
99.4 ± 3.6
 a)c)
 
100.00 
98.9 ± 1.5 
97.9 ± 2.5
 c)d)
 
100.00 
101.8 ± 1.7 
102.6 ± 3.3
 a)
 
100.00 
105.4 ± 2.7 
109.0 ± 7.2
 a)
 
OVX 8N         
26 weeks 
28 weeks 
30 weeks 
100.0 
100.6 ± 1.5 
101.4 ± 3.5 
100.0 
104.2 ± 1.5 
107.8 ± 3.5
 b)c)d)
 
100.00 
103.6 ± 1.4 
106.3 ± 3.0
 b)c)d)
 
100.00 
100.7 ± 1.3 
101.6 ± 2.5
 b)
 
100.00 
101.5 ± 1.2 
102.5 ± 3.3
 b)
 
100.00 
98.5 ± 2.3 
96.4 ± 3.3
 c)d)
 
100.00 
104.0 ± 1.8 
111.1 ± 4.6
 b)c)d)
 
100.00 
108.4 ± 3.2 
116.2 ± 5.7
 b)c)d)
 
 Table 8: static parameters of ovariectomy studies of early and late loading experimental series normalized to beginning of loading period. a) Significant to OVX 8N, b) significant to OVX 0N, c) 
 significant to SHM 8N, d) significant to SHM 0N for each study; values are presented as mean ± standard deviation 
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Table 9: bone dynamic parameters of ovariectomy studies. a) significant to OVX 8N, b) significant to OVX 0N, c) significant to SHM 8N, d) significant to SHM 0N for each study; values 
are presented as mean ± standard deviation 
 
 
Parameter  
group 
BFR.BV [%/d] MAR [µm/d] MS [%] BRR.BV [%/d] MRR [µm/d] ES [%] 
early loading       
SHM 0N 
wk20_wk22 
wk22_wk24 
1.1 ± 0.3
 a)b)
 
0.7 ± 0.4
 a)b)
 
1.3 ± 0.2
 a)
 
1.1 ± 0.2
 a)b)c)
 
47.7 ± 8.4
 b)c)
 
44.5 ± 3.5
 a)c)
 
1.0 ± 0.7
 b)
 
0.5 ± 0.3
 b)
 
1.8 ± 0.5
 b)
 
1.3 ± 0.3
 a)b)c)
 
32.1 ± 6.7
 a)c)
 
29.3 ± 2.9
 a)
 
SHM 8N       
wk20_wk22 
wk22_wk24 
1.2 ± 0.2
 a)
 
1.0 ± 0.2
 a)b)
 
1.3 ± 0.1
 a)
 
1.3 ± 0.1
 d)
 
54.0 ± 5.9
 b)d)
 
50.7 ± 6.0
 a)b)d)
 
0.7 ± 0.1
 a)b)
 
0.7 ± 0.5
 b)
 
1.7 ± 0.2
 a)b)
 
1.6 ± 0.5
 d)
 
27.2 ± 5.3
 a)d)
 
29.4 ± 6.0
 a)
 
OVX 0N       
wk20_wk22 
wk22_wk24 
1.5 ± 0.4
 a)d)
 
1.5 ± 0.4
 c)d)
 
1.4 ± 0.2 
1.3 ± 0.2
 d)
 
38.0 ± 4.5
 a)c)d)
 
42.1 ± 4.5
 a)c)
 
2.1 ± 0.4
 a)c)d)
 
1.3 ± 0.4
 a)c)d)
 
2.1 ± 0.2
 c)d)
 
1.7 ± 0.1
 d)
 
30.2 ± 3.8
 a)
 
28.4 ± 2.5
 a)
 
OVX 8N       
wk20_wk22 
wk22_wk24 
2.1 ± 0.5
 b)c)d)
 
1.6 ± 0.3
 c)d)
 
1.5 ± 0.1
 c)d)
 
1.3 ± 0.1
 d)
 
52.5 ± 4.1
 b)
 
56.7 ± 5.4
 b)c)d)
 
1.1 ± 0.2
 b)c)
 
0.8 ± 0.2
 b)
 
2.0 ± 0.1
 c)
 
1.7 ± 0.1
 d)
 
22.1 ± 4.1
 b)c)d)
 
22.6 ± 4.9
 b)c)d)
 
late loading 
      SHM 0N 
wk26_wk28 
wk28_wk30 
0.5 ± 0.1
 a)
 
0.4 ± 0.1
 a)b)
 
1.0 ± 0.1 
0.9 ± 0.1 
45.5 ± 3.5 
41.0 ± 4.2
 a)
 
0.4 ± 0.2
 b)
 
0.3 ± 0.1 
1.3 ± 0.3
 c)
 
1.2 ± 0.2
 a)
 
27.8 ± 3.9
 a)
 
28.7 ± 2.4
 a)
 
SHM 8N       
wk26_wk28 
wk28_wk30 
0.5 ± 0.2
 a)b)
 
0.4 ± 0.1
 a)b)
 
0.9 ± 0.1 
0.9 ± 0.1
 a)
 
42.1 ± 5.8
 a)
 
41.6 ± 6.3
 a)
 
0.3 ± 0.1
 b)
 
0.2 ± 0.1
 a)b)
 
1.0 ± 0.2
 a)b)d)
 
1.0 ± 0.1
 a)b)
 
28.7 ± 2.2
 a)
 
25.3 ± 3.0 
OVX 0N       
wk26_wk28 
wk28_wk30 
0.8 ± 0.2
 c)
 
0.7 ± 0.2
 c)d)
 
1.0 ± 0.1 
1.0 ± 0.1 
43.0 ± 3.2
 a)
 
40.8 ± 3.2
 a)
 
0.6 ± 0.2
 c)d)
 
0.6 ± 0.4
 c)
 
1.3 ± 0.2
 c)
 
1.2 ± 0.4
 c)
 
25.7 ± 3.4 
26.0 ± 3.4 
OVX 8N       
wk26_wk28 
wk28_wk30 
1.0 ± 0.3
 c)d)
 
0.9 ± 0.4
 c)d)
 
1.1 ± 0.1 
1.0 ± 0.1
 c)
 
48.7 ± 4.5
 b)c)
 
51.2 ± 5.2
 b)c)d)
 
0.5 ± 0.2 
0.5 ± 0.3
 c)
 
1.3 ± 0.3
 c)
 
1.4 ± 0.3
 c)d)
 
22.5 ± 3.3
 c)d)
 
21.8 ± 3.8
 d)
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4.4 Loading in pharmacological treated ovariectomized mice 
The aim of the following experiments was to investigate the combinatory effect of mechanical 
loading and treatment. Loading and pharmacological treatment were started 5 weeks after 
ovariectomy in the early loading experimental series and 11 weeks after ovariectomy in the 
late loading experimental series, respectively. Mice were subjected to 8N or 0N load and 
additionally injected with either PTH, the bisphosphonate zolendronate or the corresponding 
vehicle, which was pH adjusted mouse serum in the PTH treatment study and saline in the 
bisphosphonate treatment study. 
 
4.4.1  PTH studies 
Mice were injected daily with PTH or the corresponding vehicle for four weeks in both 
experimental series. All animals were subjected to 0N or 8N loading. 
 
Early loading – static parameters 
Figure 20 shows overlaid CT images representing the loading and treatment period for each 
group. It can be seen that both loading and PTH treatment lead to bone formation, while in the 
VEH 0N group bone loss after ovariectomy continues. The strongest bone formation can be 
seen in the PTH 8N group. 
 
Figure 20: Visualization of bone development during 4 weeks of loading period. CT images of week 20 and 
24 are overlaid and registered. Blue represents resorbed bone, yellow newly formed bone and grey 
constant bone. 
 
VEH 0N (n=8) 
As expected, vehicle injection did not influence the bone. Mice of the VEH 0N group were 
comparable to OVX 0N of the ovariectomy and loading study. The total volume remained 
stable and bone volume fraction showed a slight increase by 4.4 % from 3.8 ± 0.2 mm³ to 
4.0 ± 0.2 mm³ (Figure 21c). No changes were observed in the cortical compartment. As was 
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already seen in the ovariectomy study, the loss of trabeculae continued during the observation 
period. Tb.N. was decreased by 6.6 % at the end of the study (Figure 21f). Because trabecular 
thickness remained stable, the loss in trabecular number was not compensated and resulted in 
a 6.7 % decreased trabecular bone volume density (Figure 21h).  
 
VEH 8N (n=9) 
Loading increased total volume only slightly by 3.1 % from 8.4 ± 0.4 mm³ to 8.6 ± 0.4 mm³ 
(Figure 21a). However bone volume fraction was rising by 15.1 % from 3.8 ± 0.2 mm³ to 
4.4 ± 0.2 mm³ (Figure 21b), which resulted in an increase of full bone volume density by 
11.5 % (Figure 21c). This increase in full bone volume fraction was hardly caused by changes 
in the cortical compartment. The cortex thickened by 3.3 % (Figure 21c) resulting in an 
increase in cortical % BV of 6.4 % (Figure 21d). The main changes were seen in the 
trabecular compartment as trabeculae thickened by 17.1 % from 67.2 ± 3.2 µm to 
78.6 ± 2.7 µm (Figure 21g). However, the loss of trabeculae could not be stopped and Tb.N. 
was decreased by 6.8 % by the end of the observation period. Nevertheless, due to the 
thickening of the remaining trabeculae, Trab BV/TV was increased by 16.6 % (Figure 21h).  
 
PTH 0N (n=9) 
PTH is an anabolic drug, therefore an increase of 5.4 % in total volume was expected. Full 
bone volume fraction increased by 18.9 %, which is similar to the effect of loading (Figure 
21b). Also the effect on full bone volume density is similar to loading. At the end of the 
observation period, Full BV/TV was increased by 12.8 % (Figure 21c). Interestingly enough, 
with PTH treatment the cortex lost 4.3 % in thickness during the first two weeks of treatment, 
but regained almost everything during the last two weeks of treatment (Figure 21d). 
Meanwhile, cortical % BV remained stable during the first two weeks but was increased 
eventually by 9.7 % by the end of the observation period (Figure 21e). The main difference of 
PTH treatment compared to loading was that it seems to reduce the amount of lost trabeculae. 
By the end of the study Tb.N. was only decreased by 3.3 %, while the thickening of 
trabeculae by 15.8 % was similar to the effect of loading (Figure 21f,g). However, as more 
trabeculae are preserved the same thickening resulted in a significantly higher increase of 
trabecular bone volume density compared to the one in loaded animals. After 4 weeks of PTH 
treatment, Trab BV/TV was increased by 37.5 % (Figure 21h).  
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PTH 8N (n=9) 
The effects of PTH treatment and loading added on to each other, when they were combined. 
The full total volume was increased by 7.1 %, which was only slightly more than in PTH 
treated or loaded animals (Figure 21a). However, with an increase of 30.3 % the increase in 
bone volume fraction was significantly higher than in any other group (Figure 21b). 
Consequently, the increase of 21.7 % of full bone volume density was higher than in any 
other group (Figure 21c). These changes were due to both, changes in the cortical and in the 
trabecular compartment. At the end of the observation period the cortex thickened by 4.8 % 
from 134.6 ± 3.4 µm to 141.0 ± 3.3 µm (Figure 21d). This resulted in a 17.2 % greater 
cortical % BV (Figure 21e). In the trabecular compartment the changes were even more 
pronounced. Combined PTH treatment and loading seems to stop the continuing loss of 
trabeculae. Furthermore, a tremendous increase of 33.1 % in trabecular thickness was 
observed (Figure 21g). Trabeculae had an average thickness of 63.6 ± 2.8 µm at the beginning 
and of 84.5 ± 3.7 µm at the end of the observation period. As no trabeculae got lost and all 
trabeculae got thicker, the increase by 66.3 % in trabecular bone volume density was 
significantly higher than in any other group (Figure 21h). 
The absolute values of all static parameters are shown in Table 10. Values normalized to the 
beginning of the treatment and loading period are shown in Table 11. 
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Figure 21: static parameters of PTH 
study from early loading 
experimental series. Measurements 
normalized to first measurement at 
beginning of loading period. a), b) 
parameters from full bone; c)-g) 
parameters from trabecular 
compartment; h), I) cortical 
parameters 
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Early loading – dynamic parameters 
 
Bone formation 
Vehicle treated non-loaded mice had a bone formation rate of 1.1 ± 0.2 %/d. Loading 
increased this rate significantly to 1.6 ± 0.4 %/d during the first two weeks of the observation 
period. A small drop of BFR during the last two weeks could be observed, however, there was 
still a clear trend towards a higher BFR compared to VEH 0N animals. PTH treatment 
increased BFR up to 2.3 ± 0.6 %/d. This is significantly higher than in loaded animals. 
Combination of PTH treatment and loading increased it even up to 3.6 ± 0.8 %/d during the 
first two weeks of the observation period, representing the highest BFR of the study. 
However, during the last two weeks the rate fell down to 2.0± 0.2 %/d and was at a similar 
level as in PTH 0N animals. (Figure 22a) 
Mineral apposition rate was at 1.3 ± 0.1 µm per day in VEH 0N animals. Loading increased 
this rate significantly to 1.4 ± 0.1 µm per day during the first two weeks, however had no 
effect during the last two weeks. PTH treatment resulted in a significantly higher MAR than 
loading during the entire observation period. With 1.8 ± 0.1 µm per day combined loading 
and PTH treatment induced the significantly highest MAR of the entire study. However, the 
effect of loading fades away during the second half of the observation period as in the loaded 
vehicle treated group. Hence, similar values as for PTH 0N animals could be observed. 
(Figure 22b) 
The mineralizing surface in VEH 0N animals covered between 38.0 ± 2.3 % and 40.6 ± 1.6%. 
The portion of MS was increased in the following order: loading induced the smallest 
increase, followed by PTH treatment. The combination of PTH treatment and loading resulted 
in the significantly highest MS of 68.9 ± 4.0 % of the entire study. (Figure 22c) 
Hence, PTH and loading exert their effects on both MAR and MS and therefore increase bone 
formation rate.  
 
Bone resorption 
Bone resorption rate was highest in VEH 0N animals with 1.7 ± 0.4 %/d during the first two 
weeks and 1.2 ± 0.2 %/d during the last two weeks of the observation study. Loading 
decreased bone resorption to 1.2 ± 0.3 %/d at the beginning and 0.6 ± 0.2 %/d at the end of 
the study. Similar values were observed in the PTH treated group. Combining PTH treatment 
and loading reduced bone resorption rate significantly during the first two weeks of the study 
compared to any other group. However, during the last two weeks, similar values for all three 
4 Results 4.4 Loading in pharmacological treated ovariectomized mice 
 
~ 93 ~ 
treated groups (loading, PTH treatment, PTH treatment plus loading) were observed. All 
values were significantly lower than in the non-treated group. (Figure 22d) 
During the first two weeks, mineral resorption rate ranged between 1.8 to 1.9 µm per day for 
all groups. However, PTH treatment increased mineral resorption rate with a delay. This 
could be expected, as the physiologic function of PTH is to increase blood calcium levels by 
increasing bone resorption. Loading in combination with PTH treatment increased the rise in 
MRR significantly. (Figure 22e) 
Eroded surface was highest in VEH 0N animals. It reached values of 32.1 ± 2.7 % to 
33.7 ± 1.9 %. Both, loading and PTH treatment, reduced the amount of eroded surface to a 
similar extend (27.7 ± 5.0 % to 28.8 ± 4.6 % during the first two weeks and 23.6 ± 4.0 % to 
21.6 ± 4.2 % during the last two weeks). PTH treatment in combination with loading 
decreased ES significantly to 17.9 ± 5.6 % during the first two weeks of the observation 
period. However, as observed for BRR, during the last two weeks of the study no differences 
were observed between loaded, PTH treated or PTH treated and loaded animals. (Figure 22f) 
While BFR was influenced by both MAR and MS, the effect of PTH and loading on BRR was 
mainly due to the effect on the amount of eroded surface. Although PTH treatment in 
combination with loading even increased MRR significantly compared to vehicle treated 
animals, this was compensated by a significantly lower ES resulting in an overall lower bone 
resorption rate than in vehicle treated non-loaded animals. 
 
The values of the dynamic parameters can be seen in Table 12.
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Figure 22: dynamic parameters of PTH study in early loading experimental series. Upper row shows bone formation parameters, lower row shows bone resorption parameters 
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Late loading – static parameters 
Figure 23 shows overlaid CT images representing the loading period for each group. While a 
deteriorated bone structure can be observed in the VEH 0N group, it can be seen that both 
loading and PTH treatment improve the bone structure. The largest amount of bone formation 
can be found in the PTH 8N group. 
 
Figure 23: Visualization of bone development during 4 weeks of loading period. CT images of week 26 and 30 are 
overlaid and registered. Blue represents resorbed bone, yellow newly formed bone and grey constant bone. 
 
VEH 0N (n=8) 
The developments of static parameters in the VEH 0N group are comparable to those from the 
OVX 0N group of the ovariectomy and loading study. Total volume did not change during the 
observation period, while full bone volume fraction increased by 7.0 % from 3.8 ± 0.3 mm³ to 
4.0 ± 0.3 mm³ (Figure 24b). This resulted in a 5.4 % greater full bone volume density at the 
end of the observation period (Figure 24c). Both, cortical thickness and cortical % BV did not 
change during the study (Figure 24d, e). As already seen in the ovariectomy study, the loss of 
trabeculae continues to a small extend and by the end of the study Tb.N. was reduced by 
2.1 % (Figure 24f). This loss was compensated by a thickening of 4.5 % from of the 
remaining trabeculae (Figure 24g). Therefore trabecular bone volume density was increased, 
as well, by 11.2 % (Figure 24h).  
 
VEH 8N (n=9) 
Also loading did not change the total volume of the bone. Bone volume was increased by 
13.4 % from 3.8 ± 0.3 mm³ to 4.3 ± 0.2 mm³ (Figure 24b). This resulted in a significantly 
higher increase of full bone volume fraction by 11.7 % (Figure 24c). On one hand this was 
due to the thickening of the cortex by 5.0 % from 130.8 ± 4.5 µm to 137.33 ± 3.8 µm (Figure 
24d) and the consequently increase in cortical % BV by 8.0 % (Figure 24e). On the other 
hand, although loss of trabeculae could not be stopped, the thickening of trabeculae by 14.6 % 
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from 63.8 ± 3.1 µm to 73.1 ± 3.8 µm (Figure 24g) improved trabecular bone volume density 
by 24.1 % (Figure 24h), which contributed to the higher Full BV/TV as well. 
 
PTH 0N (n=9) 
PTH treatment increased total volume only slightly by 3.7 % from 8.8 ± 0.5 mm³ to 
9.1 ± 0.6 mm³ (Figure 24a). The effect of PTH on full bone volume fraction was stronger than 
the effect of loading. After 4 weeks of treatment it was increased by 19.5 % (Figure 24b). 
Hence, also the rise of 15.2 % in full bone volume density was higher than in loaded animals 
(Figure 24c). The fact that PTH treatment has a stronger effect than loading was not observed 
for cortical thickness, which did not change at all during the treatment period. However, the 
increase of 13.3 % in cortical % BV was higher than in the loaded group (Figure 24e). As it 
was already observed in the early loading experimental series, PTH treatment seems to stop 
the on-going loss of trabeculae (Figure 24f) and enhance the thickening of all trabeculae. 
After 4 weeks of treatment trabecular thickness increased from 62.0 ± 2.8 µm to 
74.3 ± 2.7 µm, which is an increase by 20.0 % (Figure 24g). Because no trabeculae were lost 
and mean thickness increased, trabecular bone volume density increased significantly by 
48.4 % (Figure 24h).  
 
PTH 8N (n=11) 
Also the combination of PTH and loading increased the total volume only by 4.8 % (Figure 
24a). However, bone volume was increased by 30.7 % from 3.9 ± 0.5 mm³ to 5.0 ± 0.3 mm³ 
(Figure 24b). This shows the synergistic effect of the combined PTH treatment and 
mechanical loading. The combination of both also revealed a synergistic effect on Full 
BV/TV, which was increased significantly by 26.67 % by the end of the study (Figure 24c). 
While only PTH treatment did not have an effect on cortical thickness, loading of PTH treated 
animals revealed synergistic effects as Ct. Th. was increased by 8.3 % from 131 ± 5.6 µm to 
142 ± 5.0 µm (Figure 24d). This resulted in a 22.2 % greater cortical % BV (Figure 24e). As 
already observed in the early loading study, PTH treatment stops the loss of trabeculae 
(Figure 24f). This effect was not influenced by loading in PTH treated animals. However, the 
combined PTH treatment and loading displayed their synergistic effect also for trabecular 
thickness. After 4 weeks trabeculae were thickened by 35.1 %, which was an increase from 
64.0 ± 3.0 µm to 86.4 ± 5.3 µm (Figure 24h). Since trabeculae did not vanish but got thicker, 
trabecular bone volume density was increasing significantly as well by 61.5 % (Figure 24h). 
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Absolute values of the PTH study can be seen in Table 10. Values normalized to week 26 are 
shown in Table 11. 
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Figure 24: static parameters of PTH 
study from late loading experimental 
series. Measurements normalized to first 
measurement at beginning of loading 
period. a), b) parameters from full bone; 
c)-g) parameters from trabecular 
compartment; h), I) cortical parameters 
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Late loading – dynamic parameters 
 
Bone formation 
Vehicle treated non-loaded animals showed the significantly lowest bone formation rate 
during the entire study. It was 1.8 ± 0.2 %/d during the first two weeks and dropped to 
1.0 ± 0.4 %/d during the last two weeks of the observation period. Loading increased bone 
formation rate to 2.7 ± 0.5 %/d during the first two weeks. Again a drop was observed in the 
last two weeks of the observation period resulting in a similar bone formation rate as VEH 0N 
animals. Treating animals with PTH significantly increased bone formation rate to 
4.9 ± 0.5 %/d and when loading was added it even reached 6.1 ± 0.6 %/d at the beginning of 
the study. Again in both groups a drop during the last two weeks was observed and the PTH 
0N and PTH 8N group were not significantly different anymore. (Figure 25a) 
With 1.4 ± 0.1 µm/d MAR was lowest in VEH 0N mice and with 2.3 ± 0.1 µm/d highest in 
PTH 8N animals. Again a drop was observed in all groups during the last two weeks and 
while there were tendencies towards a higher MAR in the loaded groups compared to the non-
loaded, no significant differences were observed between the two vehicle treated groups and 
the PTH treated groups, respectively. (Figure 25b) 
The mineralizing surface ranged in the first two weeks between 49.7 ± 2.4 % in the VEH 0N 
group and 77.4 ± 4.7 % in the PTH 8N group. Again a drop was observed for all groups 
during the last two weeks. However, mineralizing surface was significantly higher in the 
loaded groups throughout the entire study. (Figure 25c) 
Hence, while PTH seems to have influenced both MAR and MS, loading only exerted the 
strongest effect on MS. 
 
Bone resorption 
Bone resorption rate was highest in VEH 0N animals. It reached 1.0 ± 0.2 %/d during the first 
two weeks and dropped to 0.8 ± 0.3 %/d during the last two weeks of the study. Loading 
decreased the rate significantly to 0.7 ± 0.2 %/d at the beginning and 0.5 ± 0.3 %/d at the end 
of the study. Interestingly, PTH treatment alone did not influence bone resorption 
significantly with 0.9 ± 0.2 %/d and 0.6 ± 0.2 %/d bone resorption rate was comparable to the 
VEH 0N group. Again loading induced a significant decrease. PTH treated, loaded animals 
had a bone resorption rate of 0.6 ± 0.2 %/d which dropped to 0.4 ± 0.1 %/d at the end of the 
study. (Figure 25d) 
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Mineral resorption rate was at 1.8 ± 0.3 µm/d and dropped to 1.3 ± 0.2 µm/d in the VEH 0N 
group. Loading decreased MRR only marginally to 1.7 ± 0.2 µm/d during the first two weeks 
of the study. A drop during the last two weeks was observed in the VEH 8N group as well. 
Interestingly PTH treatment increased MRR to 2.4 ± 0.3 µm/d and 2.1 ± 0.3 µm/d, 
respectively. This is expected when the physiological function of PTH is taken into 
consideration, which is to increase the calcium levels in the blood. To do so, bone has to be 
resorbed and calcium is released from the storages within the bone. Loading in combination 
with PTH treatment even enhanced MRR to a small extend. PTH 8N mice had a MRR of 
2.5 ± 0.3 µm/d and 2.2 ± 0.4 µm/d, respectively. (Figure 25e) 
Eroded surface showed a similar pattern as bone resorption rate. The largest amount of eroded 
surface could be found in VEH 0N animals. It was 24.6 ± 1.9 % during the first two weeks of 
the observation period and covered 30.3 ± 4.9 % by the end of the observation period. 
Loading reduced the amount covered by eroded surface significantly to 19.1 ± 3.9 % and 
23.1 ± 6.0 %, respectively. In contrast to bone resorption rate, PTH treatment did reduce 
eroded surface to similar values as in loaded animals. When loading was combined with PTH 
treatment significantly less bone was covered by eroded surface. The amount was 
12.5 ± 3.2 % at the beginning of the observation period and 17.5 ± 2.8 % at the end. (Figure 
25f) 
Hence the reduction of eroded surface compensated for the increased mineral resorption rate 
and still resulted in a reduced bone resorption rate when mice were loaded or treated with 
PTH or the combination of both. 
The values of the dynamic parameters for the late loading experimental series are shown in 
Table 12. 
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Figure 25: dynamic parameters of PTH study in late loading experimental series. Upper row shows bone formation parameters, lower row shows bone resorption parameters
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Parameter 
group 
Full TV [mm³] Full BV [mm³] Full BV/TV [%] Ct.Th [µm] cort % BV [%] Tb.N [1/mm] Tb.Th [µm] Trab BV/TV [%] 
early loading 
        
VEH 0N 
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.5 ± 0.2 
8.2 ± 0.4 
8.3 ± 0.4 
8.4 ± 0.3 
3.9 ± 0.2 
3.8 ± 0.2 
3.8 ± 0.2 
3.9 ± 0.2 
52.6 ± 2.5 
45.8 ± 2.1 
45.9 ± 2.2 
46.6 ± 2.2 
144.5 ± 8.0 
139.8 ± 5.3 
138.4 ± 5.6 
139.2 ± 5.2 
38.8 ± 2.5 
34.2 ± 2.2 
34.2 ± 2.3 
34.8 ± 2.1 
2.9 ± 0.1 
2.9 ± 0.2 
2.7 ± 0.2 
2.7 ± 0.2 
77.7 ± 3.3 
66.8 ± 2.5 
65.9 ± 2.5 
67.4 ± 2.9 
18.5 ± 1.7 
14.0 ± 1.0 
12.8 ± 0.8 
13.0 ± 0.6 
VEH 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.5 ± 0.4 
8.4 ± 0.4 
8.5 ± 0.4 
8.6 ± 0.4 
3.8 ± 0.2 
3.8 ± 0.2 
4.1 ± 0.2 
4.4 ± 0.2 
50.7 ± 2.1 
45.4 ± 1.6 
48.4 ± 1.0 
50.6 ± 0.9 
137.5 ± 5.9 
135.9 ± 4.4 
137.0 ± 3.8 
140.4 ± 3.4 
36.4 ± 2.1 
33.5 ± 1.3 
34.2 ± 1.1 
35.6 ± 1.0 
3.1 ± 0.2 
3.0 ± 0.2 
2.9 ± 0.2 
2.8 ± 0.2 
77.6 ± 4.1 
67.3 ± 3.2 
72.4 ± 2.7 
78.6 ± 2.7 
19.1 ± 2.5 
14.8 ± 1.8 
15.7 ± 1.5 
17.1 ± 1.3 
PTH 0N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.5 ± 0.4 
8.2 ± 0.5 
8.4 ± 0.5 
8.6 ± 0.5 
3.9 ± 0.3 
3.7 ± 0.3 
4.0 ± 0.3 
4.4 ± 0.3 
52.0 ± 4.3 
45.8 ± 3.2 
47.4 ± 3.1 
51.6 ± 3.6 
143.5 ± 9.6 
139.5 ± 9.0 
133.4 ± 7.6 
137.0 ± 6.4 
38.0 ± 3.3 
34.4 ± 3.0 
34.2 ± 2.8 
37.7 ± 3.0 
3.0 ± 0.2 
2.9 ± 0.2 
2.8± 0.2 
2.8 ± 0.2 
77.8 ± 6.4 
65.4 ± 3.4 
68.2 ± 4.2 
75.7 ± 4.9 
18.9 ± 2.9 
14.0 ± 1.6 
16.3 ± 1.7 
19.2 ± 2.4 
PTH 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.5 ± 0.5 
8.2 ± 0.5 
8.5 ± 0.4 
8.8 ± 0.4 
3.8 ± 0.2 
3.7 ± 0.2 
4.3 ± 0.1 
4.8 ± 0.2 
51.2 ± 2.6 
45.0 ± 2.0 
50.7 ± 1.9 
54.7 ± 1.3 
136.8 ± 5.0 
134.6 ±3.4 
135.6 ± 3.8 
141.0 ± 3.3 
36.6 ± 2.0 
33.2 ± 1.4 
35.4 ± 1.7 
38.9 ± 1.4 
3.1 ± 0.2 
3.0 ± 0.2 
2.9 ± 0.2 
3.0 ± 0.3 
75.1 ± 4.2 
63.6 ± 2.8 
75.9 ± 3.2 
84.5 ± 3.7 
19.3 ± 2.3 
14.2 ± 1.8 
19.1 ± 1.4 
23.4 ± 2.0 
late loading 
        
VEH 0N 
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.7 ± 0.4 
8.6 ± 0.4 
8.6 ± 0.3 
8.7 ± 0.3 
4.2 ± 0.2 
3.8 ± 0.3 
3.9 ± 0.3 
4.0 ± 0.3 
54.6 ± 2.5 
43.9 ± 1.8 
45.3 ± 2.0 
46.2 ± 1.6 
149.1 ± 8.7 
130.7 ± 7.3 
131.4 ± 7.6 
132.7 ± 7.4 
40.4 ± 2.9 
32.2 ± 2.0 
33.0 ± 2.1 
33.3 ± 1.8 
3.0 ±0.2 
2.8 ± 0.2 
2.7 ± 0.2 
2.7 ± 0.2 
76.2 ± 4.0 
63.3 ± 2.8 
64.7 ± 3.5 
66.1 ± 3.0 
18.9 ± 1.8 
12.0 ± 1.2 
12.8 ± 1.3 
13.3 ± 1.0 
VEH 8N         
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.6 ± 0.6 
8.6 ± 0.6 
8.6 ± 0.6 
8.7 ± 0.6 
4.1 ± 0.5 
3.8 ± 0.3 
4.1 ± 0.2 
4.3 ± 0.2 
53.8 ± 3.5 
44.2 ± 1.7 
47.1 ± 1.6 
49.4 ± 1.4 
147.1 ± 10.4 
130.8 ± 4.5 
133.7 ± 4.4 
137.3 ± 3.8 
39.7 ± 2.9 
32.3 ± 1.4 
33.6 ± 1.4 
34.9 ± 1.5 
3.0 ± 0.2 
2.7 ± 0.3 
2.7 ± 0.3 
2.6 ± 0.3 
74.7 ± 6.3 
63.8 ± 3.1 
67.9 ± 3.2 
73.1 ± 3.8 
18.7 ± 3.1 
12.5 ± 1.1 
14.2 ± 1.2 
15.5 ± 1.2 
PTH 0N         
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.8 ± 0.4 
8.8 ± 0.5 
8.9 ± 0.5 
9.1 ± 0.6 
4.4 ± 0.3 
3.8 ± 0.3 
4.2 ± 0.2 
4.6 ± 0.3 
57.1 ± 3.6 
43.7 ± 2.0 
46.7 ± 1.8 
50.3 ± 1.8 
154.5 ± 11.7 
131.3 ± 4.3 
129.0 ± 3.8 
132.2 ± 3.7 
41.9 ± 3.7 
31.5 ± 1.7 
32.7 ± 1.5 
35.7 ± 1.7 
3.1 ± 0.2 
2.8 ± 0.2 
2.8 ± 0.2 
2.8 ± 0.2 
79.0 ± 5.1 
62.0 ± 2.8 
67.0 ± 2.8 
74.3 ± 2.7 
21.8 ± 3.0 
12.6 ± 1.5 
16.0 ± 2.0 
18.6 ± 1.9 
PTH 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.8 ± 0.5 
8.8 ± 0.5 
9.0 ± 0.5 
9.2 ± 0.5 
4.2 ± 0.3 
3.9 ± 0.3 
4.5 ± 0.3 
5.0 ± 0.3 
54.2 ± 1.9 
43.7 ± 1.7 
49.7 ± 1.7 
54.5 ± 1.8 
147.2 ± 5.3 
131.0 ± 5.6 
134.2 ± 5.0 
141.7 ± 5.0 
39.7 ± 1.4 
31.6 ± 1.6 
34.5 ± 1.8 
38.6 ± 1.7 
3.0 ± 0.3 
2.8 ± 0.2 
2.7 ± 0.2 
2.8 ± 0.2 
76.6 ± 3.7 
64.0 ± 2.9 
75.9 ± 4.6 
86.4 ± 5.3 
19.6 ± 2.2 
13.2 ± 1.5 
17.7 ± 1.5 
21.2 ± 1.9 
Table 10: absolute values of static parameters of PTH studies in early and late loading experimental series. Expressed as mean ± standard deviation 
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Parameter 
group 
Full TV [%] Full BV [%] Full BV/TV [%] Ct.Th [%] cort % BV [%] Tb.N [%] Tb.Th [%] Trab BV/TV [%] 
early loading         
VEH 0N 
20 weeks 
22 weeks 
24 weeks 
100.0 
101.4 ± 0.5 
102.5 ± 1.0
 a)b)
 
100.0 
101.8 ± 0.9 
104.4 ± 1.2
 a)b)c)
 
100.00 
100.3 ± 0.8 
101.9 ± 1.2
 a)b)c)
 
100.00 
99.0 ± 0.8 
99.6 ± 1.0
 a)c)
 
100.00 
100.0 ± 0.9 
101.5 ± 1.4
 a)b)c)
 
100.00 
94.5 ± 3.0 
93.4 ± 2.5
 a)b)
 
100.00 
98.6 ± 1.9 
101.0 ± 2.6
 a)b)c)
 
100.00 
91.7 ± 3.2 
93.3 ± 3.6
 a)b)c)
 
VEH 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
101.8 ± 0.7 
103.1 ± 1.0
 a)b)
 
100.0 
108.5 ± 2.6 
115.1 ± 4.2
 a)b)d)
 
100.00 
106.6 ± 2.1 
111.5 ± 3.1
 a)d)
 
100.00 
100.8 ± 1.0 
103.3 ± 1.7
 b)d)
 
100.00 
102.1 ± 1.5 
106.4 ± 3.0
 a)b)d)
 
100.00 
96.0 ± 1.8 
93.2 ± 2.6
 a)b)
 
100.00 
107.8 ± 3.6 
117.1 ± 6.0
 a)d)
 
100.00 
106.7 ± 6.9 
116.6 ± 9.8
 a)b)d)
 
PTH 0N         
20 weeks 
22 weeks 
24 weeks 
100.0 
103.0 ± 0.4 
105.4 ± 0.6
 a)c)d)
 
100.0 
106.7 ± 3.4 
118.9 ± 4.6
 a)c)d)
 
100.00 
103.6 ± 3.2 
112.8 ± 4.9
 a)d)
 
100.00 
95.7 ± 2.2 
98.4 ± 3.3
 a)c)
 
100.00 
99.4 ± 3.0 
109.7 ± 3.7
 a)c)d)
 
100.00 
97.1 ± 1.6 
96.8 ± 2.5
 c)d)
 
100.00 
104.4 ± 5.0 
115.8 ± 5.9
 a)d)
 
100.00 
116.8 ± 8.4 
137.5 ±10.9 
a)c)d)
 
PTH 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
103.5 ± 0.8 
107.1 ± 1.5
 b)c)d)+)
 
100.0 
116.6 ± 3.0  
130.3 ± 3.4 
b)c)d)+)
 
100.00 
112.6 ± 2.7 
121.7 ± 3.0
 b)c)d)+)
 
100.00 
100.8 ± 1.4 
104.8 ± 1.5
 b)d)+)
 
100.00 
106.8 ± 2.0 
117.2 ± 2.8
 b)c)d)+)
 
100.00 
96.2 ± 2.1 
99.2 ± 4.4
 c)d)+)
 
100.00 
119.5 ± 6.4 
133.1 ± 8.2
 b)c)d)+)
 
100.00 
135.5 ± 12.3 
166.3 ±16.8 
b)c)d)+)
 
late loading 
        VEH 0N 
26 weeks 
28 weeks 
30 weeks 
100.0 
99.8 ± 0.8  
101.3 ± 0.9
 a)b)
 
100.0 
103.1 ± 1.5 
106.8 ± 1.6
 a)b)c)
 
100.00 
103.3 ± 1.2 
105.4 ± 1.2
 a)b)c)
 
100.00 
100.6 ± 0.8 
101.6 ± 1.3
 a)c)
 
100.00 
102.5 ± 1.1 
103.5 ± 1.3
 a)b)c)
 
100.00 
98.5 ± 1.9 
97.9 ± 2.4 
100.00 
102.3 ± 2.2 
104.5 ± 2.1
 a)b)c)
 
100.00 
106.0 ± 2.8 
111.2 ± 4.7
 a)b)c)
 
VEH 8N         
26 weeks 
28 weeks 
30 weeks 
100.0 
100.4 ± 0.6 
101.5 ± 1.0
 a)b)
 
100.0 
107.1 ± 1.6 
113.4 ± 2.7
 a)b)d)
 
100.00 
106.6 ± 1.6 
111.7 ± 2.0
 a)b)d)
 
100.00 
102.2 ± 0.8 
105.0 ± 1.5
 a)b)d)
 
100.00 
104.0 ± 1.0 
108.0 ± 1.3
 a)b)d)
 
100.00 
97.9 ± 2.4 
96.9 ± 1.7
 a)b)
 
100.00 
106.5 ± 1.5 
114.6 ± 4.0
 a)b)d)
 
100.00 
113.2 ± 4.4 
124.1 ± 8.8
 a)b)d)
 
PTH 0N         
26 weeks 
28 weeks 
30 weeks 
100.0 
101.9 ± 0.8 
103.7 ± 1.2
 a)c)d)
 
100.0 
108.9 ± 2.8 
119.5 ± 2.1
 a)c)d)
 
100.00 
106.9 ± 2.7 
115.2 ± 1.9
 a)c)d)
 
100.00 
98.3 ± 1.5 
100.7 ± 2.6
 a)c)
 
100.00 
103.7 ± 2.2 
113.3 ± 1.8
 a)c)d)
 
100.00  
99.4 ± 1.9 
99.4 ± 2.9
 c)
 
100.00  
108.1 ± 2.9 
119.9 ± 3.5
 a)c)d)
 
100.00 
127.6 ± 7.1 
148.4 ± 7.7
 a)c)d)
 
PTH 8N         
26 weeks 
28 weeks 
30 weeks 
100.0 
101.8 ± 1.1 
104.8 ± 1.2
 b)c)d)+)
 
100.0 
115.7 ± 2.8 
130.7 ± 3.5 
b)c)d)#)
 
100.00 
113.7 ± 2.4 
124.7 ± 2.2
 b)c)d)#)
 
100.00 
102.5 ± 1.2 
108.3 ± 2.9
 b)c)d)#)
 
100.00 
109.2 ± 2.3 
122.2 ± 2.9
 b)c)d)#)
 
100.00 
98.5 ± 2.4 
99.8 ± 2.8
 c)+)
 
100.00 
118.6 ± 3.9 
135.1 ± 5.4
 b)c)d)#)
 
100.00 
134.8 ± 7.1 
161.5 ± 8.9
 b)c)d)+)
 
Table 11: static parameters of PTH studies of early and late loading experimental series normalized to beginning of loading period. a) Significant to PTH 8N, b) significant to PTH 0N, c) 
significant to VEH 8N, d) significant to VEH 0N for each study, +) combined effect of PTH and loading is additive, #) combined effect of PTH and loading is synergistic; values are presented as mean ± 
standard deviation 
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Parameter  
group 
BFR.BV [%/d] MAR [µm/d] MS [%] BRR.BV [%/d] MRR [µm/d] ES [%] 
early loading       
VEH 0N 
wk20_wk22 
wk22_wk24 
1.1 ± 0.2
 a)b)c)
 
1.2 ± 0.2
 a)b)
 
1.3 ± 0.1
 a)b)c)
 
1.3 ± 0.1
 a)b)
 
38.1 ± 2.3
 a)b)c)
 
40.6 ± 1.6
 a)b)c)
 
1.7 ± 0.4
 a)b)c)
 
1.2 ± 0.2
 a)b)c)
 
2.0 ± 0.2 
1.5 ± 0.1
 a)b)
 
33.7 ± 1.9
 a)b)c)
 
32.1 ± 2.7
 a)b)c)
 
VEH 8N       
wk20_wk22 
wk22_wk24 
1.6 ± 0.4
 a)b)d)
 
1.4 ± 0.4
 a)b)
 
1.4 ± 0.1
 a)b)d)
 
1.3 ± 0.2
 a)b)
 
47.1 ± 4.6
 a)d)
 
53.7 ± 4.8
 a)b)d)
 
1.2 ± 0.3
 a)d)
 
0.6 ± 0.2
 d)
 
1.8 ± 0.2 
1.5 ± 0.1
 a)b)
 
27.7 ± 5.0
 a)d)
 
23.6 ± 4.0
 d)
 
PTH 0N       
wk20_wk22 
wk22_wk24 
2.3 ± 0.6
 a)c)d)
 
2.1 ± 0.2
 c)d)
 
1.6 ± 0.1
 a)c)d)
 
1.5 ± 0.1
 c)d)
 
51.7 ± 6.0
 a)d)
 
64.3 ± 3.6
 a)c)d)
 
1.3 ± 0.3
 a)d)
 
0.6 ± 0.2
 d)
 
1.9 ± 0.2 
1.9 ± 0.3
 a)c)d)
 
28.8 ± 4.6
 a)d)
 
21.6 ± 4.2
 d)
 
PTH 8N       
wk20_wk22 
wk22_wk24 
3.6 ± 0.8
 b)c)d)
 
2.0 ± 0.2
 c)d)
 
1.8 ± 0.1
 b)c)d)
 
1.5 ± 0.1
 c)d)
 
65.7 ± 6.9
 b)c)d)
 
68.9 ± 4.0
 b)c)d)
 
0.6 ± 0.2
 b)c)d)
 
0.6 ± 0.2
 d)
 
1.8 ± 0.1 
2.4 ± 0.2
 b)c)d)
 
17.9 ± 5.6
 b)c)d)
 
21.0 ± 3.9
 d)
 
late loading 
      VEH 0N 
wk26_wk28 
wk28_wk30 
1.8± 0.2
 a)b)c)
 
1.0 ± 0.4
 a)b)
 
1.4± 0.1 
1.2 ± 0.1
 a)b)
 
49.7 ± 2.4
 a)b)c)
 
42.1 ± 1.9
 a)b)c)
 
1.0 ± 0.2
 a)c)
 
0.8 ± 0.3
 a)
 
1.8 ± 0.3
 a)b)
 
1.3 ± 0.2
 a)b)
 
24.6 ± 1.9
 a)b)c)
 
30.3 ± 4.9
 a)b)c)
 
VEH 8N       
wk26_wk28 
wk28_wk30 
2.7 ± 0.5
 a)b)d)
 
1.2 ± 0.3
 a)b)
 
1.6 ± 0.1 
1.2 ± 0.1
 a)b)
 
59.7 ± 3.3
 a)b)d)
 
52.3 ± 3.4
 a)b)d)
 
0.7 ± 0.2
 b)d)
 
0.5 ± 0.3
 
 
1.7 ±0.2
 a)b)
 
1.2 ± 0.2
 a)b)
 
19.1 ± 3.9
 a)d)
 
23.1 ± 6.0
 a)d)
 
PTH 0N       
wk26_wk28 
wk28_wk30 
4.9 ± 0.5
 a)c)d)
 
1.9 ± 0.3
 c)d)
 
2.1 ± 0.1 
1.4 ± 0.1
 c)d)
 
66.7 ± 1.8
 a)c)d)
 
63.8 ± 2.9
 a)c)d)
 
0.9 ± 0.2
 a)c)
 
0.6 ± 0.2 
2.4 ± 0.3
 c)d)
 
2.1 ± 0.3
 c)d)
 
19.2 ± 1.8
 a)d)
 
21.5 ± 3.3
 a)d)
 
PTH8N       
wk26_wk28 
wk28_wk30 
6.1 ± 0.6
 b)c)d)
 
2.0 ± 0.3
 c)d)
 
2.3 ± 0.1 
1.4 ± 0.1
 c)d)
 
77.4 ± 4.7
 b)c)d)
 
70.8 ± 2.7
 b)c)d)
 
0.6 ± 0.2
 b)d)
 
0.4 ± 0.1
 d)
 
2.5 ± 0.3
 c)d)
 
2.2 ± 0.4
 c)d)
 
12.5 ± 3.2
 b)c)d)
 
17.5 ± 2.8
 b)c)d)
 
Table 12: bone dynamic parameters of PTH studies. a) significant to PTH 8N, b) significant to PTH 0N, c) significant to VEH 8N, d) significant to VEH 0N for each study; values are 
presented as mean ± standard deviation 
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4.4.2 Bisphosphonate study 
At the beginning of the treatment period mice were injected once with the bisphosphonate 
zolendronate or 0.9 % NaCl, which served as a vehicle in these studies. Additionally all 
animals were subjected to 8N or 0N loading. 
 
Early loading – static parameters 
Figure 26 shows overlaid CT images representing the loading period for each group. While in 
the VEH 0N group bone loss continues, the amount of resorbed bone is reduced with 
bisphosphonate treatment. Loading increases bone formation in vehicle treated and 
bisphosphonate treated animals. 
 
Figure 26: Visualization of bone development during 4 weeks of loading period. CT images of week 20 and 
24 are overlaid and registered. Blue represents resorbed bone, yellow newly formed bone and grey 
constant bone. 
 
VEH 0N (n=9) 
In non-loaded vehicle treated mice a marginal increase of the total volume by 3.1 % from 
8.3 ±0.4 mm³ to 8.6 ±0.4 mm³ was observed after 4 weeks (Figure 27a). However, bone 
volume fraction remained stable. The marginal bone growth together with a stable bone 
volume resulted in a negligible reduction of Full BV/TV by 1.3 % (Figure 27c). Both cortical 
parameters, Ct. Th and cortical % BV were as well slightly reduced by 2.9 % and 2.5 %, 
respectively (Figure 27d,e). While the on-going effect of estrogen depletion reduced 
trabecular number by 10.2 % (Figure 27f), thickness of the remaining trabeculae stayed stable 
(Figure 27g). Nevertheless, due to fewer trabeculae, trabecular bone volume density was 
decreased by 14.2 % (Figure 27h). 
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VEH 8N (n=8) 
Total volume of loaded bones increased as well marginally by 3.0 % as it was observed in 
non-loaded animals (Figure 27a). However, loading increased bone volume fraction by 
11.8 % from 4.0 ± 0.4 mm³ to 4.5 ± 0.3 mm³ (Figure 27b). Thus an 8.5 % greater bone 
volume density was observed after 4 weeks of loading (Figure 27c). The effect of loading on 
the cortical compartment was only small. The cortex thickened by 2.8 % from 143.4 ± 8.4 µm 
to 147.8 ± 5.4 µm (Figure 27d) and cortical % BV was increased by 4.2 % (Figure 27e). 
However, as already observed in the vehicle groups of the PTH study and the OVX 8N groups 
of the ovariectomy study, loading had a greater impact on the trabecular compartment. 
Although the loss of trabeculae could not be stopped, four weeks of loading increased the 
thickness of the remaining ones by 18.0 % from 67.5 ± 3.2 µm to 79.6 ± 2.8 µm (Figure 27g). 
This thickening resulted in a 12.1 % greater trabecular bone volume density (Figure 27h).  
 
BIS 0N (n=9) 
Similarly to the vehicle treated groups, a marginal increase by 2.3 % of the total volume was 
observed in the bisphosphonate treated group (Figure 27a). Both, the effect of bisphosphonate 
treatment on full bone volume fraction and full bone volume density were comparable to the 
effect of loading. Full BV is increased by 11.5 % and Full BV/TV is 9.0 % greater after 4 
weeks of bisphosphonate treatment (Figure 27b,c). In the cortical compartment the impact of 
the antiresorptive drug was analogous to loading. The antiresorptive action could be observed 
nicely in the trabecular compartment. While in both vehicle groups loss of trabeculae 
continued, this was stopped with bisphosphonate treatment. The number of trabeculae 
remained stable at 2 per mm throughout the entire study (Figure 27f). Thickness of trabeculae 
is increased by only 5 % (Figure 27g). Although it is increased less than in loaded animals, as 
the quantity of trabeculae was preserved, bisphosphonate treatment resulted in a 14 % greater 
trabecular bone volume density than at the beginning of the study (Figure 27h).  
 
BIS 8N (n=10) 
Also combined loading and bisphosphonate treatment did not result in a higher total volume 
than in the other groups. However, both types of treatment had additive effects on bone 
volume fraction and full bone volume density. Full BV was increased by 18.8 % from 
4.0 ± 0.2 mm³ to 4.7 ± 0.3 mm³ and Full BV/TV by 14.8 % (Figure 27b,c). Loading of 
bisphosphonate treated animals thickened the cortex similarly as loading of vehicle treated 
animals (by 3.3 %). However, both effects added onto each other for cortical % BV, which 
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was increased by 7.5 % (Figure 27e). Again bisphosphonate treatment preserved trabeculae 
and with the combined loading trabecular thickness was increased by 18.8 % (Figure 27f,g). 
Thus, thickening of trabeculae was comparable to loaded animals; however, as trabecular 
number was preserved it applied to a larger amount of trabeculae. Therefore the increase in 
trabecular bone volume of 27.0 % was significantly higher than in any other group of the 
study (Figure 27h).  
Absolute values are shown in Table 13 and normalized values in Table 14.  
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Figure 27: static parameters of 
bisphosphonate study from early 
loading experimental series. 
Measurements normalized to first 
measurement at beginning of loading 
period. a), b) parameters from full 
bone; c)-g) parameters from 
trabecular compartment; h), I) 
cortical parameters 
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Early loading – dynamic parameters 
 
Bone formation 
Vehicle treated non-loaded animals showed with a rate of 1.3 ± 0.4 %/d the lowest bone 
formation rate during the first two weeks of the study. However, during the last two weeks 
bone formation rate rose to 1.4 ± 0.2 %/d. When loading was applied, bone formation rate 
was at 1.5 ± 0.3 %/d at the beginning but dropped to similar values as in non-loaded animals 
at the end of the study. While the bone formation rate of 1.4 ± 0.2 %/d during the first two 
weeks in bisphosphonate treated animals was higher as in vehicle treated animals it dropped 
to a significantly lower rate of 1.0 ± 0.2 %/d during the last two weeks of the study. Loading 
in combination with bisphosphonate treatment increased bone formation significantly to 
1.7 ± 0.4 %/d during the first two weeks. However, again a drop was observed towards the 
end of the study, resulting in a similar bone formation rate as in vehicle treated loaded 
animals, but still significantly higher as in bisphosphonate treated non-loaded animals. (Figure 
28a) 
Mineral apposition rate was similar in vehicle treated non-loaded and loaded animals during 
the entire study. It was at around 1.4 µm/d at the beginning and at around 1.3 µm/d at the end 
of the study. Bisphosphonate treatment reduced MAR to 1.3 ± 0.1 µm/d and 1.2 ± 0.1 µm/d, 
respectively. However, when loading was added to bisphosphonate treatment, it increased 
MAR to similar values as in vehicle treated animals. (Figure 28b) 
Mineralizing surface covered the smallest amount in VEH 0N animals with 33.2 ± 3.3 % and 
38.7 ± 2.8 %, respectively. In bones of loaded animals MS was increased significantly to 
46.3± 5.7 % during the first two weeks and reached even 53.0± 5.2 % at the end of the study. 
Bisphosphonate treatment increased MS surface significantly compared to vehicle treatment 
during the first two weeks of the study. However during the last two weeks it covered a 
similar amount as in VEH 0N animals and significantly less as in VEH 8N animals. 
Bisphosphonate treatment in combination with loading resulted in a similar amount of MS as 
vehicle treatment with loading at both time points. Hence, loading always increased MS no 
matter if treated with vehicle or with bisphosphonates. (Figure 28c) 
As the effect of loading or bisphosphonate treatment on mineral apposition rate was very 
small, bone formation rate seemed to be influenced mainly by mineralizing surface in this 
study. 
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Bone resorption  
The significantly highest bone resorption rate was observed in vehicle treated non-loaded 
animals with 2.5 ± 0.4 %/d and 1.6 ± 0.3 %/d, respectively. Loading reduced the rate to 
1.3 ± 0.3 %/d and 0.9 ± 0.2 %/d. With bisphosphonate treatment bone resorption went down 
to 0.9 ± 0.4 %/d at the beginning and 0.6 ± 0.2 %/d at the end of the study. This was a 
significantly lower rate than in any vehicle treated group. However, loading in 
bisphosphonate treated animals did not reduce the rate any further than bisphosphonate 
treatment alone. (Figure 28d) 
A similar pattern was observed for mineral resorption rate. The highest mineral resorption 
rates were observed for the vehicle treated groups, where MRR ranged between 1.7 µm/d and 
2.3 µm/d. Bisphosphonate treatment reduced MRR significantly to values between 1.1 µm/d 
and 1.3 µm/d. Again, no difference was observed between loaded and non-loaded 
bisphosphonate treated animals. (Figure 28e) 
With 32.5 ± 4.6 % and 31.3 ± 1.8 % eroded surface covered the largest amount in VEH 0N 
animals. Loading reduced ES to 26.7 ± 4.7 % and 23.9 ± 3.5 %, respectively. However, with 
31.0 ± 5.8 % at the beginning and 29.0 ± 3.8 % during the last two weeks eroded surface 
covered a similar amount in bisphosphonate treated animals as in vehicle treated animals. 
Again, when loading was applied to the bisphosphonate treated animals, ES was reduced, 
however, not significantly. (Figure 28f) 
Hence, bisphosphonate treatment reduced bone resorption mainly by reducing mineral 
resorption rate and not by influencing eroded surfaces while loading affected ES and not 
MRR. 
The values of the dynamic parameters can be seen in Table 15. 
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Figure 28: dynamic parameters of bisphosphonate study in early loading experimental series. Upper row shows bone formation parameters, lower row shows bone resorption parameters 
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Late loading – static parameters 
Figure 29 shows overlaid CT images representing the loading period for each group. Loading 
increases bone formation, while merely bisphosphonate treatment reduces bone resorption. 
 
Figure 29: Visualization of bone development during 4 weeks of loading period. CT images of week 26 and 
30 are overlaid and registered. Blue represents resorbed bone, yellow newly formed bone and grey 
constant bone. 
 
VEH 0N (n=8) 
Total volume was not changed and also bone volume fraction was only increased slightly by 
5.9 % from 4.3 ± 0.2 mm³ to 4.5 ± 0.3 mm³ (Figure 30a,b). This resulted in a 4.3 % greater 
bone volume density at the end of the observation period (Figure 30c). No changes could be 
noticed in the cortical compartment. As it was already seen in other vehicle groups, loss of 
trabeculae due to the effect of estrogen depletion continued. However, trabeculae got thicker 
by 7.3 % from 72.8 ± 3.7 µm to 78.2 ± 5.8 µm (Figure 30g). This is most likely a physiologic 
mechanism to maintain mechanical stability of the bone. Due to increased trabecular 
thickness, trabecular bone volume density was increased by 11.4 % by the end of the 
observation period (Figure 30h).  
 
VEH 8N (n=10) 
Loading had no effect on the total volume of the bone. However, bone volume was increased 
by 10.0 % from 4.1 ± 0.3 mm³ to 4.5 ± 0.3 mm³, which resulted in a 8.0 % greater bone 
volume density after four weeks of loading (Figure 30b,c). The impact on the cortical 
compartment was only marginally. Cortical thickness was increased by 2.8 % and cortical % 
BV by 4.3 % (Figure 30d,e). As already noticed in other studies, loading did not stop loss of 
trabeculae. However, it increased the thickness of the remaining ones in this group. Tb.Th 
was increased by 10.7 % from 71.3 ± 4.2 µm to 78.8 ± 4.3 µm (Figure 30g). Nevertheless, it 
has to be admitted that this was only slightly and not significantly more compared to the non-
loaded group of this study. Yet, the greater thickening resulted in a significantly greater 
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increase of trabecular bone volume density, compared to VEH 0N. After four weeks of 
loading Trab BV/TV was 20.6 % greater (Figure 30h). 
 
BIS 0N (n 9) 
Total volume was not changed and the increase of 7.5 % in full bone volume density was 
slightly more than in VEH 0N animals, but less than in loaded ones (Figure 30a,b). Hence, 
also the effect on Full BV/TV was less than in loaded animals. Cortical thickness remained 
stable and only a small increase by 3.2 % was observed for cortical % BV (Figure 30d,e). As 
already seen in the early loading study, the antiresorptive action of bisphosphonates could be 
monitored best in the trabecular compartment. It preserved trabecular structure as trabecular 
number remained at 2.7 per mm throughout the study (Figure 30f). Even a small thickening of 
6.1 % of the trabeculae was observed (Figure 30g). However, as in the late loading study 
compared to the early loading study more trabeculae were already lost before treatment 
started, preservation of trabeculae together with thickening did increase Trab BV/TV by 
16.4 % (Figure 30h). Nevertheless this is not as much as it was observed in the loaded group.  
 
 
BIS 8N (n= 11) 
Again Full TV was not changed throughout the observation period. The effect on full bone 
volume fraction was an additive effect of both, bisphosphonates and loading (Figure 30b). It 
was increased by 13.0 % from 4.1 ± 0.2 mm³ to 4.6 ± 0.2 mm³. This resulted in the 
significantly greatest increase of Full BV/TV in this study (10.8 %) (Figure 30c). The effect 
on the cortical compartment was significantly greater than for only bisphosphonate treated 
animals and also a trend towards a greater increase compared to only loaded animals was 
observed. Cortical thickness was increased by 3.4 %, while 4 weeks of loading and 
bisphosphonate treatment resulted in a 6.1 % greater cortical % BV (Figure 30d,e). Again 
bisphosphonate treatment preserved trabecular number. Together with a trabecular thickening 
by 12.5 % trabecular bone volume density was increased by 24.8 % by the end of the 
observation period (Figure 30f-h).  
 
Absolute values of all static parameters are shown in Table 13. Values normalized to week 26 
are shown in Table 14. 
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Figure 30: static parameters of 
bisphosphonate study from late loading 
experimental series. Measurements 
normalized to first measurement at 
beginning of loading period. a), b) 
parameters from full bone; c)-g) 
parameters from trabecular 
compartment; h), I) cortical 
parameters 
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Late loading – dynamic parameters 
 
Bone formation 
The bone formation rate of VEH 0N mice was at 1.1 ± 0.2 %/d during the first two weeks and 
at 1.0 ± 0.5 %/d during the last two weeks of the study. Loading increased bone formation 
only marginally and also bisphosphonate treatment did not influence bone formation. When 
bisphosphonate treatment was combined with loading a trend towards a higher bone 
formation rate could be observed as it was 1.3 ± 0.3 %/d during the first two weeks and 
1.3 ± 0.2 %/d during the last two weeks of the study. (Figure 31a) 
Mineral apposition rate was neither influenced by loading, nor by bisphosphonate treatment as 
it ranged between 1.2 µm/d and 1.3 µm/d for all groups during the entire study. (Figure 31b) 
Mineralizing surface covered 46.7 ± 5.0 % during the first two weeks and 45.4 ± 4.8 % during 
the last two weeks in VEH 0N animals. Again loading increased it only marginally, while 
bisphosphonate treatment did not influence the amount covered by mineralizing surface at all. 
When bisphosphonate treatment and loading were combined a slight trend towards a larger 
mineralizing surface was observed. (Figure 31c) 
 
Bone resorption  
The highest bone resorption rate was observed in vehicle treated non-loaded animals. It was at 
0.8 ± 0.3 %/d at the beginning and at 0.7 ± 0.3 %/d at the end of the observation period. 
Loading reduced the rate significantly to 0.6 ± 0.3 %/d throughout the entire study. During the 
first two weeks bisphosphonate treatment reduced BRR even further to 0.5 ± 0.2 %/d. 
However the rate increased again to 0.7 ± 0.3 %/d at the end of the study. The lowest bone 
resorption rate was observed when bisphosphonate treatment and loading were combined. 
(Figure 31d) 
A similar pattern was observed for mineral resorption rate. In vehicle treated non-loaded 
animals this rate was at 1.5 ± 0.2 µm/d at the beginning and at 1.4 ± 0.2 µm/d at the end of the 
study. Loading reduced mineral resorption rate significantly during the first two weeks, while 
no differences were observed during the last two weeks of the study. Bisphosphonate 
treatment reduced MRR to rates between 1.1 µm/d and 1.2 µm/d regardless if the loading was 
applied. (Figure 31e) 
Eroded surface covered 27.5 ± 4.4 % and 29.0 ± 4.6 %, respectively in vehicle treated non-
loaded animals. Applying loading reduced the amount to around 25 %, while bisphosphonate 
treatment did not change ES. However, combining bisphosphonate treatment and loading 
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reduced ES to similar values as only loading. In BIS 8N animals it covered 24.1 ± 5.3 % 
during the first two weeks and 24.5 ± 5.7 % during the last two weeks. (Figure 31f) 
Hence while bisphosphonate treatment reduced mineral resorption rate the effect on eroded 
surface was only mediated by loading. Both effects influenced bone resorption rate to similar 
extends, although in the first two weeks the effect of bisphosphonate treatment seemed to be 
stronger, while during the last two weeks the effect of loading seemed to be more pronounced. 
Values of dynamic parameters are shown in Table 15. 
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Figure 31: dynamic parameters of bisphosphonate study in late loading experimental series. Upper row shows bone formation parameters, lower row shows bone resorption parameters 
 ~ 121 ~ 
Parameter 
group 
Full TV [mm³] Full BV [mm³] Full BV/TV [%] Ct.Th [µm] cort % BV [%] Tb.N [1/mm] Tb.Th [µm] Trab BV/TV [%] 
early loading 
        
VEH 0N 
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.8 ± 0.3 
8.3 ± 0.4 
8.5 ± 0.4 
8.6 ± 0.4 
4.1 ± 0.3 
3.7 ± 0.4 
3.7 ± 0.4 
3.8 ± 0.3 
53.3 ± 2.4 
44.5 ± 4.5 
43.3 ± 3.5 
43.7 ± 3.1 
149.1 ± 6.4 
138.2 ± 11.7 
134.2 ± 9.7 
133.8 ± 7.7 
39.6 ± 2.0 
33.2 ± 3.9 
32.0 ± 2.8 
32.2 ± 2.4 
2.9 ± 0.2 
2.8 ± 0.2 
2.6 ± 0.2 
2.5 ± 0.2 
73.2 ± 4.3 
64.3 ± 4.1 
63.6 ± 3.4 
64.1 ± 3.5 
17.4 ± 1.6 
13.1 ± 2.4 
11.4 ± 1.8 
11.1 ± 1.6 
VEH 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.9 ± 0.7 
8.5 ± 0.8 
8.7 ± 0.7 
8.8 ± 0.7 
4.2 ± 0.4 
4.0 ± 0.4 
4.2 ± 0.3 
4.5 ± 0.3 
52.7 ± 2.2 
46.9 ± 3.0 
48.8 ± 2.5 
50.8 ± 2.2 
148.1 ± 6.8 
143.9 ± 8.4 
144.1 ± 7.0 
147.8 ± 5.4 
39.3 ± 1.7 
35.5 ± 2.9 
35.8 ± 2.4 
36.9 ± 2.0 
2.9 ± 0.3 
2.8 ± 0.2 
2.7 ± 0.2 
2.6 ± 0.2 
71.9 ± 3.8 
67.5 ± 3.2 
72.6 ± 2.3 
79.6 ± 2.8 
17.2 ± 2.3 
13.9 ± 1.8 
14.6 ± 1.7 
15.5 ± 1.6 
BIS 0N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.6 ± 0.5 
8.3 ± 0.5 
8.4 ± 0.5 
8.4 ± 0.5 
3.9 ± 0.5 
3.7 ± 0.4 
3.9 ± 0.3 
4.1 ± 0.3 
51.2 ± 2.8 
44.2 ± 2.7 
46.8 ± 1.9 
48.1 ± 1.7 
140.5 ± 6.9 
135.1 ± 6.8 
136.1 ± 4.4 
137.0 ± 4.5 
37.6 ± 2.1 
33.1 ± 2.3 
34.0 ± 1.8 
34.6 ± 1.6 
3.1 ± 0.3 
2.9 ± 0.3 
2.9 ± 0.3 
2.9 ± 0.2 
68.9 ± 4.6 
63.2 ± 2.2 
64.9 ± 2.5 
66.3 ± 3.0 
17.3 ± 2.5 
13.0 ± 1.2 
14.0 ± 0.7 
14.9 ± 0.7 
BIS 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.9 ± 0.2 
8.6 ± 0.3 
8.8 ± 0.3 
8.9 ± 0.3 
4.2 ± 0.3 
3.9 ± 0.2 
4.4 ± 0.2 
4.7 ± 0.3 
52.6 ± 2.9 
45.6 ± 1.9 
49.7 ± 1.9 
52.3 ± 2.1 
146.6 ± 8.5 
140.6 ± 5.3 
142.6 ± 5.8 
145.3 ± 6.5 
38.9 ± 2.6 
34.0 ± 2.0 
35.5 ± 2.1 
36.5 ± 2.0 
3.0 ± 0.3 
2.9 ± 0.2 
2.9 ± 0.2 
2.9 ± 0.2 
72.1 ± 4.6 
65.9 ± 4.3 
70.9 ± 4.5 
78.2 ± 6.1 
17.5 ± 2.5 
14.2 ± 1.8 
15.7 ± 1.7 
18.0 ± 2.1 
late loading 
        
VEH 0N 
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.8 ± 0.2 
8.7 ± 0.4 
8.8 ± 0.4 
8.8 ± 0.4 
4.3 ± 0.2 
4.3 ± 0.2 
4.4 ± 0.3 
4.5 ± 0.3 
55.4 ± 3.3 
49.1 ± 2.3 
50.3 ± 2.5 
51.2 ± 2.7 
157.0 ± 9.0 
147.8 ± 5.9 
149.0 ± 6.5 
150.1 ± 6.7 
41.4 ± 2.7 
36.6 ± 2.3 
37.1 ± 2.3 
37.5 ± 2.3 
2.9 ± 0.3 
2.7 ± 0.3 
2.6 ± 0.3 
2.6 ± 0.3 
77.5 ± 4.2 
72.8 ± 3.7 
75.6 ± 5.0 
78.2 ± 5.8 
19.0 ± 2.7 
14.2 ± 2.2 
15.1 ± 2.7 
15.8 ± 2.8 
VEH 8N         
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.6 ± 0.3 
8.5 ± 0.4 
8.5 ± 0.5 
8.6 ± 0.5 
4.0 ± 0.3 
4.1 ± 0.3 
4.3 ± 0.3 
4.5 ± 0.3 
52.9 ±2.0 
48.0 ± 3.6 
50.1 ± 3.5 
51.9 ± 2.9 
151.0 ± 5.4 
142.8 ± 8.8 
144.8 ± 9.5 
147.2 ± 8.0 
40.2 ± 1.7 
35.8 ± 3.4 
36.8 ± 3.4 
37.6 ± 2.7 
2.8 ± 0.3 
2.6 ± 0.2 
2.6 ± 0.3 
2.6 ± 0.3 
73.6 ± 2.9 
71.3 ± 4.2 
74.8 ± 4.1 
78.8 ± 4.3 
16.1 ± 2.9 
13.3 ± 2.1 
14.6 ± 2.2 
16.0 ± 2.2 
BIS 0N          
15 weeks 
26 weeks 
28 weeks 
30 weeks 
7.6 ± 0.8 
8.5 ± 0.9 
8.5 ± 0.9 
8.6 ± 0.9 
4.1 ± 0.5 
3.9 ± 0.4 
4.1 ± 0.5 
4.2 ± 0.5 
53.8 ± 2.4 
45.9 ± 2.1 
47.6 ± 2.2 
48.8 ± 2.3 
151.1 ± 7.6 
137.4 ± 4.5 
138.3 ± 6.0 
138.7 ± 6.1 
40.0 ± 1.8 
33.5 ± 1.3 
34.1 ± 1.5 
34.5 ± 1.6 
3.0 ± 0.2 
2.6 ± 0.1 
2.7 ± 0.1 
2.7 ± 0.1 
73.9 ± 3.8 
67.3 ± 3.1 
69.0 ± 3.8 
71.4 ± 4.0 
18.0 ± 2.0 
12.8 ± 1.3 
13.7 ± 1.5 
14.9 ± 1.6 
BIS 8N         
15 weeks 
20 weeks 
22 weeks 
24 weeks 
7.6 ± 0.3 
8.6 ± 0.3 
8.6 ± 0.3 
8.7 ± 0.3 
4.2 ± 0.2 
4.1 ± 0.2 
4.3 ± 0.2 
4.6 ± 0.2 
55.3 ± 2.2 
47.4 ± 2.4 
50.2 ± 2.4 
52.5 ± 2.3 
155.4 ± 6.3 
141.8 ± 7.4 
143.9 ± 6.6 
146.8 ± 5.8 
41.8 ± 2.0 
35.2 ± 2.0 
36.4 ± 1.8 
37.3 ± 1.6 
2.9 ± 0.2 
2.7 ± 0.3 
2.7 ± 0.3 
2.7 ± 0.3 
75.5 ± 3.5 
68.6 ± 1.7 
71.8 ± 1.8 
77.2 ± 2.2 
18.0 ± 1.8 
13.1 ± 1.8 
14.5 ± 2.0 
16.3 ± 1.9 
 Table 13: absolute values of static parameters of bisphosphonate studies in early and late loading experimental series. Expressed as mean ± standard deviation  
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Parameter 
group 
Full TV [%] Full BV [%] Full BV/TV [%] Ct.Th [%] cort % BV [%] Tb.N [%] Tb.Th [%] Trab BV/TV [%] 
early loading         
VEH 0N 
20 weeks 
22 weeks 
24 weeks 
100.0 
102.4 ± 1.3 
103.1 ± 1.6 
100.0 
100.0 ± 2.8 
101.8 ± 4.8
 a)b)c)
 
100.00 
97.7 ± 2.4 
98.7 ± 4.0
 a)b)c)
 
100.00 
97.2 ± 1.8 
97.1± 3.6
 a)b)c)
 
100.00 
96.9 ± 4.0 
97.5 ± 6.1
 a)b)c)
 
100.00 
93.0 ± 3.6 
89.8 ± 5.1
 a)b)
 
100.00 
98.9 ± 2.7 
99.8 ± 5.6
 a)b)c)
 
100.00 
87.2 ± 5.0 
85.8 ± 8.3
 a)b)c)
 
VEH 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
101.6 ± 0.9 
103.0 ± 1.2 
100.0 
105.9 ± 2.8 
111.8 ± 4.0
 a)d)
 
100.00 
104.2 ± 2.2 
108.5 ± 3.1
 a)d)
 
100.00 
100.2 ± 1.8 
102.8 ± 3.0
 d)
 
100.00 
100.9 ± 2.2 
104.2 ± 3.9
 d)
 
100.00 
93.9 ± 4.4 
91.2 ± 4.8
 a)b)
 
100.00 
107.6 ± 4.5 
118.0 ± 5.3
 b)d)
 
100.00 
105.3 ± 8.0 
112.1 ± 9.2
 a)d)
 
BIS 0N         
20 weeks 
22 weeks 
24 weeks 
100.0 
101.9 ± 0.7 
102.3 ± 1.0 
100.0 
108.0 ± 3.1 
111.5 ± 4.2
 a)d)
 
100.00 
105.9 ± 2.5 
109.0 ± 3.6
 a)d)
 
100.00  
100.8 ± 2.1 
101.5 ± 2.4
 d)
 
100.00 
102.6 ± 2.1 
104.7 ± 3.2
 d)
 
100.00 
100.1 ± 4.6 
101.5 ± 3.6
 c)d)
 
100.00 
102.8 ± 2.6 
105.0 ± 3.1
 a)c)d)
 
100.00 
107.9 ± 6.2 
114.6 ± 8.2
 a)d)
 
BIS 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
101.9 ± 1.2 
103.4 ± 0.5
+)
 
100.0 
111.2 ± 1.2 
118.8 ± 1.5
 b)c)d)+)
 
100.00 
109.1 ± 1.8 
114.8 ± 1.6
b)c)d)+)
 
100.00 
101.4 ± 1.0 
103.3 ± 1.3
 d)
 
100.00 
104.3 ± 1.5 
107.5 ± 1.4
 d)+)
 
100.00 
98.4 ± 2.5 
99.0 ± 2.0
 c)d)+)
 
100.00 
107.7 ± 1.9 
118.8 ± 4.7
 b)d)+)
 
100.00 
111.0 ± 3.6 
127.0 ± 4.7
 b)c)d)
 
late loading 
        VEH 0N 
26 weeks 
28 weeks 
30 weeks 
100.0 
100.9 ± 0.6 
101.5 ± 0.9 
100.0 
103.3 ± 1.4 
105.9 ± 2.3
 a)c)
 
100.00 
102.4 ± 1.2 
104.3 ± 2.1
 a)c)
 
100.00 
100.8 ± 0.7 
101.5 ± 1.5
 a)
 
100.00 
101.5 ± 1.0 
102.6 ± 2.0
 a)
 
100.00 
97.7 ± 2.9 
96.6 ± 3.0
 a)b)
 
100.00 
103.8 ± 1.9 
107.3 ± 3.8
 a)
 
100.00 
106.1 ± 4.3 
111.4 ± 4.8
 a)c)
 
VEH 8N         
26 weeks 
28 weeks 
30 weeks 
100.0 
100.8 ± 0.7 
101.9 ± 1.0 
100.0 
105.3 ± 2.1 
110.0 ± 4.0
 a)d)
 
100.00  
104.5 ± 1.4 
108.0 ± 3.2
 a)d)
 
100.00 
101.2 ± 1.1 
102.8 ± 1.7
 b)
 
100.00 
102.1 ± 0.9 
104.3 ± 2.6 
100.00 
98.6 ± 3.4 
96.8 ± 3.5
 a)b)
 
100.00 
104.9 ± 2.6 
110.7 ± 5.7
 b)
 
100.00 
110.3 ± 4.1 
120.6 ± 11.1
 d)
 
BIS 0N          
26 weeks 
28 weeks 
30 weeks 
100.0 
100.4 ± 0.9 
101.1 ± 1.0 
100.0 
104.1 ± 1.7 
107.5 ± 2.1
 a)
 
100.00 
103.7 ± 1.4 
106.3 ± 2.2
 a)
 
100.00 
100.6 ± 1.3 
100.9 ± 1.4
 a)c)
 
100.00 
101.9 ± 1.4 
103.2 ± 2.3
 a)
 
100.00 
100.3 ± 1.2 
100.9 ± 2.0
 c)d
 
100.00 
102.4 ± 1.9 
106.2 ± 3.3
 a)c)
 
100.00 
107.0 ± 4.1 
116.4 ± 6.8
 a)
 
BIS 8N         
20 weeks 
22 weeks 
24 weeks 
100.0 
100.2 ± 0.7 
101.9 ± 0.9
+)
 
100.0 
106.2 ± 1.1 
113.0 ± 2.6
 b)c)d)+)
 
100.00 
106.0 ± 1.1 
110.8 ± 2.0
 b)c)d)+)
 
100.00 
101.5 ± 1.0 
103.6 ± 2.2
 b)d)+)
 
100.00 
103.4 ± 1.2 
106.1 ± 2.0
 b)d)+)
 
100.00 
100.4 ± 1.0 
99.3 ± 1.7
 c)d)+)
 
100.00 
104.6 ± 2.0 
112.5 ± 3.9
 b)d)+)
 
100.00 
110.9 ± 3.2 
124.8 ± 5.5
 b)d)+)
 
 Table 14 static parameters of bisphosphonate studies of early and late loading experimental series normalized to beginning of loading period. a) Significant to BIS 8N, b) significant to BIS 0N, c) 
 significant to VEH 8N, d) significant to VEH 0N for each study, +) combined effect of BIS and loading is additive; values are presented as mean ± standard deviation  
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Parameter  
group 
BFR.BV [%/d] MAR [µm/d] MS [%] BRR.BV [%/d] MRR [µm/d] ES [%] 
early loading       
VEH 0N 
wk20_wk22 
wk22_wk24 
1.3 ± 0.4
 a)
 
1.4 ± 0.2
 b)
 
1.5 ± 0.2 
1.4 ± 0.1
 b)
 
33.2 ± 3.3
 a)b)c)
 
38.7 ± 2.8
 a)c)
 
2.5 ± 0.4
 a)b)c)
 
1.6 ±0.3
 a)b)c)
 
2.3 ± 0.2
 a)b)c)
 
1.8 ±0.2
 a)b)
 
32.5 ± 4.6
 c)
 
31.3 ± 1.8
 a)c)
 
VEH 8N       
wk20_wk22 
wk22_wk24 
1.5 ± 0.3 
1.4 ± 0.4
 b)
 
1.4 ± 0.1 
1.3 ± 0.1 
46.3 ± 5.7
 d)
 
53.0 ± 5.2
 b)d)
 
1.3 ± 0.3
 a)b)d)
 
0.9 ± 0.2
 a)b)d)
 
2.0 ± 0.2
 a)b)d)
 
1.7 ± 0.1
 a)b)
 
26.7 ± 4.7
 d)
 
23.9 ± 3.5
 b)d)
 
BIS 0N       
wk20_wk22 
wk22_wk24 
1.4 ± 0.2 
1.0 ± 0.2
 a)c)d)
 
1.3 ± 0.1
 a)
 
1.2 ± 0.1
 a)d)
 
43.3 ± 4.4
 a)d)
 
42.3 ± 3.3
 a)c)
 
0.9 ± 0.4
 c)d)
 
0.6 ± 0.2
 c)d)
 
1.3 ± 0.1
 c)d)
 
1.1 ± 0.1
 c)d)
 
30.9 ± 5.8 
29.0 ± 3.8
 c)
 
BIS 8N       
wk20_wk22 
wk22_wk24 
1.7 ± 0.4
 d)
 
1.4 ± 0.4
 b)
 
1.5 ± 0.1
 b)
 
1.3 ± 0.1
 b)
 
49.4 ± 3.6
 b)d)
 
52.7 ± 4.1
 b)d)
 
0.8 ± 0.3
 c)d)
 
0.6 ± 0.2
 c)d)
 
1.2 ± 0.1
 c)d)
 
1.2 ± 0.1
 c)d)
 
28.3 ± 4.5 
25.8 ± 4.6
 d)
 
late loading 
      VEH 0N 
wk26_wk28 
wk28_wk30 
1.1 ± 0.2 
1.0 ± 0.5
 a)
 
1.3 ± 0.2 
1.2 ± 0.2 
46.7 ± 5.0
 a)
 
45.4 ± 4.8
 a)c)
 
0.8 ± 0.4
 a)b)c)
 
0.7 ± 0.3
 
 
1.5 ± 0.2
 a)b)c)
 
1.4 ± 0.2 
27.5 ± 4.4 
29.0 ± 4.6
 a)
 
VEH 8N       
wk26_wk28 
wk28_wk30 
1.2 ± 0.4 
1.1 ± 0.4 
1.3 ± 0.2 
1.2 ± 0.2 
48.5 ± 3.5
 b)
 
50.4 ± 6.0
 b)d)
 
0.6 ± 0.2
 d)
 
0.6 ± 0.3
 
 
1.3 ± 0.3
 a)d)
 
1.4 ± 0.3 
25.6 ± 4.0 
25.2 ± 5.3
 b)
 
BIS 0N       
wk26_wk28 
wk28_wk30 
1.0± 0.3 
1.1 ± 0.4 
1.2 ± 0.1 
1.2 ± 0.2 
44.6 ± 5.6
 a)c)
 
44.2 ± 3.1
 a)c)
 
0.5 ± 0.2
 d)
 
0.7 ± 0.3
 
 
1.1 ± 0.1
 d)
 
1.2 ± 0.2 
28.1 ± 5.5
 a)
 
30.6 ± 3.4
 a)c)
 
BIS 8N       
wk26_wk28 
wk28_wk30 
1.3 ± 0.3 
1.3 ± 0.2
 d)
 
1.3 ± 0.1 
1.2 ± 0.1 
50.6 ± 3.6
 b)
 
53.1 ± 4.7
 b)d)
 
0.4 ± 0.2
 d)
 
0.5 ± 0.2
 
 
1.1 ± 0.1
 c)d)
 
1.2 ± 0.2 
24.1 ± 5.3
 b)
 
24.5 ± 5.7
 b)d)
 
Table 15: bone dynamic parameters of bisphosphonate studies. a) significant to BIS 8N, b) significant to BIS 0N, c) significant to VEH 8N, d) significant to VEH 0N for each study; values 
are presented as mean ± standard deviation 
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4.5 Physiome map 
The physiome map provides a good tool to directly compare the effects of the different treatment 
and loading regimens at both starting points. To get a better overview, the vehicle groups from 
the PTH and bisphosphonate studies were pooled with respective ovariectomized groups from 
the ovariectomy study for each experimental series.  
In general, it can be noticed that for all parameters a higher effect can be seen in the loaded 
groups compared to their non-loaded controls. What is also striking is that PTH exerts the most 
prominent effect in almost all parameters at both starting points 5 and 11 weeks after 
ovariectomy. Except for Full TV sham operated mice start at a higher level when the loading 
period begins, no matter if it is 5 or 11 weeks after ovariectomy. The number of all animals in all 
groups can be seen in Table 16. 
 
group SHM 
0N 
SHM 
8N 
OVX/VEH 
0N 
OVX/VEH 
8N 
PTH 
0N 
PTH 
8N 
BIS 0N BIS 8N 
# of animals in 
early loading 
study 
7 9 27 27 9 9 9 10 
# of animals in 
late loading 
study 
8 8 26 25 9 11 9 11 
Table 16 number of animals during all studies per group 
 
Static parameters 
Full bone 
The physiome maps of full bone parameters demonstrate the different effects of ovariectomy. 
Due to the lack of estrogen longitudinal growth of the bone is increased while bone volume 
fraction and subsequently bone volume density are decreased in ovariectomized animals. 
During the treatment period total volume was increased most significantly when PTH and 
loading were combined. This is followed by the effect from merely PTH treatment. However, 
while during the late loading experimental series the effects of all other treatments (BIS 0N, BIS 
8N, VEH 8N) did not differ significantly from each other, loading increased the total volume in 
the early loading experimental series, both in combination with bisphosphonate and vehicle 
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injection. In contrast loading did not show any significant effects on sham operated animals at 
any time point. The physiome map of Full TV can be seen in Figure 32 
 
Figure 32: physiome map of Full TV. Early loading studies are represented with ○ and Δ, while late loading studies are 
represented with □ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group 
see Table 16. 
 
While the effects of treatment on total volume were more restrained, a large impact of all 
treatments was observed for the bone volume. Again the significantly strongest effect in both 
experimental series was observed, when PTH and loading were combined. During the early 
loading experimental series merely PTH treatment increased FULL BV to the same extend as the 
combination of bisphosphonate treatment and loading. This is in contrast to the late loading 
experimental series, where the effect of BIS 8N was significantly less than the effect of PTH 
treatment. In both experimental series loading showed a stronger effect than bisphosphonate 
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treatment alone. However, also merely bisphosphonate treatment could still significantly 
improve full bone volume fraction. Compared to sham operated animals, any treatment in 
ovariectomized animals had a significantly stronger effect than loading of sham animals in the 
early loading experimental series. This was also found in the late loading experimental series, 
however not for bisphosphonate treatment. The physiome map of Full BV can be seen in Figure 
33 
 
Figure 33: Physiome map of Full BV. Early loading studies are represented with ○ and Δ, while late loading studies are 
represented with □ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group 
see Table 16. 
 
The physiome map of full bone volume fraction illustrates the bone loss after OVX. While the 
SHM groups show a time-dependent increase in Full BV/TV, it is severely decreased in the OVX 
groups at the time-points when the treatment starts.   
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As mentioned before, combined PTH treatment and loading exerted the significantly strongest 
effect on Full BV/TV, no matter when treatment and loading were started. Both groups reached 
BV/TV values above their basal levels; however they could not reach the time matched SHM 0N 
values. While in the early loading series all other treatments (PTH 0N, BIS 8N and BIS 0N) 
caused an intermediate increase in Full BV/TV, PTH 0N exceeded the effects of BIS 8N and BIS 
0N in the late loading groups. This was caused by the apparently higher efficacy of early 
bisphosphonate treatment (with and without loading) compared to the late treatment start. 
However, at both time-points loading added additive to bisphosphonate treatment. Loading alone 
was more effective than bisphosphonate without loading in both experimental series. The 
physiome map of Full BV/TV is shown in Figure 34. 
 
Figure 34: Physiome map of Full BV/TV. Early loading studies are represented with ○ and Δ, while late loading studies are 
represented with □ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group 
see Table 16. 
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Cortical compartment 
Also in the cortical compartment the effect of ovariectomy was visible. While at both time-
points, 5 and 11 weeks after OVX, the cortex was getting thinner, thickness was increased in 
sham operated animals. 
Cortical thickening throughout the loading and treatment period was mainly influenced by 
loading and not by pharmacological treatment. Loading increased Ct. Th by the same extend in 
all loaded groups of the early loading series. When loading was started after 11 weeks, cortical 
thickening apparently was susceptible to a second stimulus as the cortex thickened significantly 
more in PTH treated mice than in bisphosphonate treated or vehicle injected mice.  
During the early loading experimental series the cortical thinning continued in untreated animals. 
This could be stopped with bisphosphonate injection. However, as Ct. Th had reached a 
minimum value in the late loading experimental series before treatment started, the preserving 
effect of bisphosphonate treatment did not result in an improvement compared to non-treated 
animals. When only PTH was injected, cortical thickness dropped in the first two weeks even 
more than in non-treated mice in both experimental series. This loss was compensated in the last 
two weeks and after 4 weeks of treatment values reached the same level as non-treated mice.  
Cortical thickness can be seen in Figure 35. 
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Figure 35 Physiome map of Ct. Th. Early loading studies are represented with ○ and Δ, while late loading studies are 
represented with □ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group 
see Table 16. 
 
In ovariectomized animals cortical % BV was reduced at both time points, 5 and 11 weeks after 
ovariectomy, while it stayed almost stable in sham operated animals. 
PTH treatment in combination with loading induced the most prominent increase in cortical % 
BV in both series. In the early loading series all other treatments (PTH 0N, BIS 8N, BIS 0N, 
VEH 8N) induced similar effects and improved cort % BV in comparison to non-treated animals. 
In contrast in the late loading experimental series, only PTH treatment or loading could increase 
this value (with the highest effect seen in PTH treated animals). However merely bisphosphonate 
treatment did not induce significant changes compared to non-treated animals. Interestingly, after 
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the first two weeks in the early loading series PTH 0N animals even lost as much cortical % BV 
as VEH 0N mice and just showed a noticeably increase in this parameter during the last two 
weeks of treatment. 
Cortical % BV is shown in Figure 36. 
 
Figure 36: Physiome map of cortical % BV. Early loading studies are represented with ○ and Δ, while late loading studies are 
represented with □ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group 
see Table 16. 
 
Trabecular compartment 
While at the age of 20 weeks no difference in Tb.N was observed between ovariectomized and 
sham operated animals, OVX mice at the age of 26 weeks had significantly less trabeculae than 
SHM mice.  
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Vehicle treated animals constantly lost trabeculae during both experimental series. This loss 
could be reduced with PTH treatment or almost stopped with bisphosphonate treatment. In the 
early experimental series bisphosphonate treatment slightly increased Tb.N. The on-going loss in 
vehicle treated animals is clearly a continuing effect of ovariectomy, as in sham operated animals 
Tb.N was not changed during the course of the experiment. 
Trabecular number can be seen in Figure 37 
 
Figure 37: Physiome map of Tb.N. Early loading studies are represented with ○ and Δ, while late loading studies are represented with □ and 
◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group see Table 16. 
 
After ovariectomy trabeculae were thinned, while a thickening of trabeculae was observed in 
sham operated animals at the start of the treatment. 
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PTH treatment in combination with loading had the strongest effect in both experimental series. 
In the early experimental series, loading thickened trabeculae significantly more than PTH 
treatment. The opposite effect was observed in the late experimental series, where PTH treatment 
induced a greater thickness than 4 weeks of loading or combined bisphosphonate treatment and 
loading. Only bisphosphonate treatment did not result in thicker trabeculae in any of the studies. 
In general it can be said, that the effect of loading on Tb. Th was higher in the early loading 
series than in the late loading series. This was also true for sham operated mice. 
Trabecular thickness is shown in Figure 38. 
 
Figure 38: Physiome map of. Early loading studies are represented with ○ and Δ, while late loading studies are represented with 
□ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group see Table 16. 
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As trabeculae were getting thinner and Tb.N was reduced after OVX, also Trab BV/TV was 
reduced 5 and 11 weeks after ovariectomy, while the increased in Tb.Th resulted in an increase 
in Trab BV/TV in sham operated animals. 
Within one treatment period, the effects of treatments on Trab BV/TV where highest in PTH 8N, 
followed by PTH 0N, BIS 8N, VEH 8N, and BIS 0N. Despite for the sham operated groups, 
loading always significantly increased trabecular bone volume density compared to the 
corresponding non-loaded groups. As Trab BV/TV was still declining in non-treated animals 
during the early experimental series, it has to be admitted that the overall effect of any treatment 
was stronger in the early experimental series than in the late experimental series. 
Trab BV/TV is shown in Figure 39. 
 
Figure 39: Physiome map of Full TV. Early loading studies are represented with ○ and Δ, while late loading studies are 
represented with □ and ◊. Grey boxes mark data normalized to treatment start at week 20 and 26, respectively. For n per group 
see Table 16.  
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Dynamic parameters 
 
The following chapter will provide a summary and comparison of the dynamic parameters of all 
studies in both experimental series. 
 
Bone formation 
Bone formation rate was lowest in sham operated mice and increased in all OVX animals, 
showing that the estrogen depletion increased bone turnover rates. The highest values were found 
in PTH treated mice. Bisphosphonate treated and vehicle treated mice showed about the same 
BFR in both experimental series. When loading was combined with pharmacological treatment, 
it increased the effect of bisphosphonate treatment at all-time points. However, in combination 
with PTH treatment a significantly higher BFR could only be seen during the first two weeks but 
not during the last two weeks of both experimental series. While in the late experimental series 
both sham operated groups had a significantly lower bone formation rate than any other group, 
BFR of SHM 8N mice in the early experimental series did not differ significantly from the 
VEH 0N group.  
Mineral apposition rate was significantly elevated in the PTH treated groups at all-time points. 
However, a decline was observed from the first two weeks to the last two weeks. While in the 
first two weeks loading significantly increased MAR in PTH treated animals, no significant 
differences could be observed during the last two weeks of both experimental series. 
Bisphosphonate treatment resulted in similar MAR as in sham operated animals in the early 
experimental series. However, during the late experimental series SHM mice showed a 
significantly lower MAR than any other group of this series. Loading increased mineral 
apposition rate in bisphosphonate, vehicle treated animals and sham operated animals during the 
last two weeks of the early experimental series.  
Mineralizing surface was significantly higher in all loaded ovariectomized animals than in their 
non-loaded control groups. However, in sham operated mice no differences were seen in the late 
experimental series. The largest MS at all-time points was found in PTH treated mice subjected 
to loading. While in vehicle and PTH treated animals of the early experimental series an increase 
in MS over time could be observed, a decrease was found for the same groups in the late loading 
experimental series. However, PTH treated animals showed the largest MS at both time points in 
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the late experimental series and during the last two weeks of the early experimental series. All 
bone formation parameters can be seen in Figure 40. 
a)  
b)  
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c)  
Figure 40: bone formation parameters a) bone formation rate (BFR), b) mineral apposition rate (MAR), c) mineralizing 
surface (MS). The early loading study is presented with a white background while the late loading study is presented with a grey 
background 
 
Bone resorption 
In the early experimental series bone resorption rate was reduced by at least 20% compared to 
the corresponding vehicle treated non-loaded group, when loading or pharmacological treatment 
was applied. In bisphosphonate treated loaded mice it was even reduced by 70% during the first 
two weeks of treatment. During this time BRR in bisphosphonate treated mice was significantly 
lower than in PTH 0N or vehicle treated mice, while PTH 8N animals showed the lowest BRR. 
At all-time points vehicle treated non-loaded mice had a highly significant increased bone 
resorption rate compared to any other group in the early loading series. This difference was not 
as prominent in the late loading series. Sham operated loaded mice showed the lowest bone 
resorption during the whole late experimental series. While tendencies towards a reduced bone 
resorption rate in the loaded group were found when bisphosphonate treatment was combined 
with loading, significant differences can be found in PTH treated mice. Mineral resorption rate in 
the early experimental series was lowest in bisphosphonate treated mice and also in the late 
experimental series only SHM 8N mice had a lower MRR. Treatment with PTH increased MRR 
significantly. This effect was even enhanced, when loading was added to the PTH treatment.  
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Loading reduced eroded surface in all groups. PTH treatment reduced the amount of ES at 
almost all time points. This effect was enhanced when loading was added, as PTH 8Nmice 
showed the lowest ES at any time point in both experimental series. Bisphosphonate treated 
animals showed similar ES as vehicle treated or sham operated groups. When loading was 
combined with bisphosphonate treatment, eroded surface was reduced significantly. Bone 
resorption parameters are shown in Figure 41. 
a)  
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b)  
c)  
Figure 41: bone resorption parameters a) bone resorption rate (BRR.BV), b) mineral apposition rate (MRR), c) mineralizing 
surface (ES). The early loading study is presented with a white background while the late loading study is presented with a grey 
background 
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5 Discussion 
 
 
5.1 Model, Methods and experimental design 
We used the mouse tail model, developed at the Institute for Biomechanics, to study the 
interaction of mechanical loading with osteoporosis treatment. Mice are well suited for 
experimental research. Not only because they are small, cheap and easy to handle, but also most 
biological mechanisms are similar to those in humans. Another advantage is that the genome of 
the mouse has been mapped and therefore a wide range of genetically modified strains are 
available to specifically study certain genetic effects. The use of standardized inbred mouse 
strains reduces the required number of animals per experiment remarkably. Standardization of 
experiments can be enhanced by standardized housing conditions, which can be achieved much 
easier in small animals than in large ones. It has to be admitted, that growth plates of bones in 
mice, in contrast to human bone, never close. Therefore murine bones continuously grow during 
the entire lifetime. Another difference compared to human bone, is that the cortex of mouse bone 
does not show a structure of haversian canals and osteons. However, the main focus of the 
studies presented in this thesis was to investigate trabecular remodeling. Therefore the mouse 
bone was well suited. 
 
The ovariectomized mouse as model for postmenopausal osteoporosis 
In humans, the most common form of osteoporosis is postmenopausal osteoporosis which is 
caused by cessation of estrogen production. Estrogens are necessary to maintain the balance 
between bone resorption and formation. When the production of these hormones is not sufficient 
anymore, bone remodeling is shifted towards higher resorption, resulting in deteriorated bone 
mass and bone morphologic parameters [257, 258]. Therefore human postmenopausal 
osteoporosis is characterized by increased bone turnover with a negative balance between 
formation and resorption resulting in bone loss. 
We used ovariectomy to induce estrogen depletion in our mice. Ovariectomy resulted in 
significant loss of bone mass and increased bone formation and resorption rates. These effects 
are similar to those described in studies performed in human bones [257, 258]. In our studies 
almost all static parameters decreased after ovariectomy. Full and trabecular BV/TV were 
decreasing significantly, as well as cortical % BV. However, while trabeculae got thinner in 
5 Discussion 5.1 Model, Methods and experimental design 
 
~ 140 ~ 
ovariectomized animals, their number was not reduced much compared to intact animals. The 
cortex was getting thinner as well when estrogens were lacking. This deteriorated bone structure 
also reduces mechanical bone stability, as has been shown recently in a  study performed  at our 
institute [259]. Similar changes can be found in humans after menopause and the reduced 
mechanical stability of bones increases fracture risk in humans significantly [3, 14]. 
However, sex hormones are known to not only balance bone formation and resorption, but also 
have different effects on bone [95]. Sex hormones for example influence the levels of growth 
hormones. Indeed we found an accelerated longitudinal growth in the OVX animals compared to 
the controls. The investigated tail vertebra was longer and bone volume as well as trabecular 
volume increased significantly more during the course of our experiments. Moreover, castrated 
animals were found to be heavier than the control animals at the age of 20 and 26 weeks, 
respectively. On the one hand this was due to an increased growth resulting out of the lack of sex 
hormones. On the other hand, Gloy et al. described that ovariectomized animals have an 
increased body fat content [260], which might also be a reason for the weight gain in our OVX 
mice.  
In general it can be said that ovariectomy in the mouse is a suitable model to mimic 
postmenopausal osteoporosis. The animals show a high turnover bone loss, but no fractures. 
However, as we investigated bone remodeling, fractures were not necessary for our research and 
therefore would not be tolerable from an ethical point of view.  
 
The mouse tail – a loading model with yellow bone marrow 
To investigate the effect of loading in bone, mimicking the situation in human osteoporotic bone, 
the bone of interest has to fulfill certain requirements: 
The bone should be preferably small and accessible for micro-CT measurements. Furthermore it 
has to be accessible to apply loading and the bone has to represent the human condition during 
postmenopausal osteoporosis. 
As humans get older, the red bone marrow, which used to be the source for hematopoietic stem 
cells, slowly turns into yellow fatty bone marrow at many sites [261, 262]. It was also shown that 
in osteoporotic patients the content of bone marrow fat is higher than in age matched controls 
[262]. Other studies have shown an inverse relation between lipid concentration of HDL and 
BMD [263]. A possible link between the fat and the bone metabolism was found just recently by 
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Kim et al. [264], who investigated the levels of monocyte chemo attractant protein-1 (MCP-1) 
production in ovariectomized rats. Fat tissue of OVX rats expressed higher values of MCP-1 
than that of sham operated animals. Furthermore, the study showed that cell culture medium 
extracted from fat tissue from ovariectomized rats stimulated osteoclastogenesis to a higher 
extend than medium from control animals. This led to the conclusion that elevated MCP-1 levels 
in ovariectomized animals contribute at least in part to the increased bone loss. As in 
ovariectomized mice the weight gain is higher than in sham operated mice it can be assumed that 
similar mechanisms apply for these animals. The tail vertebrae in mice do contain yellow bone 
marrow [265]. Furthermore it has been shown that the content of yellow marrow fat increases 
after ovariectomy. Furthermore, Gimble et al. could show in the same study in rats that there is a 
negative correlation between yellow bone marrow and bone mineral density [266]. In contrast to 
our findings, another study, also performed in rats, could not detect any bone loss after 
ovariectomy at sites of yellow bone marrow. Even though a high bone turnover was apparent, no 
difference in bone mineral density was observed between ovariectomized and sham operated rats 
after 6 months [267]. Li et al. state that an imbalance between bone formation and resorption can 
only be found at sites of red marrow. One of the reasons could be the fact that yellow bone 
marrow is less vascularized than red bone marrow. Therefore, osteoclast precursors, nutrients 
and hormones which are all delivered via the vascular system cannot reach the bone as well as in 
red bone marrow. Consequently, this difference in vascularization leads to a more favorable 
environment for bone resorption at sites of red bone marrow. These findings are not only 
contradictory to our studies but also to the clinical situation found in humans. Ovariectomized 
mice in our studies showed a clear loss in Trab BV/TV already 5 weeks after ovariectomy. 
Bouxsein et al. discovered a loss of vertebral trabecular bone volume after ovariectomy for all 
tested mouse strains, except for C3H/HeJ mice [215]. Furthermore, a study performed at the 
institute recently could show, that ovariectomy increases both bone formation rate and bone 
resorption rate, compared to sham operated mice [268]. 
Another advantage of using the mouse tail vertebra is that it contains more trabecular bone than 
mouse tibia or ulna, which are often used in other osteoporosis studies . Ulna and tibia belong to 
the long bones which do not contain many trabeculae. However, osteoporosis in humans appears 
mainly in trabecular bone. 
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One disadvantage of the tail vertebra is, that in order to load the vertebra pins have to be inserted 
into the adjacent vertebrae. However, the pinning procedure and loading were tolerated well. 
Unfortunately, some mice had to be excluded from the study due to tissue swelling around the 
pins, which sometimes worsened during the loading period. No distinct underlying cause was 
found, but one reason could be adverse effects due to the pin-material or accidentally destruction 
of certain structures, such as muscles, tendons and vessels during the pinning procedure. This 
can result in an impaired healing process. Of course this problem could have been avoided by 
loading model which does not need pins. 
In contrast to many other loading models, where load is applied to the tibia or ulna and the contra 
lateral side is used as a control, the studies presented in this thesis used non-loaded animals as 
controls, which could be seen as a disadvantage. However, loading of tibia or ulna and the 
therefore necessary flexing of the adjacent joints can cause pain or unpleasant sensations even 
after loading. Hence the contra lateral side might be used more for walking resulting in a non-
physiologic overload of this side and an avoidance of loading at the ipsilateral side during 
normal walking. This unbalanced use of both legs could falsify the results. As the caudal 
vertebrae are not directly used during walking none of these effects can be observed in the tail 
model. Moreover, climbing behavior, where the tail is used for, did not seem to be reduced in 
loaded animals compared to non-loaded controls. 
In conclusion the mouse tail vertebra is very well suited to study the effects of loading on 
postmenopausal osteoporosis. It is a small, easy accessible bone that mimics human conditions 
well. Furthermore the use of the tail vertebra has no adverse effects on the animals. 
 
In vivo micro-CT and longitudinal design 
Our studies were designed as longitudinal studies, which helps to reduce the number of animals 
per experiment and is in accordance with the 3R concept. With in vivo micro-CT measurement 
the effect of ovariectomy, loading and pharmacological treatment on mouse bone could be 
monitored over a long period of time and morphological parameters could be calculated at a 
three-dimensional level. This is a great advantage over cross-sectional studies and 
histomorphometry. In cross-sectional studies just one time point can be evaluated and inter-
individual differences can overlay treatment effects. Furthermore, bone is a three-dimensional 
construct. Therefore, evaluating just two- dimensional histological slides will never result in the 
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same exact and deep insight into the structure as a three-dimensional evaluation. As bones of 
mice are relatively small, a very high resolution can be achieved in an appropriate scanning time. 
This is another advantage of using small animals, such as mice. 
Until recently, histology used to be the standard method to evaluate dynamic parameters. 
Although bone formation parameters can be evaluated easily with this method, it is hard to 
specify bone resorption parameters as, of course, resorbed bone cannot be evaluated any more. A 
standard technique is TRAP staining, which stains for active osteoclasts and therefore gives an 
estimation of the current number of osteoclasts and the amount of surface they are covering. 
However, a new method was developed at our institute recently. This allows to register images 
from longitudinal in vivo micro-CT measurements and evaluate bone formation and bone 
resorption parameters at a three dimensional level [42]. As in vivo scans are used, follow up 
measurements are possible and bone remodeling can be followed over a longer time. This is in 
contrast to histology, where just one measurement per animal is possible.  
Physiome map 
Often it is difficult to compare the results of different studies due to differences in study design, 
treatment periods and differing basal values between groups. In our project we used the same 
time course and experimental setup for all experimental series. This allows the comparison of 
different treatment groups.  
To overcome inter-individual differences of the absolute values we normalized the results to a 
certain time point. This normalization was used to create a physiome map. The physiome map is, 
to our knowledge a unique tool to plot the bone morphologic parameters of different studies 
together in one diagram. This overview makes it possible to directly compare the effects of each 
treatment and to evaluate and compare the development of bone parameters in intact and 
ovariectomized animals. Of course, results from other studies can be added as well, which 
increases the information value of the physiome map. 
 
5.2 Results 
 
5.2.1 Loading in ovariectomized mice 
The effect of loading the 6
th
 caudal vertebra in ovariectomized and sham operated mice was 
studied. Depending on the experimental series, the studies started 5 or 11 weeks after 
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ovariectomy. This time points were chosen accordingly to a study performed recently, in our 
laboratory [43]. In this study 15 week old mice were ovariectomized or sham operated and 
measured with in vivo micro-CT every second week for the next 12 weeks. It was shown that 
bone loss after ovariectomy proceeds in two phases. The first phase with fast bone loss lasts until 
about week 8 followed by the second phase of slow bone loss, where a plateau is reached. These 
results support the findings by Boyd et al., who studied the effects of ovariectomy in rats and 
found the bone loss to occur in two phases as well. However, because the remodeling in rats 
takes much longer the first fast phase was in the first three months after ovariectomy, followed 
by the slower phase [269]. Boyd also proposed that any treatment should be started in the first 
three months, as in that time bone response to treatment is much better than in the later slower 
phase. According to the findings of the previous study from our institute we chose the two 
different time points for the starting of the loading and treatment period. Five weeks after 
ovariectomy bone loss is still in the fast phase, while eleven weeks after ovariectomy it has 
reached its plateau. 
In general, it can be said that loading had much bigger effects in ovariectomized mice than in 
sham operated animals. However, in both groups, an early start of loading induced a larger 
increase in bone mass than a late loading start. Mice seem to grow more during the early phase 
than in the late experimental series. Sham operated non-loaded mice (SHM 0N) have a stronger 
increase in full, trabecular and cortical bone mass as well as in trabecular and cortical thickness 
when the treatment is started early compared to a late treatment. Apparently, if the growing rate 
is faster, also loading seems to have a stronger effect on the bones. The effect difference between 
SHM 0N and SHM 8N mice is much bigger in the early loading study for Trab BV/TV, Tb.Th 
and Ct.Th than in the late loading study. Similar findings are known from human medicine. In 
children physical activity contributes to gain a high bone mass, whereas in adults, which are not 
growing anymore, physical activity rather helps maintaining the peak bone mass achieved in 
adulthood than increasing bone mass [270-272]. However, mice do not close the growth plates 
and therefore continue growing throughout their whole life time. Nevertheless, a higher growth 
rate seems to increase the effect of loading. Another possible explanation for the lack of response 
in late loading sham operated mice could be that due to growing these mice already have a high 
bone mass and loading of 8N is not sufficient anymore to induce osteogenic signals. Several 
studies, using mice of different strains differing in bone mass have shown that the effect of 
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loading but also ovariectomy is dependent on the basal bone mass [215, 251, 273]. A former 
study performed at the Institute for Biomechanics showed that C3H/HeJ mice, which have a high 
bone mass do not react as well to loading as C57BL/6J mice of the same age, which have a much 
lower bone mass.  
The effect difference in our studies between loaded and non-loaded ovariectomized mice is much 
bigger in the early loading study. As non-loaded ovariectomized mice in the early loading study 
still decrease in Trab BV/TV, OVX 8N mice also have to counteract on this loss, whereas 
OVX 0N mice of the late loading study already increase Trab BV/TV. Therefore, the increase 
from OVX 8N compared to OVX 0N mice in the late loading study is even less. The reason for 
this difference could be that as the mice in the early loading study did not lose so much bone it is 
easier for them to regain more bone mass after loading. Maybe also the BMU are more active in 
these mice, so that the shift towards an increasing bone mass caused by mechanical loading has a 
greater effect. 
 
Ovariectomy and the resulting estrogen depletion are known to increase bone remodeling rates. 
This has been shown in many previous studies [183, 232, 274] and the findings were confirmed 
by our results. Bone formation rate was increased in both experimental series with OVX 
compared to SHM mice. Also mineral apposition rate was elevated in the ovariectomized mice in 
both experimental series. While in the early loading experimental series there was only a trend 
towards an elevated MAR in OVX mice compared to sham operated animals, in the late loading 
experimental series OVX 8N mice showed a significantly higher MAR. Mineralizing surface 
was not affected by ovariectomy, but by loading. This leads to the conclusion that osteoblasts 
deposit more osteoid in a certain time but at fewer places in loaded ovariectomized animals. 
When comparing the absolute values of the formation parameters of all groups it can be noticed 
that in the early loading experimental series not only mineral apposition rate but also bone 
formation rate have higher values than in the late loading experimental series. One of the 
reasons, especially in the sham operated mice, could be that mice reach skeletal maturity at the 
age of about 20 weeks [275]. At this age they have reached their peak bone mass, however, the 
cross sectional geometry increases up to the age of about 24 weeks. This period of reaching 
skeletal maturity corresponds to the age that mice have during the loading period in the early 
loading experimental series. Therefore, as they are still growing and reaching skeletal maturity 
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bone formation parameters might be enhanced compared to mice of the late loading experimental 
series, which already have reached their peak bone mass and have reached full skeletal maturity. 
When load is applied to fully mature bones at peak bone mass, the resulting strains are less than 
in younger animals. Therefore, the applied load of 8N probably was not appropriate to induce a 
sufficient mechanical loading signal. This could also explain, why sham operated mice of the 
early loading study show some reaction to the loading while sham operated mice of the late 
loading study are hardly affected by loading. Furthermore, ovariectomized mice are still in the 
fast bone loosing period during the early loading experimental series. Maybe, when the bone loss 
reaches a steady state in the late loading experimental series also bone remodeling slows down 
and the turnover is not as high as it was at the beginning anymore. The strains induced by 8N 
loading are different in ovariectomized and sham operated animals. As it is well known that 
strain rates do influence the outcome of mechanical loading [226, 251], it could be helpful if in 
further studies the strains are determined and the amount of load is adjusted induce the same 
strain in all groups. 
In a high turnover remodeling state not only bone formation but also bone resorption parameters 
are elevated. The results from our studies show that mineral resorption rate has higher absolute 
values in the early loading experimental series than in the late loading experimental series. The 
same factors as for mineral apposition rate could be the reason for the differences between early 
and late loading experimental series. (On one hand skeletal maturity, which is not yet reached in 
the early loading study but in the late study. On the other hand mice in the early study are still in 
the fast bone loosing period after ovariectomy, while bone loss in the late study has reached the 
slower phase.) In both experimental series at least a trend towards an elevated MRR in 
ovariectomized mice could be observed. Eroded surface was reduced by loading in both series. 
In the late loading experimental series OVX 8N mice even showed the lowest eroded surface of 
all groups, which is in accordance with previous studies from our institute [276]. Furthermore, 
the biggest difference between loaded and non-loaded mice was observed in the early loading 
experimental series. This again supports the idea, that younger mice or animals in the fast bone 
loosing period are more susceptible to mechanical loading than at an older age and in the plateau 
phase. Bone resorption rate, although reduced by loading as well was highest in ovariectomized 
animals in both experimental series.  
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These findings show, that mechanical loading has a beneficial effect on ovariectomized mice. It 
increases bone formation parameters and decreases bone resorption. Due to hormone depletion 
after ovariectomy, bone remodeling is elevated. Both bone formation and resorption are 
increased, however, the balance is shifted towards a higher bone resorption.  When this increased 
bone resorption can be alleviated, for example with antiresorptive treatment, bone loss can be 
stopped or slowed down and eventually bone formation can exceed bone resorption.  
The positive effects of mechanical loading in ovariectomized mice on bone remodeling have 
been shown previously in mice and rats as well as in humans [183, 206, 224, 232, 274, 277]. 
 
5.2.2 Loading in pharmacological treated ovariectomized mice 
To treat mice with pharmacological substances, the two most often applied medications from 
human medicine were used. As an anticatabolic treatment served the bisphosphonate 
zolendronate and as an anabolic treatment the hormone PTH. Again two different starting points 
for the treatment were chosen. The early point was during the phase of fast bone loss 5 weeks 
after the ovariectomy and with the second time point treatment started when the osteopenia was 
already established and bone loss was progressing slower. For each medication own vehicle 
control groups were studied as well. Additionally, half of the mice were subjected to 8N loading, 
while the other half served as a control at 0N load. The aim was to investigate not only the effect 
of pharmacological treatment or mechanical loading on ovariectomized mice, but also to gain 
insight into the combinatorial effect of these two and to investigate this in a longitudinal study 
approach. 
 
5.2.2.1 PTH studies 
The physiological function of PTH is to increase blood Ca
2+
 levels if needed. Therefore, it 
increases osteoclast activity and the release of calcium, as bones function as internal Ca
2+ 
storages. However, if PTH is given in an intermittent fashion, it increases bone formation and 
enhances bone quality. PTH is so far the only EMEA approved anabolic drug to treat 
osteoporosis. It enhances bone remodeling and shifts the remodeling balance from net resorption 
back to net bone formation. These effects have been observed in studies on humans for many 
years [25, 29, 278, 279]. Injection of PTH alone already had a big impact on bone parameters. 
However, the combination of PTH injection and loading has been found to be additive or 
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synergistic in several studies [190, 280, 281]. In the studies presented in this thesis the 
combination of PTH and loading induced the biggest changes in almost all parameters. Only 
Tb.N was not changed with combined treatment, however a decline was observed in the other 
groups. For most parameters, PTH alone has a bigger effect than loading alone. However, Ct.Th 
first decreased in both PTH 0N groups and returns back to basal values towards the end of the 
treatment period. In contrast, in all other groups of both experimental series Ct.Th increases 
during the whole study. An additive effect was found for all static parameters in the early loading 
experimental series and for most of the static parameters in the late loading experimental series. 
However, the combinatorial effect on Full BV/TV, Ct.Th and Cort % BV was synergistically and 
almost synergistically on Tb.Th in the late loading experimental series.  
An explanation for this synergistic effects could be that both, PTH and mechanical loading, 
stimulate the same or interacting biochemical pathways. For example, it was found, that PTH as 
well as loading increase IGF-1 levels [165]. Furthermore, a study performed by Carvalho et al. 
showed that intracellular signals like cAMP, IP3 and protein kinase C increase with mechanical 
strain. However, their levels are increased even more when PTH was added to the cells [190]. 
PTH not only increases the stimulation of the same biochemical pathways as mechanical loading, 
but it is important for sensitizing osteoblasts for osteogenic signals. This is done probably by 
enhancing the mobilization of intracellular calcium via the aforementioned intracellular signals 
[282]. Chow et al. subjected rats to thyroidparathyroidectomy (TPTX) [281]. These rats were 
lacking hormones produced by the thyroid and parathyroid gland, namely Thyroxin, Calcitonin 
and PTH. Applying mechanical stimulation to these rats did not increase bone formation rate, 
while a significant increase was observed in intact animals. When hormone deficient rats 
received PTH prior to the loading, bone formation rate increased significantly. However, when 
PTH was injected after the loading, dynamic parameters did not change. This proofs that 
physiological levels of PTH are important for osteoblasts to be able to react to mechanical 
stimuli. 
While in our studies PTH injections alone exert a greater effect on many parameters than loading 
alone as it was also found in another study [283], there is at least one study that did not find a 
more positive effect of only PTH injection [281]. However, this difference is probably due to the 
fact that this study used rats instead of mice. 
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It is well known that mechanical loading induces bone formation at sites of high stresses and 
strains resulting in improved biomechanical parameters and higher bone strength. The question is 
whether the bone gain induced by PTH treatment results in similar improvements of 
biomechanical parameters. McAteer et al. compared the amount of bone gain after PTH 
treatment or mechanical loading with the resulting increase in bone strength [283]. With both 
treatment regimens bone strength was increased by 20%. However, bone mineral content was 
only increased by 4% with mechanical loading while an increase of 11% was observed after PTH 
treatment. This implies that loading ads bone at biomechanical important sites, whereas PTH 
treatment leads to bone gain at all sites, no matter if stresses or strains are high or low. When 
combining loading with PTH treatment Roberts et al. found a trend towards a more localized 
bone formation at biomechanical relevant sites [284]. Therefore, it would be interesting in 
further studies to do a strain energy density analysis of treated bones and perform biomechanical 
tests. One study supporting the idea that PTH might override the local mechanical control of the 
bone has recently been performed at our institute [285]. The authors did not see any differences 
in strain energy density (SED) between quiescent and resorption sites in PTH treated animals, 
whereas in vehicle treated animals SED values were higher at resorption sites than at quiescent 
sites. 
While in our studies in the trabecular compartment PTH exerted a positive effect on most statical 
parameters, cortical thickness was not increased by PTH treatment. Moreover, in the first two 
weeks, in both experimental series, a loss in cortical thickness was observed, which was 
compensated in the last two weeks. These findings are consistent with a study by Zhou et al., 
who evaluated the effect of PTH on cortical and cancellous bone at different skeletal sites [280]. 
While a strong increase in the cancellous compartment was observed, PTH treatment added only 
a little bone at the tibia but did not influence cortical width significantly in the vertebra. In this 
study 3 or 7 weeks of PTH treatment were sufficient to restore basal values, when the treatment 
was started 4 weeks after the ovariectomy. This is consistent with our findings. In the early 
loading experiment, where PTH treatment started 5 weeks after ovariectomy, basal values were 
restored after 4 weeks of treatment. However, in the late loading experimental series, with 
treatment starting 11 weeks after ovariectomy, bone loss was probably too progressed, as in this 
study PTH treatment alone could not restore basal values. When loading was added to the 
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pharmacological treatment, however, basal values were also reached in the late loading 
experimental series. 
In the dynamic parameters mineral apposition rate was increased by PTH treatment in both 
experimental series. However, while during the first two weeks a significant difference between 
loaded and non-loaded PTH treated animals was observed, there was no difference between the 
two groups during the last two weeks in either of the experimental series. Especially in the last 
two weeks of the late loading study a drop in MAR was observed in PTH treated animals. 
Similar findings were also discovered in bone formation rate. It is increased by PTH treatment 
and loading, however in the last two weeks no difference between PTH treated loaded and non-
loaded mice was observed. Furthermore, a drop in absolute values was found for PTH treated 
mice. Comparable results were found in other studies performed in mice as well [165, 286]. In 
the study of Childress et al., bone formation rate started to decline after 7 weeks of PTH 
treatment because the response to PTH started to plateau [286]. Solely PTH treatment has been 
found to induce a uniform formation throughout the entire bone [284]. However, in combination 
with loading the localized formation, due to the mechanical loading is augmented by PTH 
treatment. This study found a high correlation for the apposition pattern between the bones of 
rats that received bending and vehicle treatment and those receiving bending and PTH treatment. 
Therefore, the authors draw the conclusion that PTH enhances the mechanical induced bone 
formation. However, it is well known that a minimum strain is needed to induce bone formation. 
Maybe after two weeks of intensive bone formation the strains produced by the loading with 8N 
in our studies were not sufficient anymore to induce bone formation and hence no differences 
were observed between loaded and non-loaded PTH treated mice. Nevertheless, mineralizing 
surface showed a clear load dependent response throughout the entire study in both experimental 
series, however still elevated by PTH treatment. Therefore, the amount of surface covered by 
osteoblasts did not change during the study, only the mineral apposition rate. That might be due 
to single osteoblasts that are more active and produce more osteoid.  
Our data for resorption parameters is somewhat inconsistent. While in the early loading 
experiment mineral resorption rate was elevated in PTH treated mice only in the last two weeks, 
it was increased in the entire treatment period in the late loading experimental series. Bone 
resorption rate was decreased in both studies and eroded surface was mainly reduced by loading, 
but also to some extend by PTH treatment. While an effect of loading in combination with PTH 
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treatment on eroded surface was observed only during the first two weeks but not during the last 
two weeks in the early loading it was the other way in the late loading study. The decreased 
eroded surface could simply be due to the fact that bone formation is occurring at so many sites, 
that there are fewer possibilities for osteoclasts to resorb bone. Only mineral resorption rate is 
increased with PTH treatment compared to vehicle treatment. However, other studies have 
shown that bone resorption is increasing after administration of PTH. As the hormone initiates 
new BMUs, first it has to promote the differentiation of osteoclasts from hematopoietic 
progenitors. However, due to the fact that bone formation and resorption are coupled and 
osteoclasts prepare the bone for osteoblasts, one would expect the bone resorption parameters to 
increase to the same extend and to the same time or even earlier, as formation parameters. 
However, this was not the case in our studies, as in the early loading experimental series mineral 
resorption rate only increased during the last two weeks, when mineral apposition rate already 
started to decline. This supports the idea that PTH exerts osteoclast independent stimulatory 
effects on bone formation.  
One study, performed by Dognig et al., showed that after PTH infusion the number of osteoblasts 
increased, without requiring the proliferation of progenitors [30]. Therefore, the authors 
suggested that PTH also activates bone lining cells. Another study could proof that osteoclast 
independent mechanisms contribute to the increase in bone formation [26]. In this study PTH or 
RANKL was infused in mice. With both types of treatment osteoclast number increased, 
however, to a higher extend in RANKL treated animals. Osteoblast numbers on the other hand 
increased to the same extend in both treatments. Hence, the increase of osteoblasts per osteoclast 
was higher in PTH treated animals than in RANKL treated animals and also osteoblast activity 
was higher in those animals. Activation of lining cells and other osteoclast independent pathways 
could explain the initial strong response to PTH treatment followed by a decline of mineral 
apposition rate in the last two weeks and an increase in mineral resorption rate at the same time.  
In general the findings of our experiments  imply that PTH treatment in combination with 
loading is beneficial at all times of treatment start and even though solely PTH injection already 
exerts a more distinctive effect on many parameters than loading alone, combining both 
treatments contributes to an even higher effect. 
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5.2.2.2 Bisphosphonate studies 
Bisphosphonates are probably the best known anticatabolics. They inhibit resorption by 
decreasing osteoclast activity and increasing osteoclast apoptosis. Therefore, bisphosphonates 
prevent further bone loss after menopause and eventually increase bone mass. Questions arouse 
if the reduced remodeling also impairs the positive effect of mechanical loading in 
bisphosphonate treated animals and humans. In the studies presented here, an additive effect of 
the combination of loading and pharmacological treatment was found for many parameters in 
both experimental series. Only for Trab BV/TV and Ct.Th in the early loading experimental 
series no additive effects were observed. As VEH 0N mice still lose in Trab BV/TV and Ct.Th in 
the early loading study, while they gain bone mass in the late loading study, the effect difference 
between loaded and non-loaded vehicle treated mice was much bigger in the early loading study. 
However, the effect of bisphosphonate injection or loading on these parameters is almost the 
same in both experimental series. There are several other studies supporting our findings, which 
showed additive effects of mechanical loading and bisphosphonate treatment as well [287-289]. 
Sugiyama et al. investigated the effect of dynamic load on mouse tibiae in combination with 
daily risendronate injection. In this study an additive effect on Trab BV/TV was found [287]. 
However, Stadelmann et al. did not find an additive effect of bisphosphonate treatment and 
mechanical loading. When evaluating mechanical loaded tibias the outcome was similar as with 
bisphosphonate treatment alone. However, at the area of highest strain in the tibia they could 
show that the combined effect on bone parameters was significantly smaller than the sum of the 
single effects. This lead to the suggestion that there might be a negative effect of bisphosphonate 
treatment and loading at very high levels of strain [290].  
The anticatabolic action of bisphosphonates can be seen very nice in our mice in Tb.N. In both 
bisphosphonate treated groups of both studies Tb.N remained stable, while it was decreasing in 
vehicle treated animals. Loading did not influence Tb.N but Tb.Th as trabeculae became thicker 
in loaded groups compared to non-loaded groups.  
An anticatabolic mode of action implies that bone resorption is reduced. As bone formation and 
bone resorption are coupled during bone remodeling one would expect also bone formation to be 
reduced. In our studies in the non-loaded bisphosphonate treated animals mineral apposition rate 
and bone formation rate were similar as in vehicle treated non-loaded animals and only in a few 
reduced compared to vehicle treated controls. Mineral apposition rate of bisphosphonate treated 
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animals in the early loading experimental series was even lower than in vehicle treated non-
loaded animals. The same was found during the last two weeks of the early loading series in 
bone formation rate as well as for mineral apposition rate during the first two weeks of the late 
loading experimental series. However, when loading was applied on the bones no reduced bone 
formation was found and both mineral apposition rate and bone formation rate were similar to 
vehicle treated loaded animals in both experimental series. This shows that the effect of loading 
is not blocked by bisphosphonate treatment. Similar results were obtained also in other studies. 
In one study, Jagger et al. loaded the caudal vertebra of rats that were subjected to 
bisphosphonate treatment [289]. Bisphosphonate treatment did not inhibit the increase of 
dynamic and static bone formation parameters in these bones. However, Jagger et al. also 
evaluated dynamic parameters of the tibias, which did receive bisphosphonate treatment but were 
not affected by loading. In these bones a reduction of mineral apposition rate was found [289]. 
However, in the loaded vertebrae no differences in bone formation parameters were observed 
compared to non-treated animals. In another study, bisphosphonates were injected for three 
weeks, followed by a short period of loading [288]. Non-loaded bisphosphonate treated animals 
showed a significantly lower trabecular mineralizing surface than vehicle treated animals but no 
differences between treatment groups could be observed for the loaded animals. Moreover, 
significant higher bone formation parameters were observed in the bisphosphonate treated loaded 
group compared to the treated non-loaded group.  
Resorption parameters are reduced significantly in our studies in both experimental series. While 
in the early loading experimental series the effect of loading on bisphosphonate treated mice is 
not as strong as in vehicle treated mice, significant differences between the loaded and non-
loaded bisphosphonate treated animals can be observed in the late loading study. This could be 
due to different basal levels in the two experimental series. While vehicle treated mice of the 
early loading series show a significantly higher mineral resorption rate and bone resorption rate 
than in the late loading experimental series, no differences can be observed in the absolute values 
of the bisphosphonate treated mice of these two series. Therefore, the absolute reduction in 
resorption parameters is higher in the early loading series, already without loading and probably 
cannot be reduced any further by loading.  
Studies performed on humans showed that the activation frequency is reduced with 
bisphosphonate treatment [39]. However, it would be interesting to know if it is only the 
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initiation of new BMUs that is reduced or also the amount of resorbed bone per osteoclast. To 
investigate this Allen et al. assessed parameters of the resorption cavities in bisphosphonate 
treated dogs [291]. They could show that bisphosphonate treatment significantly reduces 
resorption area and resorption width. However, only a trend towards a reduced resorption depth 
compared to vehicle treated animals was observed. According to these findings they conclude 
that not osteoclast activity but osteoclast number per BMU is reduced. In our studies bone 
resorption rate and mineral resorption rate of both experimental series are significantly lower in 
bisphosphonate treated mice than in vehicle treated animals. However, no effect of 
pharmacological treatment in eroded surface was observed. This is somewhat in contradiction to 
the findings of Allen et al., as these results would rather suggest a reduction in osteoclast activity 
and not the spots where bone is resorbed. However, as with our method not the single osteoclasts 
but their effects on the bone structure at a three dimensional level are observed, a reduced 
number of osteoclasts per resorption pit could result in a reduced mineral resorption rate as well. 
 
5.2.3 Comparison PTH and Bisphosphonates 
To allow an easy comparison of all experimental series, we normalized the data for each animal 
and created a physiome map.  
It can be noted that PTH treated animals show the highest values at the endpoint of the studies 
for all parameters, except for Tb.N. Often loaded groups have higher values than their 
corresponding non-loaded groups. The fact that PTH treatment increases not only static but also 
dynamic parameters stronger than bisphosphonate treatment was also discovered in humans. 
Keaveny et al. investigated the effects of teriparatide and alendronate on vertebral strength in 
osteoporotic women [292]. They could clearly show that vertebral compressive strength is 
increased by both kinds of treatments. However, the increase with PTH is markedly higher than 
with bisphosphonate treatment. Furthermore, while vertebral strength remained stable between 6 
and 18 months of alendronate treatment, it almost doubled with PTH treatment in the same time. 
Finkelstein et al. investigated the effect of PTH treatment and bisphosphonate treatment in 
osteoporotic men [279]. They measured bone mineral density of the spine and the femur and 
could show that it increases significantly more in men treated with PTH than in those treated 
with alendronate or the combination of PTH and alendronate.  
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The findings that PTH apparently exerts more beneficial effects on bone than bisphosphonate 
treatment lead to the question why bisphosphonates are still the most often prescribed 
pharmacological treatment and not PTH. Also in a sequential therapy antiresorptives, such as 
bisphosphonates are often used in first place followed by a sequence of PTH treatment [21]. 
Recently, Cusano and Bilezikian discussed this problem and stated some reasons why PTH is not 
used more often [293]. PTH has to be administered daily with a subcutaneous injection which is 
more time consuming and unpleasant for the patient than the oral administration of 
bisphosphonates. Furthermore, PTH is expensive and antiresorptive therapy has proofed to be 
efficacious as well. In addition, so far there was no head to head study favoring PTH against 
bisphosphonate treatment when fractures are a study endpoint. Also bisphosphonates are in use 
for osteoporosis treatment already since middle of 1990s while teriparatide was approved by the 
EMEA for use in osteoporotic patients in 2003. The duration of the treatment period with PTH 
must not be longer than two years and it should only be administered once in a lifetime. This 
period is consistent with the findings that PTH loses its efficacy after some time. Bilezikian calls 
this time, when PTH is maximal anabolic the “anabolic window” [21]. As PTH initially 
stimulates bone formation and just after a while increases bone resorption, as well it is most 
beneficial up to a period of about two years in humans. After this period, however, all bone 
turnover parameter go back to their baseline levels and no beneficial effect can be observed 
anymore. Some tendencies that support this were already to be seen in our experiments. Bone 
formation rate and mineral resorption rate decreased during the last two weeks; however both of 
them are still significantly higher than in any other group. Bone resorption parameters would 
have been expected to be elevated as well with PTH treatment. However, at no time point bone 
resorption rate of PTH treated animals exceeds the rate of ovariectomized vehicle treated 
animals. During the entire loading and treatment period bone resorption rate is always in the 
range of sham operated or bisphosphonate treated animals. However, in the late loading 
experimental series mineral resorption rate is elevated above the values of any other group. 
Probably in this group PTH already started to increase bone resorption parameters. The two-year 
time frame that was stated for humans cannot be transferred to mice one by one. This is simply 
due to the fact that the metabolism in mice is faster as in humans. For example while the life 
span of an osteoblast is 10-12 days in a mouse it is about 150 days in humans. Also average bone 
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formation rate with 0.150 µm
2
/µm/d is much higher in mice than in humans with just 
0.038 µm
2
/µm/d [51]. 
When in a sequential therapy antiresorptive drugs are used before anabolics are administered, a 
drug dependent time delay was observed until bone mineral density started to increase with PTH 
treatment. This time delay was up to 6 months after bisphosphonate treatment [21, 293]. 
However, following other antiresorptive drugs such as raloxifene, bone mineral density increased 
immediately, as soon as PTH was administered. Nevertheless, a study performed by Bilezikian, 
with different baseline bone turnover markers found a good and immediate response to PTH 
treatment after bisphosphonate treatment [21]. Therefore, Bilezikian stated that not specifically 
the antiresorptive drug but the baseline bone turnover rate is important for the efficacy of the 
PTH treatment. 
Some studies also investigated the effect of administering PTH and bisphosphonates at the same 
time and not in a sequential fashion. As PTH is increasing the bone formation and 
bisphosphonates are decreasing bone resorption one could expect beneficial effects of this 
combination compared to a monotherapy. However, the results from these studies are somewhat 
conflicting. Some studies report that the anabolic action of PTH is blunted when both PTH and 
bisphosphonates are given at the same time [279, 294]. Other studies, mainly in animals, did not 
find any negative effects for the combination of these two drugs [295-297]. One study also 
investigated the effect of combined PTH and alendronate in mice. They distinguished between 
the effects on the primary spongiosa, representing non-remodeling bone, and secondary 
spongiosa, representing remodeling bone [298]. While an additive effect of the combination of 
these two drugs was found in the primary spongiosa, which is consistent with most animal data, 
no additive effect was found for the secondary spongiosa which is consistent with most human 
data. The authors state that one reason for this difference could be that in non-remodeling bone 
no coupling of osteoblasts and osteoclasts can be found and therefore bone formation can 
increase without a necessarily increase in bone resorption. However, in remodeling bone, bone 
formation and bone resorption are coupled and the impeding action of bisphosphonates on bone 
remodeling is blunting the anabolic action of PTH. 
When looking at the previous findings, it could be beneficial to start a sequential treatment with 
injection of PTH and after withdrawal to continue with bisphosphonate treatment. Thereby the 
anabolic action of PTH treatment could exert the full beneficial effect at the beginning of the 
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treatment and once PTH has to be stopped, resorption of the newly formed bone can be 
prevented with bisphosphonate treatment. Studies performed on humans support this idea and 
show very promising results. After PTH treatment is ceased, therapy was continued with 
bisphosphonate medication. With this treatment bone gain was continued compared to bone loss 
in patients receiving placebo after PTH treatment [299-301]. Also as PTH treatment exerts more 
positive effects on the bone structure than bisphosphonate treatment in our studies, it seems 
beneficial to start with a course of PTH treatment followed by bisphosphonates to preserve the 
new bone structure.  
In our studies loading was always added to the pharmacological treatment. In all groups the 
loaded animals showed a higher gain in bone parameters than the non-loaded mice. However, as 
can be seen in Table 17, only bisphosphonate treatment does not seem to have many beneficial 
effects compared to only loading in ovariectomized mice. This is in contrast to PTH treatment. 
The effects of solely PTH administration can be compared to those of bisphosphonates in 
combination with loading. Combined loading and PTH treatment have the strongest effects in 
both experimental series. In the late loading experimental series even synergistic effects were 
found for some static parameters when these two are combined. Therefore, although data from 
animal experiments always has to be handled carefully when it is going to be applied in human 
conditions, but if one wants to give recommendations out of the presented data they would be the 
following:  
Pharmacological treatment should always be combined with mechanical loading as the effect of 
the combination of both is more beneficial than a monotherapy. PTH treatment in combination 
with loading has the most positive effects. Taken into consideration that the time of these 
beneficial effects is limited and usually bone loss is severe when patients are diagnosed with 
osteoporosis for the first time it is worth considering PTH as the first line drug, followed by 
bisphosphonates, again in combination with loading. 
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Table 17: comparison between PTH treatment and bisphosphonate treatment. Effects of both pharmacological treatments 
were compared to effects of only mechanical loading as this would be the easiest way to improve bone mass. If pharmacological 
treatment is given it should improve bone parameters more than mechanical loading. 
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In the presented studies the effect on ovariectomized mice of PTH as an anabolic 
pharmacological treatment and the bisphosphonate zolendronate, as an antiresorptive 
pharmacological treatment in combination with mechanical loading was investigated. The 
acquired data was put together in a physiome map. This allowed a direct comparison of all 
treatment options. However, this physiome map is not exhaustive. It could be interesting to 
compare the results of the present studies to other types of pharmacological treatments, such as 
selective estrogen receptor modulators, like raloxifene, or RANKL antibodies like denosumab. 
As both of them are rather antiresorptive drugs it would be interesting to see if their effect is 
more in the range of bisphosphonates or of PTH.  
All experiments have been performed in mice. Since there are many genetically altered mouse 
strains available, it is possible to use different mouse strains and therefore simulate different 
bone conditions. For example SAMP 6 mice are a model for senile osteoporosis. Signs that are 
typical in human senile bone appear in these mice already at an early age [120]. Therefore, they 
are an interesting model to investigate the effect of pharmacological treatment on this bone. 
While postmenopausal osteoporosis is a high turnover osteoporosis with a high bone remodeling 
rate, senile osteoporosis is a low turnover osteoporosis with a lower bone remodeling rate. Hence 
it could be appealing to not only compare the effects on the static parameters, but also the 
absolute values of the dynamic parameters. If the entire bone remodeling rate is reduced it would 
be interesting to see whether PTH increases bone formation parameters to the same level as it 
does in ovariectomized mice or at least to the same percentage or if this increase is smaller. Also 
it would be interesting to know if bisphosphonate treatment can reduce the bone dynamic 
parameters even more or if it does not affect them at all. Other potentially attractive mouse 
strains are SOST knock out and SOST over expressing mice. SOST is a gene highly expressed in 
osteocytes and with its product sclerostin it has been found to inhibit bone formation. Moreover, 
it has been discovered that PTH inhibits the expression of SOST and therefore increases bone 
formation and exerts its anabolic effects [302]. Kramer et al. could show that in mice over 
expressing SOST, anabolic action of PTH is blunted. SOST k.o. mice, already had a high bone 
mass, before treatment was started. However, the anabolic action of PTH was blunted in these 
animals as well, as BMD in treated and non-treated animals did not differ significantly [303]. It 
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would be worth investigating if these SOST k.o. mice react to mechanical loading the same way 
as ovariectomized mice did or if higher loads are needed to induce a reaction or if no reaction at 
all can be induced anymore as the bone mass is already quite high. Furthermore, it could be 
worth to study the effects of other pharmacological treatment over a longer time. For example, if 
bisphosphonates, although they only reduced bone resorption rate to a certain extend in 
ovariectomized mice, are able to reduce bone resorption rate as well in these mice. In addition if 
bisphosphonates are given for a longer period of time, if they could potentially inhibit the 
increased bone formation due to the lack of SOST. There are also many other knock out mouse 
strains that show a different bone physiology than wild-type mice. The following section will 
just briefly describe some of the strains. 
In 2002 Hoff et al. published a study about the CT/CGRP k.o. mouse. In these animals the 
calcitonin (CT)/ calcitonin gene related peptide alpha (CGRP) was knocked out. The mice were 
found to have a higher trabecular bone volume and a higher bone formation rate at the age of 1 
and 3 months, compared to wild type animals. Furthermore, they did not lose bone after 
ovariectomy and showed a higher response to PTH treatment than control mice. This was shown 
by increased levels of serum calcium concentration and urine deoxypyridinoline crosslinks [304]. 
Other mice that have been shown to be resistant against bone loss after ovariectomy are 
osteopontin k.o. mice [305]. Another genetically modified mouse strain are GDF8 knockout 
mice. As a member of the transforming growth factor beta (TGF-β) super family, GDF8 
(myostatin) regulates skeletal muscle growth in a negative way. The k.o. mice have been found 
to have twice the muscle mass as wild-type mice. But also BMD and BMC were affected. DEXA 
and pQCT measurements revealed that these mice have about 20 % higher cortical BMC at the 
metaphysis of the femur. Furthermore, cortical thickness at the femur was increased by 10 % 
[306]. Manipulation at the hypothalamic level also effects bone mass. Neuropeptide Y (NPY) is 
expressed in the hypothalamus in increasing levels during fasting. Mice lacking this factor have 
been shown to have a significant increase in bone mass. Mice over expressing NPY have been 
shown to significantly reduce bone mass. Therefore, NPY was identified for being very 
important to maintain bone homeostatic signals. It induces an increased bone mass in times of 
obesity, when NPY levels are low, and decreases bone mass under starving conditions, when 
NPY levels are high to save energy [307]. Kong et al. reported in 1999 about mice lacking 
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osteoprotegerin ligand (OPGL). Osteoblasts are not able to support osteoclastogenesis anymore. 
Therefore, these mice severe osteopetrosis due to the complete lack of osteoclasts [308].  
But not only new data could be acquired and added to the physiome map. It is also worth 
investigating further into the data that is presented here. Recently, the local strains of bones from 
ovariectomized mice were compared in 3D with bone formation and resorption sites at our 
institute [309]. According to the mechanostat theory, bone formation would be expected to occur 
at sites of high strains, while bone resorption occurs at sites of low strains. However, with 
pharmacological treatment bone formation and resorption does not necessarily have to follow 
these rules. It has been shown for example that solely PTH treatment induces a uniform bone 
formation while in combination with mechanical load it increases the local bone formation [284]. 
Nevertheless, the bones in that study were only analyzed with means of histology. Comparing 
local strains and bone formation and resorption sites at a three dimensional level at different time 
points of a longitudinal study would give a better insight where and how new bone is deposited 
or old bone resorbed. Furthermore, not only the effect of two different pharmacological 
treatments on the distribution of bone formation and resorption can be evaluated, but also the 
combination of these with loading. Biomechanical tests also provide a good possibility to 
evaluate the bone quality and biomechanical quality of the newly formed bone from the different 
loading and treatment regimes. Therefore, it could be interesting to perform mechanical tests on 
the loaded and treated bones, but also on non-loaded but treated bones.  
Another future experiment could also investigate the development of static and dynamic bone 
parameters once treatment is stopped. As bisphosphonates have a longer half time it would be 
expected that they exert a longer positive effect on bone than PTH. However, with PTH bone 
parameters increased to a much higher extend than with bisphosphonates. Therefore, even if 
some bone is lost after a certain time, bone mass could still be the same as in bisphosphonate 
treated mice. 
Ovariectomized mice are a good model to mimic postmenopausal osteoporosis. Also the 
treatment effects were similar to those observed in humans. Therefore, the data suits very well to 
be implemented into a computer simulation model. With the help of such a model, build upon in 
vivo data and verified with this data the change in static and dynamic parameters of human bones 
can be predicted well. In the future this could give clinicians chances to not only predict the 
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efficacy of a treatment but also to choose the appropriate treatment for the patients based on solid 
data. 
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met, our desire fulfilled, their work is done. The prayer you sent up has been answered. And now it is 
time to move on. 
 
When people come into your life for a SEASON . . . Because your turn has come to share, grow, or learn. 
They bring you an experience of peace, or make you laugh. They may teach you something you have 
never done. They usually give you an unbelievable amount of joy. Believe it! It is real! But, only for a 
season. 
 
LIFETIME relationships teach you lifetime lessons; things you must build upon in order to have a solid 
emotional foundation. Your job is to accept the lesson, love the person, and put what you have learned 
to use in all other relationships and areas of your life. It is said that love is blind but friendship is 
clairvoyant. 
 
 
Last but not least I must not forget those without whom we would not have gotten any results 
and would only know a fraction of what we know about life and science: All the mice that 
support thousands of scientists everyday at their work. 
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